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Experimental animal evidence suggests that there is a major
interaction between the renin-angiotensin system and the sympathetic
nervous system. The present studies investigate whether this interaction
occurs in healthy man. The activity of the renin-angiotensin system was
altered by infusion of low doses of angiotensin II, angiotensin converting
enzyme inhibitors and saralasin infusion. The sympathetic nervous system
was stimulated either by physiological stimuli or by infusion of
noradrenaline, tyramine or isoprenaline. The studies were performed on
the general circulation by intravenous infusion and on the localised




There is considerable evidence for an interaction between the renin-
angiotensin system (RAS) and the sympathetic nervous system (SNS) from
animal studies but the evidence in man is conflicting. The present
investigations sought evidence for such an interaction in healthy man. The
studies were in two main groups, those that sought a postsynaptic
interaction whereby angiotensin II (All) augments the effect of released
noradrenaline (NA), and those that sought a presynaptic interaction
whereby All augments the release of NA.
The first study sought a postsynaptic interaction by infusion of All
and NA alone and in combination. There was a significant synergistic
effect of AII/NA with respect to systolic blood pressure (BP). There was
no interaction with regard to diastolic BP. The fact that this interaction
was limited to systolic BP suggests that this interaction occurs in the
myocardium rather than the peripheral vasculature or may be an effect
on intravascular volume. A renal AII/NA interaction causing retention of
sodium/fluid might account for this.
A series of experiments were performed to investigate a possible
renal tubular antinatriuretic interaction. These showed that both All and
NA had direct antinatriuretic effects. There was however no synergistic
antinatriuretic effect. It seems unlikely that the postsynaptic AII/NA
interaction is due to sodium/fluid retention.
The next study therefore investigated the possibility that All
augments the inotropic response to beta receptor stimulation. The
combination of All/isoprenaline caused a marked increase in stroke volume
above that seen with isoprenaline alone. There are several possible
mechanisms but a regional redistribution of venous blood from the
splanchnic bed increasing cardiac filling seems most likely.
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In contrast when looking for a presynaptic interaction All did not
alter the release of NA nor haemodynamic responses to physiological
stimulation by bicycle exercise, cold pressor test, forearm isometric
handgrip, standing from lying nor pharmacological stimulation of NA
release by tyramine infusion.
These studies relied on measurement of plasma NA as an index of
sympathetic tone which has recognised limitations. The next studies sought
evidence for a presynaptic interaction by an alternative methodology. By
very low dose infusion of hormone into the brachial artery the isolated
forearm vasculature of man in vivo was studied. It was shown that All
did not augment the vasoconstriction caused by the incremental infusion
of NA. By contrast All was shown to augment the vasoconstrictor
response to sympathetic stimulation by lower body negative pressure.
These studies suggest that in the peripheral vasculature All acts by a
presynaptic mechanism, probably through increased NA release.
Conclusions: These studies suggest that All increases the
presynaptic local release of NA but this effect is not of sufficient
magnitude to spill over into plasma altering venous plasma NA. With
regard to the effect of NA after it has been released (postsynaptic
effect), All does not influence the effects of NA on the peripheral
resistance vessels, but synergistically augmentes the rise in systolic BP
seen with NA and increases the effect of beta-agonlsm on stroke volume.
In intact man during systemic infusion a regional redistribution of venous





ACE angiotensin converting enzyme
BP blood pressure
FBF forearm blood flow
HR heart rate
ISO isoprenallne
LBNP lower body negative pressure
NA noradrenaline
RAS renin-angiotensin system
SNS sympathetic nervous system
SV stroke volume
TYR tyramine
A list of abbreviations relevant to the renal sodium excretion studies
described in chapters four to six may be found on page 70
OVERVIEW OF INVESTIGATIONS
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Each study has been coded for the following features:
1. Systemic or local: This describes whether the study involves
systemic intravenous infusions and measures haemodynamic and venous
plasma hormone responses to infusion and/or stimuli or whether the study
involves the local intra-arterial infusion of drug and measures the local
forearm blood flow response to infusion and/or stimulus
2. Manipulation of the renin-angiotensin system: This describes
whether the study has involved "activating" the RAS by All infusion or
salt depletion thereby comparing normal All with Raised All or whether
the "activity" of the RAS has been reduced by pharmacological
interruption thereby comparing normal All with Low AII.
3. Manipulation of the sympathetic nervous system: The method of
stimulation of the SNS has been given. Stimulation was achieved by
infusion of pharmacological agents or NA, or by "physiological" stimuli.
4. Site of interaction investigated: The site of interaction
investigated by the study is indicated. Broadly this may be either
presynaptic, whereby All enhances the release of NA, or postsynaptic
whereby All augments the effects of previously released NA. There is
considerable overlap for site of interaction in the studies and the reader
is referred to the Discussion for further information.
The OVERVIEW OF INVESTIGATIONS is intended as a quick
reference guide for the reader to give a general plan of the studies in
this thesis. The overview is given below and at the beginning of the




3. The effect of Intravenous Infusion of angiotensin II and noradrenaline
alone and in combination on blood pressure, heart rate and plasma
noradrenaline.
[Systemic: Raised All: NA infusion: Postsynaptic]
4. The effect of angiotensin II on renal sodium excretion.
[Systemic: Raised All: None: Direct All action]
5. The effect of noradrenaline on renal sodium excretion.
[Systemic: None: NA infusion: Direct NA action]
6. The effect of angiotensin II and noradrenaline alone and in
combination on renal sodium excretion.
[Systemic: Raised All: NA infusion: Postsynaptic]
7. The effect of angiotensin II on the stroke volume response to beta
agonism.
[Systemic: Raised All: Beta-agonist infusion: Postsynaptic]
8. The effect of angiotensin II on endogenous noradrenaline release.
[Systemic: Raised All: Physiological stimuli of SNS: Presynaptic]
9. The effect of angiotensin II on the haemodynamic and plasma
noradrenaline responses to tyramine infusion.
[Systemic: Raised All: NA release by tyramine infusion: Presynaptic]
10. The effect of local angiotensin II on the forearm blood flow
response to noradrenaline.
[Local: Raised All: NA infusion: Postsynaptic]
11. The effect of local angiotensin II on the forearm blood flow
response to lower body negative pressure.
[Local: Raised All: Physiological stimulus (LBNP): Presynaptic]
12. Studies employing pharmacological interruption of the renin-
angiotensin system.
(a) The effect of local angiotensin converting enzyme inhibition on
the forearm blood flow response to lower body negative pressure.
[Local: Low All: Physiological stimulus (LBNP): Role of local ACE
activity]
(b) The effect of systemic angiotensin converting enzyme inhibition
and reinfusion of angiotensin II on the forearm blood flow response to
lower body negative pressure
[Local: Low All: Physiological stimulus (LBNP): Role of circulating ACE]
(c) The effect of saralasin on the forearm blood flow responses to
lower body negative pressure in sodium replete subjects.
[Local: Low All: Physiological stimulus (LBNP): Presynaptic]
(d) The effect of saralasin on the forearm blood flow responses to
lower body negative pressure in sodium deplete subjects.






The stimulus for the studies presented in this thesis derived from
my developing clinical interest in the treatment of hypertension and heart
failure. With the wider recognition of the neuro-endocrine changes that
occur in these pathological conditions a number of approaches have been
used to treat hypertension and heart failure more or less specifically.
These include the sympathetic nervous system (SNS) blocking agents with
varied sites of action including prazosin, bethanidine, guanethidine, beta-
blocking agents, methyldopa and clonidine. The potent angiotensin
converting enzyme (ACE) inhibitors interfere with the renin-angiotensin-
system (RAS). The calcium channel blocking agents, hydralazine, nitrate
therapy and diuretic therapy also have Important roles to play in the
management of hypertension and/or heart failure.
Reviewing the literature it is clear that the complex physiological
and pathophysiological interactions between different components of the
neurohormonal systems involved remain uncertain. This thesis reports
studies to systematically investigate the interaction between the RAS and
the SNS in healthy human volunteers.
THE RENIN-ANGIOTENSIN-SYSTEM (RAS).
(Reviews: Laragh and Sealey, 1973; Oparil and Haber, 1974; Davis and
Freeman, 1976; Fraser et al, 1979; Haber and Carlson, 1983; Hall et al,
1986)
The RAS is a major factor in the short and longterm regulation of
arterial pressure. This is achieved by a hormonal cascade system which
has been characterised in detail and is illustrated in figure 1.1. Renin is a
circulating enzyme of molecular weight 40,000 daltons in its active form,
Figure 1.1
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The Renin-angiotensin system. Renin from renal and vascular sources acts
on circulating renin-substrate to produce the inactive decapeptide
angiotensin I. In the presence of angiotensin converting enzyme
angiotensin I is further split to give the active octapeptide angiotensin II.
Angiotensin II has many biological activities. It acts (1) on the adrenal
cortex to release aldosterone, (2) directly on the kidney to cause efferent
arteriolar constriction and affects renal tubular function, (3) to cause
central stimulation of thirst and also causes water retention by
stimulating the release of antidiuretic hormone from the posterior
pituitary, (4) directly on vascular smooth muscle receptors to cause
vasoconstriction of resistance vessels, (5) has an inotropic effect on the
myocardium and (6) interacts with the sympathetic nervous system to
augment the release and effect of noradrenaline.
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produced mainly in the juxta glomerular cells of the afferent arteriole in
the kidney. Renin is specific for and acts to cleave renin substrate (a
circulating alpf^-globulin, angiotensinogen) to produce the inactive
decapeptide angiotensin I (A-I). A-I itself is of little biological activity
though in high concentrations A-I may alter intrarenal blood flow,
stimulate thirst and have a central pressor effect. The next step in the
cascade is the cleavage of A-I to the octapeptide angiotensin II (All). This
is performed by angiotensin converting enzyme (ACE) which is located in
endothelial plasma membranes. The main source of ACE is in the
pulmonary vasculature though it has recently been shown that ACE and
other components of the RAS are also located in a variety of tissues
including brain and heart (Campbell, 1987; Jin et al, 1988). The All
generated is the primary active component of the RAS hormonal cascade
(figure 1.1) and is discussed shortly. All has a short half-life in the
circulation estimated to be approximately 15-20 seconds or one circulation
time. All is rapidly taken up into tissues and enzymatically degraded or is
broken down within the circulation by angiotensinases to angiotensin III
(AIII) and smaller inactive fragments. A-III is a heptapeptide which retains
some physiological activity. A-III binds tightly to All receptors and can
stimulate aldosterone release and has a weak pressor effect. The
physiological role of AIII remains in doubt.
Control of the RAS cascade occurs at the beginning with renin
release; no other stage is thought to be rate limiting though may be
targets for pharmacological interference. Davis and Freeman (1976) have
reviewed the mechanisms of control of renin secretion in detail. There
are three main mechanisms influencing renin release from the kidney.
(1) Via intrarenal receptors which are of two types. Firstly renal
vascular receptors which respond to changes in wall tension in the
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afferent arteriole. The receptors are influenced by changes in transmural
pressure, alterations in diameter of the afferent arteriole, renal
sympathetic activity that alters renal arteriolar tone and to intrinsic
myogenic factors. The second receptor is the macula densa which is
influenced by changes in sodium and chloride in the tubular lumen and
appears to respond to changes in electrolyte load rather than changes in
concentration.
(2) The renal sympathetic nerves which end in the juxtaglomerular
cells and in the smooth muscle of the renal arterioles. They alter renin
release by exerting a direct action on the juxtaglomerular apparatus, by
effecting renal arteriolar tone and the vascular receptor, and by altering
glomerular capillary pressure and the filtered sodium load.
(3) Several humoral agents alter renin release including AN,
vasopressin, adrenaline and noradrenaline (NA), sodium and potassium ions
and prostaglandins.
Feedback control thus occurs. An increase in All concentration
results in decreased renin secretion by increased sodium retention and an
increase in extracellular fluid volume, direct negative feedback, direct and
indirect systemic vasoconstriction and direct sodium load effects on the
macula densa (Oparil and Haber, 1974).
ANGIOTENSIN II.
(Reviews: Laragh and Sealey, 1973; Severs and Daniels-Severs, 1973;
Oparil and Haber, 1974; Page and Bumpus, 1974; Simpson, 1981;
Goodfriend, 1983; Haber and Carlson, 1983; Mendelsohn. 1985)
All is the main active component of the RAS cascade described
above. All is a polar octapeptide of molecular weight 1031 daltons. The
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principal physiological actions are illustrated in figure 1.1. All acts on
specific receptors in all its target tissues including adrenal, vascular
smooth muscle, myocardium, kidney, brain and liver. The cellular
consequences of AII binding to receptor remain for the most part obscure.
Calcium flux and turnover of phosphatidyl inositol have been implicated as
the intracellular "second messenger" in the response of vascular smooth
muscle and adrenal zona glomerulosa cells to AII.
All has many biological activities. The main physiological actions are
as a direct vasoconstrictor of resistance vessels and as a major stimulus
to secretion of aldosterone from the adrenal zona glomerulosa. All is one
of the most potent pressor substances known. This action has a rapid
onset occurring within 10-20 minutes of a stimulus such as acute
haemorrhage causing hypotension. All is responsible for increasing the
release of aldosterone which in turn causes sodium retention and
potassium loss via an action on the distal tubule and collecting duct in
the kidney.
In addition All has a number of other actions which have been
described but of which the physiological significance is unclear. Thus as
well as an immediate direct vasoconstrictor effect a separate "slow-
pressor" effect occurring after prolonged infusion of All is well
recognised. A continuous infusion of small doses of All into animals and
man produces a progressive rise in blood pressure. In contrast infusion and
boluses of high doses of All are associated with tachyphlaxis. All has an
inotropic action on the myocardium which may affect arterial pressure
directly.
AII has a number of effects that alter volume homeostasis which
influences the longer term regulation of arterial pressure. These include
several direct intrarenal effects on sodium and water excretion which may
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influence volume homeostasis. All causes direct stimulation of tubular
transport of sodium and water and also causes efferent arteriolar
constriction. The latter increases tubular reabsorption by altering the
physical forces of the peritubular capillary and possibly by lowering vasa
recta blood flow.
All also has stimulatory effects on thirst and release of antidiuretic
hormone. These actions may be effects of All on the central nervous
system. Access of circulating All appears to be limited to structures
lacking a blood brain barrier. The three susceptible areas are (1) the area
postrema which mediates a pressor action of All in many species, (2) the
subfornical organ which provokes thirst, secretion of antidiuretic hormone
and a pressor action in response to All and (3) the organum vasculosum
which may also mediate these effects.
The pressor effect of All action on the central nervous system is
mediated by increased sympathetic outflow. All affects the sympathetic
nervous system at other sites. All stimulates sympathetic ganglia and
causes adrenaline release from the adrenal medulla. In addition facilitation
of sympathetic neurotransmission has been recognised as an additional
mechanism whereby All can affect cardiovascular function.
Many of these effects of All occur only at pharmacological doses or
may be demonstrated only under abnormal experimental conditions and
their physiological importance is uncertain. However the facilitation of
sympathetic neurotransmission may occur at levels of All within the
physiological range and is discussed in detail below.
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ANGIOTENSIN FACILITATION OF SYMPATHETIC NEUROTRANSMISSION
The evidence in experimental animals
It has been recognised for almost three decades that All can
facilitate peripheral sympathetic neurotransmission. In experiments on the
dog hindpaw Zimmerman (1962) showed that the pressor response to All
was reduced by acute sympathectomy. Importantly the response to both
NA and tyramine remained unchanged. In addition stimulation of the cut
lumbar sympathetic nerves restored the pressor response to All in most
instances. That the effect on peripheral sympathetic neurotransmission can
be considered separately from any putative central effect was also
demonstrated at an early stage. Zimmerman (1967) showed that in
conditions in which All caused a marked increase in the pressor response
to peripheral nerve stimulation in cutaneous and renal vascular beds of
the dog there was no response to intracarotid and intravertebral injection
of All. The extensive work in isolated tissue preparations and
experimental animal preparations has recently been reviewed (Westfall,
1977; Vanhoutte et al, 1981; Zimmerman et al, 1984: van Zwieten and de
Jonge, 1986).
The effects of All on peripheral sympathetic neurotransmission
include potentiation of release of NA both from unstimulated nerves and
in response to nerve stimulation, blockade of reuptake of NA, potentiation
of the postsynaptic effects of NA and increased NA synthesis (figure 1.2).
Potentiation of release of noradrenaline from unstimulated nerves.
Several laboratories have shown that All can cause the release of NA
from presynaptic sites. In early experiments Baum (1963) showed that the
vasoconstrictor activity of All was reduced in dogs pretreated with
reserpine and Distler and coworkers (1965) showed that AII caused NA
depletion of porcine arterial strips and that the contractile effect of
Figure 1.2










Possible sites of interaction between the renin-angiotensin system and the
sympathetic nervous system. (1) Mobilisation and release of endogenous
noradrenaline (NA) from presynaptic sites. (2) The sensitisation of vascular
postsynaptic adrenoceptors. (3) The blockade of the neuronal reuptake of
NA. (4) The presynaptic facilitation of the amount of NA released per
nerve impulse.
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All was reduced by pretreatment with reserpine. It was concluded that
the action of All on vascular smooth muscle was mediated by liberation
of NA from the sympathetic nerve endings. Later Drimal and Boska (1973)
showed that the positive inotropic action of All in the dog heart was
reduced by prior NA depletion by reserpine. They suggest that All acts in
part by causing the release of NA in a tyramine-like fashion. Palaic and
Panisset (1969) demonstrated that high doses of All increase the release
O
of H-labelled NA and reduced reuptake and retention of NA in the
unstimulated vas deferens of the guinea pig. Hughes and Roth (1971)
O
demonstrated a small increase (5-10%) in the basal efflux of H-labelled
NA from isolated rabbit portal vein and coeliac artery however the same
dose of All Increased the stimulated ^H-labelled NA efflux by 30-150%.
Knape and van Zwieten (1987) showed that reserpine pretreatment reduced
the pressor response to high doses of All in pithed rats in which the
central nervous system effects can be excluded. In addition bilateral
adrenalectomy did not alter the pressor response to All. They conclude
that part of the vasoconstriction at high doses of All is caused by the
activation of presynaptic All receptors in sympathetic nerve terminals
resulting in catecholamine release.
These studies and others indicate that All may cause the release of
preformed NA in a tyramine like manner. However it is also clear that
the effect occurred only at very high doses of All and in isolated tissue
preparations and abnormal circumstances such as pithed rat preparations.
It must be concluded that this effect of All does not play a role under
physiological conditions.
Potentiation of release of noradrenaline during nerve stimulation.
The prejunctional facilitation of sympathetic neurotransmission in vascular
smooth muscle by enhancement of the amount of NA released per nerve
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Impulse is well supported by a large volume of published work from many
laboratories. Many authors have shown that the pressor response to
peripheral nerve stimulation is potentiated by All at doses which cause
little or no change in the response to exogenous NA (Zimmerman, 1962;
Review: Zimmerman, 1978; Panisset and Bourdois, 1968; Kadowitz et al,
1971; Antonaccio and Kerwin, 1981; Clough et al, 1982; de Jonge et al,
1982; Story and Ziogas, 1986). Other studies have confirmed that All
causes an increased release of radiolabeled NA during nerve stimulation
and have confirmed this mechanism (Palaic and Panisset, 1969; Starke,
1971; Hughes and Roth, 1971; Zimmerman et al, 1972; Ziogas et al, 1985).
This potentiating effect of All on NA release during nerve stimulation can
be blocked by saralasin, an All analogue and antagonist (Zimmerman,
1973; Blumberg et al, 1975; Malik and Nasjletti, 1976; Review: Westfall,
1977; Kawasaki et al, 1982; Ziogas et al, 1985).
This finding suggests that the presynaptic facilitation is mediated by
presynaptic All receptors, located at sympathetic nerve terminals in
vascular smooth muscle. Furthermore these effects have been
demonstrated to occur at low circulating levels of All that may well be
of physiological and pathophysiological significance.
Blockade of reuptake of noradrenaline. All was shown to block
uptake of NA in tissue slices (Palaic and Khairallah, 1967a; Palaic and
Khairallah, 1967b) and this was therefore postulated as an early
explanation of the facilitating action of All on sympathetic
neurotransmission (Khairallah, 1972; Zimmerman and Gomez, 1965;
Panisset and Bourdois, 1968). However this effect was seen at high doses
of All and was not seen at lower doses in preparations that showed
potent inhibition of uptake by cocaine, a known inhibitor (Pals and
Masucci, 1968; Schumann et al, 1970; Starke, 1970). Also the potentiating
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effect of All persisted in the presence of an uptake inhibitor, whereas the
response to a second uptake inhibitor was abolished (Schumann et al,
1970; Starke, 1970). These findings are therefore incompatible with the
inhibition of NA uptake as a major action of AIL
Potentiation of the postsynaptic effects of noradrenaline. A
postsynaptic facilitation of sympathetic neurotransmission by All has also
been postulated. The evidence for this effect stems from three
observations. Firstly that All potentiates the response to exogenous NA in
a number of tissue and vascular preparations. Secondly that reduction in
All by treatment with ACE inhibitors or its pharmacological blockade with
saralasin reduces the response to exogenous NA in similar preparations
including pithed rats. Thirdly that after treatment with ACE inhibitors or
saralasin, infusion of All restores the response to NA (Panisset and
Bourdois, 1968; Zimmerman, 1973; Clough et al, 1983; de Jonge et al,
1983; Kaufman and Volmer, 1985; Weber et al, 1989). One repeated
finding in such studies is that where investigated in the same preparation
the facilitatory action of All during nerve stimulation is more consistent
and is of considerably greater magnitude (Zimmerman and Gomez, 1965;
Malik and Nasjletti, 1976; Kawasaki et al, 1982; Zimmerman et al, 1987;
Isaacson and Reid, 1990). However many studies demonstrating a
facilitatory effect of All during nerve stimulation have failed to show an
effect of All on exogenous NA (Benelli et al 1964; Bell, 1972; Kadowitz
et al, 1972; Zimmerman et al, 1972; Turker, 1973; Johnson et al, 1974;
Furukawa et al, 1983).
Taken together these findings suggest that there is a specific
postsynaptic interaction of All facilitating the effects of released NA, but
which is of lesser magnitude than the presynaptic interaction demonstrable
during nerve stimulation, and appears to occur at high rather than
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reduced All levels. This action therefore may be relevant only in
pathophysiological circumstances.
Increased noradrenaline synthesis. All increases the biosynthesis of
NA at levels which have no effect on release of NA in innervated tissues
such as rat and guinea pig atria or rat vas deferens. The process appears
to occur at the tyrosine hydroxylase step and may involve the synthesis
of new enzyme protein. This mechanism therefore may act as a long-term
homeostatic mechanism, whereas the facilitation of transmitter release is
more likely to be responsible for immediate and short term actions of All
(Roth, 1972).
Summary. These findings are summarised in figure 1.3 representing
the mechanisms of interaction of the RAS and SNS (after van Zweiten
and de Jonge, 1986). The diagram emphasises the two interactions that
appear to be of most physiological relevance on the basis of the animal
experimental evidence. That is firstly the presynaptic facilitation of NA
release by All, and secondly the postsynaptic sensitisation of
adrenoceptors, the alphaj -receptors represented within the synaptic cleft
and the alph^-recptors outwith the synaptic cleft.
The work in animals has not only revealed a number of sites of
interaction but also Zimmerman et al (1984) emphasise in their review
that a significant interaction between the RAS and the SNS occurred only
in circumstances in which the RAS was activated either by infusion of
exogenous All, or by studying salt deplete animals or pithed rats in whom
the plasma renin activity is increased (de Jonge et al, 1982). Despite this
conclusion investigators who have previously sought evidence for a
RAS/SNS interaction in man have usually done so in subjects with normal
RAS activity and have suppressed this further by administering an ACE
inhibitor or infused saralasin.
Figure 1.3
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[after van Zweitan and de Jonge 1986]
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Figure 1.3 legend
Schematic representation of the presynaptic and postsynaptic effects of
angiotensin II on adrenergic nerve endings. The stimulation of presynaptic
angiotensin II receptors enhances the release of noradrenaline from
presynaptic sites. In addition postsynaptic alphaj- and alpha2~
adrenoceptor responses are facilitated by postsynaptic angiotensin II
receptors.
[after van Zwieten P.A. & de Jonge A., 1986]
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The evidence in human studies
The evidence in man is conflicting. This is in part because of the
limitations of experimentation in man. Information has been obtained from
manipulation of the RAS and SNS either separately or simultaneously.
Thus data have been obtained from the effects of All infusion and the
use of pharmacological inhibitors of the RAS and these have been coupled
with the use of "physiological stimuli" of the SNS such as cold pressor
testing or with pharmacological stimuli or blockade of the SNS.
Infusion of angiotensin II. Infusion of All alone produces no change
in plasma NA in healthy man (Beretta-Piccoli et al, 1980; Nicholls et al,
1981; Mendelsohn et al, 1980) and hypertensive man (Beretta-Piccoli et al,
1980). This has been interpreted as showing no interaction between the
RAS and the SNS (Nicholls et al, 1981). However in studies were other
pressor agents have been infused, such as phenylephrine, plasma NA falls
as the pressor effect Increases (Eckberg et al, 1986). Therefore the
finding that during infusion of All plasma NA levels are maintained may
be the first evidence that an RAS/SNS interaction occurs in man.
Treatment with angiotensin converting enzyme inhibitors. Most other
investigations in man have used ACE inhibitors and have produced further
conflicting results. Treating normal volunteers with ACE inhibitors usually
causes no change in plasma NA (Ajayi et al, 1985; Millar et al, 1981;
Millar et al, 1982; Niarchos et al, 1982; Campbell et al, 1985) but others
have shown an increase (MacGregor et al, 1981; Ibsen et al, 1983). Similar
findings occur in hypertensive subjects, ACE inhibition usually causing no
change in plasma NA (Manhem et al, 1981; Millar et al, 1981; Morganti
et al, 1980; Zanella et al, 1981; Bravo and Tarazi, 1979) or occasionally
increased plasma NA (Hulthen and Hokfelt, 1978; Mohara et al, 1986).
The response of patients with heart failure has been rather more
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consistent in that treatment with ACE inhibitors has uniformly been
associated with reductions in plasma NA (Curtiss et al, 1978; Turini et al,
1979; Cody et al, 1982; Fitzpatrick et al, 1983; Cleland et al, 1984).
However these results do not support a direct RAS/SNS interaction as
ACE inhibitor treatment causes marked improvement in haemodynamic
indices in patients with heart failure which in itself would produce
reduction in plasma NA.
Infusion of saralasin. Infusion of saralasin, an All antagonist, is
confounded by partial agonist activity. Infusion in man causes either an
increase in plasma NA (McGrath et al, 1977; Vlachakis et al, 1978) or no
change in plasma NA (Carey et al, 1978).
Responsiveness to noradrenaline after ACE inhibitor treatment.
Conflicting results have also been obtained when assessing the pressor
responsiveness to NA infusion after ACE inhibitor treatment. In one study
the responsiveness was unchanged (Vierhapper et al, 1986) and in another
the pressor responsiveness was diminished, but interestingly could be
restored by infusion of AN (Imai et al, 1982). Responsiveness to NA
infusion after ACE inhibition is also reduced in hypertensive subjects
(Fruncillo et al, 1985).
Physiological stimulation of the SNS after ACE inhibitor treatment.
In studies in which the SNS has been stimulated physiologically or
pharmacologically, ACE inhibitor treatment has been shown to have no
effect on plasma NA in healthy man (Ibsen et al, 1983; Millar et al,
1982; Niarchos et al, 1982; Becker et al, 1986) though in one study the
plasma NA response to standing from supine was increased by ACE
inhibitor treatment but to none of the other manoeuvres investigated
(Reid et al, 1983). In hypertensive patients the plasma NA response to
physiological stimulation may be unaffected (Manhem et al, 1981) or
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increased (Morganti et al, 1980; Zanella et al, 1981) by treatment with an
ACE inhibitor.
There is therefore a wealth of experimental animal evidence
supporting a major interaction between the RAS and the SNS. However
there is much conflicting data in the literature reporting studies in man.
This thesis reports studies to systematically investigate the interaction







All subjects were healthy normal volunteers. All had a normal
medical assessment including physical examination, biochemical and
haematological profile, urinalysis and electrocardiogram. None were on
regular medication of any sort. Subjects were required to abstain from self
medication prior to and during the course of the studies. Subjects were
also required to abstain from alcohol for 36 hours before each study day
and to abstain from caffeine containing drinks and smoking on the morning
of the study. Sodium intake was not strictly controlled but each subject
was asked to adhere to their usual diet throughout the study period and,
where possible to maintain a similar pattern of meals for three days prior
to each study day which was assessed by estimation of 24 hour urinary
sodium excretion.
Consent
All subjects were provided with a study information sheet and after
explanation gave written informed consent.
Ethical approval
All studies were performed after approval by the Medical and Dental
research ethics committee of the University of Dundee, or the Medical




The following procedures and analyses were performed by myself.
Intravenous infusion
Intravenous cannulae were placed into antecubital veins using 1%
lignocaine (Antigen Ltd, Ireland) to provide local anaesthesia. Intravenous
infusions were given at the indicated rate by means of constant rate
infusion pumps (Perfusor E Secura, B. Braun Melsungen AG, West
Germany).
Measurement of blood pressure and heart rate
Throughout each experiment the electrocardiogram and heart rate
were continuously monitored by an ECG oscilloscope (Hewlett Packard,
USA) and blood pressure was recorded semi-automatically (Dinamap - Vital
signs monitor 1846, Critikon, Tampa, Florida, USA).
Measurement of cardiac output
Cardiac output was measured by a non-invasive acetylene rebreathing
technique (Irvine et al, 1983). This technique was chosen as a reproducible
non-invasive measurement that avoids the need to place pulmonary artery
catheters or inject radioisotope on repeated occasions in normal volunteers,
procedures that are not ethically appropriate. The intrasubject coefficient
of variation (CV) for the measurement of cardiac output was 10.7%,
calculated for the five repeated measures recorded on the dual placebo day




A standard oral hydration protocol was used (Roberts and
Daneshmend, 1981). An initial water load of 15-20 mls/kg was given to
drink over 10 minutes. Subsequently the subject stood to pass urine every
20 minutes until the end of the study. An aliquot of each urine sample
was saved for later analysis. After voiding, a replacement volume of water
equal to that of urine passed was given to drink. In this way a steady
state water diuresis was established over an equilibration period of 2 hours
(six 20 min urinary clearance periods).
The following excretion and clearance indices were calculated in the
standard manner (Roberts and Daneshmend, 1981). Clearance (C) was
calculated as UV / P, where U = urinary concentration, V = urinary flow
rate and P = plasma concentration. Creatinine clearance (Cq.) was used as
a measure of glomerular filtration rate (GFR). Fractional excretion (FE)
was calculated as absolute excretion divided by C£r. Lithium clearance
(CLj) was used to estimate proximal tubular outflow (Thomsen, 1984).
Osmolar clearance (Cosm) was calculated as UosmV/Posm. Distal delivery
(DD) of sodium was calculated according to the conventional formula
^Na+^H20 anc* fractional distal delivery (FDD) as (C]>qa+Cj^2o)/C(-r.
Absolute resorption of sodium by the distal nephron (RDj^a) was calculated
as (^Lj-C^gJxPj^g and fractional reabsorption as sodium by the distal
nephron (FRDNa) as (Cjj-CNa)/CLi
Lower body negative pressure
Lower body negative pressure (LBNP) was used as a method of
stimulating sympathetic vasoconstriction in a number of studies described
in this thesis and is discussed here in detail.
Method used: LBNP was applied using the method described by
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Brown et al (1966). Subjects rested supine with a plastic-covered steel cage
enclosing the lower limbs and hips and sealed above the level of the
anterior superior iliac spines. Suction was applied by an industrial vacuum
to produce a constant negative pressure of 20 cm of water (15 mmHg).
The alteration from atmospheric pressure was both applied and relieved
rapidly. This degree of LBNP was chosen as it reduces forearm blood flow
without affecting systemic blood pressure or heart rate and without
activating carotid baroreceptors (vide infra).
Cardiovascular responses to LBNP: The present day technique of
LBNP was described in the early 1960's to study responses to gravitational
change (Stevens and Lamb, 1965; Brown et al, 1966). The cardiovascular
responses are well established. LBNP causes blood pooling in lower limbs,
1 O 1
buttocks and pelvis demonstrated by pooling of plasma bound I (Wolthuis
et al, 1974). This results in a fall in central venous pressure and an
increase in forearm vascular resistance at all degrees of LBNP. Increasing
degrees of negative pressure (from 20 mmHg up to 80 mmHg) cause an
increase in heart rate, a fall in systolic blood pressure, pulse volume and,
with the higher degrees of LBNP a fall in diastolic blood pressure (Steven
and Lamb, 1965; Brown et al, 1966; Ardlll et al, 1967; Johnson et al, 1974;
Abboud et al, 1979). Stroke volume and cardiac output fall (Stevens and
Lamb, 1965; Murray et al, 1968). At sustained high degrees of LBNP most
subjects experience syncope or presyncope, and some subjects will
experience syncope as low as 30 mmHg sustained LBNP (Murray et al,
1968). In contrast lesser degrees of LBNP ( <20 mmHg ), as used in this
thesis, cause marked reductions in forearm blood flow without affecting
arterial blood pressure (Zoller et al, 1972; Johnson et al, 1974). These
workers showed, in studies where the degree of LBNP was increased
through a range from low to high degrees, that approximately 70% of
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maximal reduction in forearm blood flow occurred before onset of any
change in arterial pressure (Zoller et al, 1972; Johnson et al, 1974).
Evidence for reflex sympathetic forearm vasoconstriction: The
evidence that the vasoconstriction seen during LBNP is mediated via the
SNS is threefold. Firstly the reduction in forearm blood flow can be
abolished by the local arterial administration of bretylium tosylate (Brown
et al, 1966) and is attenuated by bethanidine infusion or prior
sympathectomy (Ardill et al, 1967). Secondly direct recordings of human
forearm muscle sympathetic nerve activity have shown increased activity
during LBNP (Sundlof and Wallin, 1978). Finally there is a rise in plasma
NA during sustained LBNP which correlates with the of fall in central
venous pressure (Goldsmith et al, 1982; Grassi et al, 1985).
Hormonal changes during LBNP: I have commented on the change in
plasma NA. Plasma renin release is also stimulated at high degrees of
LBNP that cause hypotension (Baylis et al, 1978; Mark et al, 1978). This
release can be blocked by propranolol and is therefore mediated via the
SNS (Mark et al, 1978). The onset of symptoms of syncope is associated
with a marked increase in plasma antidiuretic hormone, but this does not
occur in asymptomatic individuals (Baylis et al, 1978; Goldsmith et al,
1982).
It is therefore widely thought that low levels of LBNP act by
unloading "low pressure" cardiopulmonary receptors responsive to falls in
central venous pressure, resulting in reflex sympathetic constriction in
forearm resistance vessels. Higher levels of LBNP unload these "low
pressure" receptors but by reducing arterial pressure also unload carotid
baroreceptors (Wolthuis et al, 1974; Mark and Mancia, 1983).
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Introduction to the alternative methodology used in chapters ten to twelve
The studies described in chapters three and seven to nine rely upon
changes in arterial pressure, heart rate, stroke volume and plasma hormone
levels to investigate the interaction between the RAS and the SNS in man.
In chapters ten to twelve studies are described which use an alternative
methodology to investigate this interaction.
The technique is that of intra-arterial infusion of hormone or placebo
and concomitant measurement of forearm blood flow by strain gauge
plethysmography illustrated in figure 2.1.
Subjects
Twenty healthy volunteers (19 male and 1 female: mean age 26 years,
range 21-33 years) took part in one or more of the experiments described
in chapters ten to twelve. All studies were performed at least one week
apart. Studies were performed after volunteers had rested supine in a quiet
clinical laboratory for a minimum of 30 min. The room temperature
(between 25 and 28 C) was maintained within +/- 1 C for each study.
Intra-arterial infusion
A 27 standard wire gauge steel cannula (Cooper's needle Works, Aston
Lane, Birmingham, UK) was inserted into the brachial artery of the non-
dominant arm using 1% lignocaine hydrochloride (Antigen Ltd, Ireland) to
provide local anaesthesia. Infusions were given alone (at 1.0 ml/min) or in
combination (each at 0.5 ml/min), to give a continuous infusion rate of 1.0
ml/min throughout each experiment, by means of constant rate infusion
pumps (Harvard 944A).
Angiotensin II (Calbiochem, USA) was prepared in saline (0.9% NaCl,
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Travenol, UK) immediately prior to infusion. All other hormone infusions
are described in the individual chapters.
Measurement of forearm blood flow
Forearm blood flow (FBF) was measured in both arms using venous
occlusion plethysmography with temperature compensated mercury-in-silastic
strain gauges (Whitney, 1953). Collecting cuff pressure was 40 mmHg and
wrist cuff occlusion pressure was 200 mmHg. Flows were recorded for 10s
in every 15s. The mean of the final 5 measurements of each recording
period was used for analysis.
Analysis of forearm blood flow recordings.
Percentage changes in blood flow in the infused and non-infused
forearm were calculated by the formula given below:
F(0)
where F^ and F^ represent measured forearm blood flows (F) before (0)
and at time (t) during intervention.
Where repeated measures are compared the data were transformed to
the ratios of blood flow in the infused and non-infused forearm. This
method of analysis was chosen to minimise the interference of variations
in blood flow affecting both arms produced by extraneous factors (after
Greenfield and Patterson, 1954).
In their original paper Greenfield and Patterson note that extraneous
influences and/or interventions resulted in some general alterations in the
circulation, and even at rest there are continual adjustments of the
peripheral circulation. Assuming all general alterations act symmetrically
and cause equal percentage as opposed to absolute effects on the two
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forearms then the following equation holds for our experiments:
EC(t) = FC(0) 0R EC(t) = FC(0)
P pi X FNC(t)
NC(t) NC(0) FNC(0)
where Fqq) represents the resting blood flow in the cannulated (C),
infused forearm and Fjsjqq) represents the resting blood flow in the non-
cannulated (NC), non-infused forearm during the baseline period, and
FNC(t) rePresents the observed blood flow in the non-cannulated forearm
at time t during experimental intervention and Ec(t) is the expected blood
flow in the cannulated forearm at time t if alterations are due only to
general factors.
The effect of experimental intervention is to make the observed
blood flow Fc(t) Instead of the expected blood flow Ec(t) *n t*ie
cannulated forearm. The observed flow may be expressed as a percentage
of the expected by the formula:
Percentage = ^c(t) x
EC(t)
= FC(t),FNC(0) x 100
FC(0)"FNC(t) (after Greenfield and Patterson, 1954)
In the final formula it can be assumed that aPProaches
unity and for any given set of experimental observations is constant. Thus
the formula may be reduced to:
Percentage = Fc(t) x
FNC(t)
In our experiments and illustrations where repeated measures are
compared the data have been transformed to Fc(t/FNC(t) rati°s rather
than percentages. The expected ratio is therefore unity and alterations in
the ratio can be taken as due to experimental intervention rather than to
extraneous general influences on the circulation.
Figure 2.1
LOWER BODY NEGATIVE PRESSURE
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Legend to figure 2.1
Experimental procedure for arterial infusion studies
Arterial infusion is performed via the left brachial artery in the
resting supine subject. Forearm blood flow is measured in both forearms
and compared to show the local effect of infusate.
Also illustrated is the subject within the body box which allows the
rapid application of lower body negative pressure to the supine resting
subject. This was used as indicated in individual chapters.
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Handling of blood samples prior to analysis
Intravenous cannulae were placed (vide supra) into antecubital veins
using 1% lignocaine to provide local anaesthesia. Intermittent blood samples
were taken via the indwelling cannula to cause the least disturbance of the
resting subject.
Aliquots (5 ml) were taken into chilled lithium heparin tubes for
measurement of NA.
Aliquots (10 ml) were taken into chilled glass tubes containing a
solution of 0.05 M O-phenanthroline, 2 g/1 neomycin, 0.125 M EDTA
disodium salt and 2% ethanol for measurement of All.
Aliquots (5 ml) were taken into chilled potassium EDTA tubes for
measurement of aldosterone.
Aliquots (10 ml) were taken into chilled tubes containing 60 mg
potassium EDTA and 4000 kallikreln units of aprotinin (Trasylol, Bayer UK,
UK) for measurement of atrial natriuretic peptide (ANP).
The samples for measurement of NA, All, aldosterone and ANP were
immediately centrifuged at 4C, separated and stored at -70C (NA and All)
or -20C (aldosterone and ANP) until assayed.
Aliquots were taken into plain glass tubes for measurement of
creatinine, osmolality and electrolytes. The blood was allowed to clot at
room temperature and serum separated and stored at -20C until assayed.
Measurement of serum and urinary electrolytes and osmolality.
Serum and urinary sodium and potassium were measured by an
indirect reading ion specific electrode (Beckman System E2A). Serum and
urinary osmolalities were measured by the freezing point depression method
(Advanced Osmometer, Camlab).
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Measurement of plasma noradrenaline
Plasma noradrenaline was measured by our double isotope
radioenzymatic assay (Brown and Jenner, 1981). The intra-assay coefficient
of variation for this method in our laboratory was 8.0% and the inter-assay
coefficient of variation was 11.1%. [Noradrenaline analyses for the studies
in chapter three and chapter eight were performed by myself, thereafter
analyses were performed by laboratory staff of our Department].
The following analyses were performed by technical staff of the
Department of Clinical Pharmacology and *the Department of Clinical
Biochemistry, Ninewells Hospital and Medical School, Dundee .
Measurement of serum and urinary creatinine
Serum and urinary creatinine were measured on an autoanalyser by
the modified Jaffe method (Cobas Bio, Roche Diagnostica, Basle,
Switzerland).
Measurement of plasma All
Plasma All was measured, after plasma extraction, by a commercially
available radioimmunoassay kit (Immuno-diagnostics Ltd, Washington, Tyne
and Wear, UK). The intra-assay coefficient of variation for this method in
our laboratory was 2.2% and the inter-assay coefficient of variation was
12.1%.
Measurement of plasma aldosterone
Aldosterone was also measured by radioimmunoassay using a
commercially available kit (Serono Diagnostics Ltd, Woking, Surrey, UK).
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The intra-assay coefficient of variation for this method in our laboratory
was 6.6% and the inter-assay coefficient of variation was 14.7%.
Measurement of plasma renin activity
Plasma renin activity was measured by radioimmunoassay of
angiotensin I generated during a 1.5 hour incubation at 37C with a
commercially available kit (CIS, UK, Ltd, High Wycombe, Buckinghamshire,
UK). The intra-assay coefficient of variation for this method in our
laboratory was 1.8% and the inter-assay coefficient of variation was 10.8%
Measurement of plasma atrial natriuretic peptide
Plasma ANP levels were measured by a commercial radio¬
immunoassay (Amersham International Ltd, Little Chalfont,
Buckinghamshire, UK) after plasma extraction (Sep-Pak cartridges, Waters
Associates). The intra-assay coefficient of variation for this method in our
laboratory was 8.5% and the inter-assay coefficient of variation was 7.2%.
Measurement of serum and urinary lithium concentration *
Serum and urinary lithium were measured by flame emission
photometry on an atomic absorption spectrometer (Pye Unicam SP9,
Phillips, Cambidge, UK).
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LIST OF PHARMACOLOGICAL AGENTS:
1. Angiotensin II: Hypertensin Ciba [CIBA-GEIGY Ltd, Switzerland.];
val -hypertensin II-asp-beta-amide was diluted in 5% dextrose to final
concentration of 0.25 or 0.5 mcg/ml for intravenous infusion. Angiotensin II
(Calbiochem, Behring Diagnostics, USA) was prepared in 0.9% saline for
intra-arterial infusion.
2. Noradrenaline: Levophed [Winthrop Laboratories, UK]; lmi containing
lmg noradrenaline base as acid tartrate with 2 mg sodium metabisulphate
as stabilising agent. Noradrenaline was diluted as stated in 5% dextrose
alone or 0.9% saline with lmg/ml ascorbic acid as anti-oxidant (Evans
Medical Ltd, UK; ascorbic acid 500mg in 5mls stabilised with sodium
metabisulphate 0.1% w/v).
3. Isoprenaline: Saventrine [Pharmax Ltd, UK]; lmg/ml stabilised
solution of isoprenaline hydrochloride BP for injection was diluted in 5%
dextrose for intravenous infusion.
4. Tyramine: Tyramine [BDH Ltd, UK] was prepared as a solution
(lOmg/ml) for human administration to be diluted in 5% dextrose for
intravenous infusion by the Pharmacy Manufacturing Unit, Ninewells
Hospital and Medical School, Dundee, UK.
5. Enalaprilat: Enalaprilat 5mg/ml [Merck Sharp & Dohme Ltd, UK]
was diluted in 0.9% saline for intra-arterial infusion.
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6. Saralasin: [Sar -Val -Ala ]-Angiotensin II as acetate salt [Sigma
Chemical Co Ltd, UK] was diluted in 0.9% saline for intra-arterial
infusion.
7. Enalapril: Innovace 20mg [Merck Sharp & Dohme Ltd, UK]
8. Captopril: Capoten Tablets 25mg [ER Squibb & Sons Ltd, UK].
9. Frusemide: Lasix Tablets 40mg [Hoechst UK Ltd, UK].
10. Lithium; Camcolit 250 [Norgine Ltd, UK]; containing 250 mg
lithium carbonate BP (equivalent to 6.8 mmol).






The effect of intravenous infusion of angiotensin II alone and in
combination on blood pressure, heart rate and plasma noradrenaline
Introduction
In this study evidence was sought for a postsynaptic interaction
between the RAS and SNS by constructing a dose-response curve to infused
exogenous NA in the presence and absence of exogenous AIL
Methods
Ten normotensive volunteers (nine male) were studied. Each volunteer
attended on four separate occasions. On each occasion they had performed
a 24 hour urine collection for assessment of sodium excretion. On each
study day, three intravenous cannulae were inserted, two in one arm and
one in the opposite arm. The forearm with two cannulae was used for the
infusions while the opposite arm was used for blood sampling.
After 20 min supine rest, blood pressure (BP) and heart rate (HR)
were measured and a blood sample taken for subsequent measurement of
plasma NA and plasma All levels. Thereafter, they were infused with
either All dissolved in 5% dextrose at the rate of 2 ng/kg/min on two
occasions or with vehicle solution on the other two occasions. This infusion
lasted 90 min. After 20 min of this infusion, measurements were made of
BP and HR and blood sampled for plasma NA and AIL Thereafter, a
second infusion was begun. On two days they were infused with NA
(Levophed, Winthrop) in 0.9% saline containing 1 mg/ml ascorbic acid in a
stepwise fashion, each step lasting 10 min. Each step consisted of NA in
doses of 0, 10, 20, 35, 50, 75 and 100 ng/kg/min. On two other days,
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vehicle solution was infused in an identical manner. Both the first
All/dextrose infusion and the second NA/saline infusion were terminated at
the same time. The four study days were administered in a randomised
single-blind fashion. Overall therefore, the volunteers received dextrose
followed by saline, All followed by saline, dextrose followed by NA and All
followed by NA. The study protocol is illustrated in figure 3.1.
Blood pressure was measured by a semi-automatic sphygmomanometer
placed on the arm with the blood sampling intravenous cannula. Blood
samples were taken immediately before cuff inflation for BP measurement.
Heart rate was recorded from the ECG monitor. Blood samples for
measurement of plasma NA and All were taken during the last minute of
each infusion increment.
All data were analysed by two way analysis of variance (ANOVA) to
look for a significant effect of NA, a significant effect of All and a
significant synergistic interaction between NA and All.
Results
The 24 hour urinary sodium excretion (mmol/24 h) was similar on all
four study days, i.e. 173+/-79 on the dextrose/saline day, 144+/-31 on the
All/saline day, 186+/-66 on the dextrose/NA day and 168+/-13 on the
AII/NA day.
Figure 3.2 shows the systolic BP (SBP) data. Despite 20 min initial
supine rest, SBP still fell throughout the 90-min study period. In the
presence of All alone, SBP rose at the end of the study period but overall
All had no statistically significant effect on SBP (ANOVA). On the other
hand, the stepwise infusion of NA did significantly (P<0.05, ANOVA)
increase SBP. Of major interest, however, is that there was a statistically








Figure 3.3 shows the diastolic BP (DBP) data. This differs markedly
from the SBP data. All alone did significantly (P<0.05, ANOVA) increase
DBP. The stepwise infusion of NA also increased DBP significantly.
However, there was no statistically significant interaction between All and
NA in the DBP data. Indeed it is clear from fig. 3.3 that the DBP
response to AII/NA was merely additive, i.e. the response to All and NA
together could be predicted by summing the response to NA and the
response to AIL
Figure 3.4 shows the HR data. All had no statistically significant
effect on HR while the stepwise infusion of NA produced a statistically
significant (P<0.05, ANOVA) reflex bradycardia. ANOVA showed that, as
with SBP, there was a statistically significant (P<0.05, ANOVA) synergistic
interaction when NA and All were infused together.
Figure 3.5 shows the mean BP data. Both All and NA increased mean
BP significantly. There was also a significant synergistic interaction with
AII/NA.
Linear regression was performed between the HR response and the
mean BP response to NA for each individual on each study day. Overall
the slope of the HR/mean BP regression line was -0.30+/-0.14 in the
absence of All and was -0.27+/-0.13 in the presence of AIL This difference
was not statistically significant by paired t-test.
Figure 3.6 shows the plasma NA data. Plasma NA did not change on
the placebo or the All only study day. Plasma NA increased in the
expected stepwise fashion during the incremental infusion and there was no
significant difference in the plasma NA response whether All was infused
or not. The third infusion rate in this study produced the kind of plasma
NA levels which are found in normal volunteers performing bicycle exercise
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(Struthers et al, 1986).
Table 3.1 shows the plasma All results. Clearly plasma All levels
Increased during the infusion of AN and these levels were not affected by
the coincidental infusion of NA. The AII levels produced are within the
physiological range in that salt-deplete individuals usually have higher
plasma AII levels than were generated by these AII infusions.
Figure 3.1
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Legend to figure 3.1
Each volunteer received two concomitant Infusions of an incremental
noradrenaline infusion (or placebo) and a constant rate infusion of
angiotensin II (or placebo).
There were therefore four separate study days with the listed combinations
of infusion being given in a single blind randomised fashion.
Figure 3.2
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Legend to figure 3.2
Change in systolic blood pressure (BP, mmHg) in 10 normotensive
volunteers during the infusion of placebo, angiotensin II (All), noradrenaline
(NA) or AII/NA. See text for details. Two way ANOVA showed that All
had no significant effect while NA did significantly increase systolic BP.
There was also a significant synergistic interaction with AII/NA (ANOVA).




Legend to figure 3.3
Change in diastolic blood pressure (BP, mmHg) in 10 normotensive
volunteers during the infusion of placebo, angiotensin II (All), noradrenaline
(NA) or AII/NA. See text for details. Two way ANOVA showed that both
All and NA increased diastolic BP significantly while there was no




Legend to figure 3.4
Change in heart rate (beats/min) in normotensive 10 volunteers during the
infusion of placebo, angiotensin II (All), noradrenaline (NA) or AII/NA. See
text for details. Two way ANOVA showed that All had no significant
effect while NA did significantly decrease heart rate. There was also a
significant synergistic interaction with AII/NA (ANOVA). No individual





Legend to figure 3.5
Change in mean blood pressure (BP, mmHg) in 10 normotensive volunteers
during the infusion of placebo, angiotensin II (All), noradrenaline (NA) or
AII/NA. See text for details. Two way ANOVA showed that both All and
NA increased mean BP significantly. In addition, there was a significant
synergistic interaction with AII/NA (ANOVA). ^<0.05 paired t-test between





Legend to figure 3.6
Plasma noradrenaline (NA, pg/ml) in 10 normotensive volunteers during the




Plasma All levels (pg/ml) [means+/-s.d.] at baseline, at end of first infusion alone
(i.e. dextrose or All), during both infusions (i.e. dextrose or All plus saline or NA)
or at the end of both infusions.
5%D/saline AN/saline 5%D/NA AII/NA
Baseline 12.9+/-10.4 13.4+/-10.6 9.6+/-3.9 10.9+/-6.7
End of first infusion 14.2+/-5.0 26.8+/-12.4 9.2+/-4.3 31.3+/-13.4
alone
During both infusions - - 7.2+/-3.4 28.2+/-8.6
End of both infusions 10.4+/-5.1 39.9+7-36.8 9.2+7-4.1 35.7+7-22.6
All, angiotensin II; NA, noradrenaline; 5%D, 5% dextrose;
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Summary
In this study evidence was sought for a postsynaptic interaction
between All and NA. Ten normotensive volunteers were infused with
dextrose/saline, AN/saline, dextrose/NA or AII/NA in a randomised single
blind fashion. The respective increases in SBP were -4+/-6, -2+/-9, 4+/-6
and 14+/-16 mmHg on respective study days and at comparative time
intervals while the corresponding increases in DBP were 2+/-4, 6+/-7, 9+/-6
and 14+/-8 mmHg. ANOVA confirmed that All and NA had a synergistic
interaction (P<0.05) in elevating SBP while there was merely an additive
effect in elevating DBP. Plasma NA and All levels were unchanged by the
coincidental presence of All and NA, respectively, which excludes a
generalised pharmacokinetic interaction between All and NA. This study
therefore provides support for a postsynaptic AII/NA interaction with






The effect of angiotensin II on renal sodium excretion in man
Introduction
The RAS is crucial for the maintenance of sodium balance (Laragh and
Sealey, 1973). The role of aldosterone in enhancing renal sodium
reabsorption is well recognised (Davis, 1974). Less well established is the
direct effect of All itself on renal sodium handling in man. In experimental
animals, however, there is now a considerable body of evidence to suggest
that physiological levels of All exert a direct antinatriuretic effect, mainly
at the proximal tubule (Johnson and Malvin, 1977; Olsen et al, 1985). A
few studies, using mainly pharmacological doses, have shown that All also
reduces sodium excretion in man (Finnerty et al, 1961; Hollenberg et al,
1976; Usberti et al, 1985). The usual approach to assessing the renal
physiological significance of All in man, however, has been to employ
angiotensin converting enzyme inhibitors. The interpretation of such studies
is difficult because of the enhanced production of other renally active
substances such as prostaglandins and kinins by these drugs (Usberti et al,
1985; McCaa, 1979; Shoback et al, 1983; Swartz and Williams, 1982;
Brunner et al, 1981). ACE inhibitors also reduce aldosterone secretion
which may in itself induce a natriuresis (Shoback et al, 1983). A further
complication in the study of renal sodium handling is the significant
hypotensive response that can be induced by these drugs. Finally, the renal
tubular site of action of All in man, unlike animals, is still not known. In
this study we have therefore investigated the effects of low-dose All
infusion on renal sodium handling in man. The lithium clearance technique
was used as lithium may act as a specific marker for proximal tubular
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sodium handling. In addition, conventional clearance parameters based on
the generation of 'solute free water', were estimated, in parallel, to
independently corroborate the lithium method.
List of abbreviations
These abbreviations are used throughout chapters 4-6 and section three
(discussion):
Ccr» CH20 Cjj, CNa and Cosm, creatinine, free water, lithium, sodium
and osmolar clearances respectively; FDD, fractional distal delivery; FEfvja
and FEjj, fractional excretion of sodium and lithium, respectively; FRD^,
fractional reabsorption of sodium by the distal nephron; GFR, glomerular
filtration rate; absolute reabsorption of sodium by the distal
nephron; Uosm, urinary osmolality.
Methods
Six salt-replete male normal volunteers aged 20-37 years (mean 24
years) were studied on two separate occasions at least one week apart.
Volunteers attended the clinical laboratory at 08.30 hours on the morning
of the study. All had fasted (food and drink) from 22.00 hours the previous
evening. Each volunteer ingested 500mg of lithium carbonate at 22.00 hours
at the beginning of their fast before the study day.
Subjects were seated and an intravenous cannula was placed in each
antecubital fossa at the start of the experiment. A steady state water
diuresis was established over a period of 2 h (six 20 min urinary clearance
periods, as described in general methods). After a further two clearance
periods (clearance periods A and B), an intravenous infusion of either
carrier [30 ml of 5% dextrose](placebo day) or All (1 ng/kg/min), in 30 ml
of carrier, was commenced (i.e. at the start of clearance period C) and
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continued for 20 min. Urine was collected at the end of clearance periods
A and B, at the end of the infusion period (C), and for two further periods
(D and E). The order of the infusions was random and single blind.
Venous blood (35 ml) was collected 12 min into each of the two
clearance periods before infusion (periods A and B), during the infusion
period (period C) and during the two clearance periods after the infusion
(periods D and E). Samples were aliquoted for measurement of plasma All,
plasma aldosterone and creatinine, osmolality and electrolytes. Two 20 ml
urine aliquots were taken at the end of each urinary clearance period.
Osmolality was measured on the experimental day and the remaining
aliquot was preserved at -20 C for later electrolyte and creatinine
measurement.
Analysis
All parameters after infusion (clearance period C) were compared
with the pre-infusion baseline period (period B) by Student's t-test for
paired samples. A P value of <0.05 was considered to represent a
statistically significant difference. Data are presented as means+/-sem.
Results
Twenty-four hour sodium excretion before the placebo day was 187+/-
28 mmol and 177+/-17 mmol on the All day. The serum lithium levels on
the two experimental days were 0.19+/-0.01 and 0.20+/-0.01 mmol/1,
respectively. Sitting blood pressure did not change on either study day
(table 4.1).
UOSm was mosmol/kg in all subjects on both study days and did
not change significantly during either experiment. Urinary flow rate and
sodium excretion on the two experimental days are shown in fig. 4.1. FDD
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and FEj^j are shown in fig. 4.2 Urinary potassium excretion (Uj^Vj, Cq.,
RDj^g, FRD^a and FEj^a are shown in table 4.1.
There was no significant change in any parameter on the placebo day.
Urinary flow rate and absolute and fractional sodium excretion fell
significantly after infusion of AIL Potassium excretion declined though this
decrease just failed to reach statistical significance. Both parameters of
proximal tubule function investigated, FE^j and FDD, also declined sharply
during infusion of All, suggesting that All enhanced proximal tubular
sodium reabsorption. RDj\ja fell significantly during infusion of All, although
FRDNa was unchanged (Table 4.1). For all secretory parameters the onset
of action was rapid and all values rose quickly back towards baseline after
cessation of the All infusion. All and aldosterone levels on each of the 2
study days are shown in Table 4.1. Basal levels of both hormones were
higher than most quoted ranges for normal resting subjects in the supine
position but our volunteers were studied sitting and stood every 20 min to
void, both of which will tend to increase All and aldosterone levels. All
levels rose in all subjects during infusion though the peak value remained
well within the physiological range. Aldosterone levels rose during the
infusion of All but did not reach a peak until the post infusion period D.
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TABLE 4.1
Mean arterial pressure, urinary potassium excretion (U^V), C0 FENa> RDNa'
FRDjyjg, aldosterone levels and All levels on each of tne two study days.
Urinary clearance periods A and B represent baseline periods, period C is the period
of the infusion and periods D and E are recovery periods.
Urinary clearance period
Study day A B C D E
MAP (mmHg)
Placebo 88+/-4 86+/-4 84+/-4 84+/-4 89+/-4
All 82+/-3 87+/-3 87+/-4 85+/-2 51+1-5
Ui^V (umol/min)
Placebo 45+/-9 46+/-8 41+/-5 48+/-5 45+1-5
All 43+/-5 44+/-5 45+1-5 44+1-1 45+1-5
C^j. (ml/min)
Placebo 114+/-5 109+/-4 113+/-3 111+/-3 108+/-3
All 103+/-3 111+/-3 113+/-3 112+/-3 110+/-4
fen <%)
Placebo 0.85+/-0.33 0.83+/-0.30 0.75+/-0.24 0.72+/-0.23 0.75+/-0.29
All 0.88+/-0.20 0.74+/-0.20 0.56+/-0.17** 0.69+/-0.24 0.72+/-0.25
RDkt (mmol/min)
Placebo 4.48+/-0.55 4.48+/-0.29 4.53+/-0.35 5.14+/-0.76 4.38+/-0.37
All 3.86+/-0.35 3.86+/-0.38 3.25+/-0.39* 3.88+/-0.49 3.83+/-0.25
frdKP (%JPlacebo 96.7+/-0.5 97.3+/-0.4 97.5+/-0.3 97.8+/-0.4 97.4+/-0.3
All 96.7+/-0.5 97.1+/-0.3 97.5+/-0.3 97.4+/-0.3 97.6+/-0.2
Aldo (pg/ml)
Placebo 158+/-25 166+/-25 187+/-29 169+/-29 -
AN 194+/-32 238+/-32 281+/-49 292+/-32 -
All (pg/ml)
Placebo 29+/-5 30+/-3 30+/-4 25+1-5 -
All 24+/-3 30+/-6 48+/-9** 31+/-4 -
MAP, mean arterial pressure; Aldo, aldosterone. All values are means+/-sem.





























Legend to figure 4.1
Urinary flow rate (V) and urinary sodium excretion (UjvjgV) on each of the
two study days. Each bar represents a 20 min clearance period. The
horizontal arrow indicates the duration of the infusion period. Results are
mean+/-sem. Statistical significance: * P<0.01 vs period B. Placebo and All
indicate placebo or angiotensin II infusion days respectively.
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Figure 4.2


































Legend to figure 4.2
FEj j and FDD on each of the two study days. Each bar represents a 20
min clearance period. The horizontal arrow indicates the duration of the
infusion period. Results are mean+/-sem. Statistical significance: * P<0.01




Angiotensin II (All; 1 ng/kg/min) or 5% dextrose (placebo) was infused
in six normal male volunteers, pretreated with 500 mg of lithium
carbonate, who were undergoing maximal water diuresis. This dose of All
caused a circulating increment in plasma All within the physiological range
(27+/-4 to 48+/-9 pg/ml).
Compared with placebo, All caused a significant fall in urinary
sodium excretion (113+/-13 to 82+/-10 umol/min). This antinatriuretic effect
occurred without a fall in creatinine clearance (107+/-3 versus 113+/-3
ml/min).
All caused a significant fall in fractional lithium clearance (28+/-2 to
23+/-1 %). This may indicate a proximal tubular effect of AIL All also
reduced fractional distal delivery [(sodium clearance plus free water
clearance) divided by creatinine clearance], another measure of proximal
tubular outflow. A parallel change in these two separate markers of
proximal function supports an action of AN at this nephron segment.
Furthermore, the antinatriuretic effect of All was unlikely to be due
to stimulation of aldosterone secretion because (a) the fall in sodium
excretion was temporally dissociated from the rise in aldosterone secretion,
(b) potassium excretion also tended to fall during All infusion and (c)
aldosterone has a distal nephron effect, while, in this study, proximal
nephron fractional reabsorption of sodium increased and distal nephron
fractional reabsorption of sodium was unchanged.
These observations suggest that physiological increments in All can
have an antinatriuretic effect in man, which, at least initially, results from







The effect of noradrenaline on renal sodium excretion in man
Introduction
In recent years evidence has accumulated to suggest that the renal
SNS is an important regulator of sodium excretion (DiBona, 1977; Gill,
1979). SNS activity consists of two components, localised synaptic NA
release and spillover into the general circulation. Lately it has been
suggested that small increments in circulating NA are capable of a
systemic haemodynamic effect. Two studies have shown that infusion of
physiological doses of NA increases blood pressure and reduces heart rate
in supine resting subjects (Izzo, 1983; Scriven et al, 1983). This study
examines the question of whether similar increments in circulating NA
influence renal sodium handling in man.
Methods
Nine normal volunteers (aged 19-37 years, mean 25 years) were
examined on two separate occasions at least one week apart. Volunteers
attended the clinical laboratory at 08.30 hours on the morning of the
study. All volunteers were salt-replete as assessed by timed urine
collections (mean +/-sem 24-h sodium excretion 185+/-21 mmol). All had
fasted (food and drink) from 22.00 hours the previous evening. Seven of the
volunteers ingested 500mg of lithium carbonate (Camcolit, Norgine,
Oxford,UK) at 22.00 hours, the beginning of their fast before the study day
(the other two volunteers had no lithium on either study day).
Subjects were seated and an intravenous cannula was placed in each
antecubital fossa at the start of the experiment. A steady state water
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diuresis was established over a period of 2 h (six 20 min urinary clearance
periods, as described in general methods). A further 20 min period was
taken as baseline (period A) after which an infusion of NA at 25 ng/kg
/min in 5% dextrose vehicle, or vehicle solution only (placebo), was
commenced and continued for another four urinary clearance periods, B-E
(i.e. until the end of the experiment). The order of these infusions was
random and their administration single blind.
Blood samples for measurement of plasma All, NA, aldosterone and
serum electrolytes and creatinine, were taken 12 min into the baseline
period (period A), during the first infusion period (B) and during the third
infusion period (D). An aliquot of urine was collected for measurement of
creatinine and electrolyte.
Analysis
The haemodynamic and urinary data (the latter logarithmically
transformed) were analysed by repeated measures analysis of variance
(SPSS). This analysis examined the effect of time (periods A-E), treatment
(placebo, NA) and treatment over time. Where a significant (P<0.05)
treatment/time interaction was identified individual time points were
compared by paired t-test. Plasma NA, All and aldosterone levels were
compared to basal levels on each of the 2 study days by paired t-test.
Results
Baseline sodium excretion (+/-sem) on the placebo and NA study days
was not significantly different (116+/-13 and 142+/-19 pmol/min,
respectively). Creatinine clearance was also similar on the two study days
(Table 5.1). Lithium clearance was 25.8+/-2.6 ml/min on the placebo day
and 28.1+/-2.6 ml/min on the NA day (not significant). Heart rate, blood
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pressure, plasma NA, All and aldosterone levels for the 2 study days are
shown in Table 5.1. There was no significant haemodynamic changes during
the infusion of NA. The infusion increased plasma levels of NA (P<0.01)
but there was no significant changes in circulating aldosterone or AIL
The change in sodium excretion from baseline during infusion of
placebo, or NA, is shown in fig. 5.1. Sodium excretion declined with time
but there was also a significant treatment/time interaction (ANOVA,
P<0.01). Paired t-tests showed a significant (P<0.01) difference between
placebo and NA for periods D and E. Creatinine clearance did not change
significantly with time and there was no difference between treatment
days. Lithium clearance declined on the NA day compared to the placebo
day (ANOVA, 0.01 <P<0.02). Paired t-tests showed that this difference was




Sitting haemodynamic, hormonal and creatinine clearance measurements for
























































Means +/- sera. SBP= systolic blood pressure; DBP= diastolic blood pressure;
HR= heart rate; Cq = creatinine clearance; NA= noradrenaline; P= placebo;
AII= angiotensin; ALDO= aldosterone.
A= baseline and B-E= periods of measurement.















































Legend to figure 5.1
Change in sodium excretion (Uj\jaV) from baseline (A) on placebo day and
NA day for periods B-E. The change in lithium clearance (CLi) from
baseline is shown in the same format on the lower part of the figure. Bars




Low-dose (25 ng/kg/min) NA infusion, resulting in a physiological
plasma increment (280 pg/ml), was antinatriuretic in normal salt-replete
male subjects. The reduction in sodium excretion (-20%, P<0.01) occurred
without any change in the glomerular filtration rate but was associated
with a significant (P<0.02) decline in lithium clearance. These results
suggest that changes in circulating NA, within the physiological range, can
decrease sodium excretion in man by enhancing proximal tubular
reabsorption. These findings extend previous investigations in man which
used pharmacological doses of NA and are in agreement with animal







The effect of angiotensin II and noradrenaline alone and in combination on
renal sodium excretion in man.
Introduction
The independent role of the renal sympathetic nervous system (SNS)
on sodium excretion has also been established (DiBona, 1982) and studied
further in chapter five. However, AII/NA facilitation has been clearly
demonstrated for the vascular tree in animals but experimental work also
suggests that All can modulate the effect of the SNS on renal function.
Investigation of a possible interaction between the RAS and SNS on sodium
excretion in rats showed that renal nerve induced antinatriuresis and
antidiuresis required the presence of All, suggesting it may perform a
facilitatory role at the level of the renal tubules (Handa and Johns, 1987;
Johns, 1987a). All may also modulate the effect of renal nerve stimulation
at the glomerulus (Pelayo et al, 1984). Furthermore the effect of renal
sympathetic activity in experimentally induced heart failure may in part be
due to an interaction with the RAS (Kon et al, 1985; Ichikawa et al,
1987). Such an interaction may be of importance in the altered renal
function of cardiac failure in man, in which both the RAS and the SNS are
activated (Curtiss et al, 1978; Dzau et al, 1981). We studied a possible
interaction between the RAS and the SNS on sodium excretion in man by
the infusion of low doses of All and NA alone and in combination.
Methods
Seven male normal volunteers (mean age 25, range 20-37) were
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studied on four separate occasions 5-8 days apart. Volunteers attended the
clinical laboratory at 08.30 hours on the morning of the study. All had
fasted (food and drink) from 22.00 hours the previous evening. They were
seated and an intravenous cannulae placed in veins in both forearms. A
steady state water diuresis was established over an equilibration period of
2 hours (six 20 min clearance periods, as described in general methods).
After a further clearance period (clearance period A) an intravenous
infusion of either placebo (P - 5% dextrose) or NA (25 ng/kg/min in 5%
dextrose) was commenced and infused in a volume of 1.0 ml/min
throughout the rest of the study (clearance periods B-E). After a further
clearance period (period B) a second infusion of either placebo (P - 5%
dextrose) or All (1 ng/kg/min) was given for one 20 minute clearance
period (period C) in a volume of 2.0 mls/min, after which it was
discontinued. The infusions were given in randomised single blind fashion.
Urine samples were obtained at the end of all clearance periods (A-E).
Venous blood (35 mis) was sampled during the 12th minute of each
collection period A-E. Each sample was aliquoted into four for
measurement of plasma NA, All, aldosterone and finally creatinine,
osmolality and electrolytes.
Analysis
The results for change over time and effect of NA were analysed by
linear regression analysis (Wallenstein et al, 1980). This analysis takes
account of the development of an effect of NA over time which would
bias any estimate of the effect of All calculated as the difference
between the value in the All infusion period and either the previous or
succeeding period. To minimise such bias, regression analysis was used to
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fit a time trend for each subject, using the data from the two periods
prior to All infusion and the two periods after infusion. The value
corresponding to the All infusion period was not used in the estimation of
the time trend. The effect of All for each subject was taken to be the
proportionate reduction from the value predicted by the time trend for the
All infusion period, using the actual value at the time of All infusion to
estimate the proportionate reduction. Similarly the placebo arms of the
study were analysed by linear regression analysis to take account of change
over time and allow a valid assessment of the time trend caused by the
administration of NA by comparison with the time trends when NA was
not administered. The effect of All is expressed as a percentage change
with confidence intervals for the percentage changes coincident with the
period of All infusion. Blood pressure, heart rate, creatinine clearance and
plasma hormone levels were analysed by repeated measures analysis of
variance (MANOVA) and subsequent paired t-testing where significant
differences were indicated by MANOVA (Nie et al, 1975).
Results
Twenty four hour sodium excretion and baseline sodium excretion
(Period A) were not significantly different for any of the four study days
(155+/-19; 148+/-19; 167+/-22 and 192+/-41 mmol/24hours for P/P; P/AII;
NA/AII and NA/P days respectively). Urinary osmolality was below 64
mosm/kg in all subjects on all study days. This confirms suppression of
endogenous vasopressin. Creatinine clearance was similar on all study days
and was not changed by infusion of All, NA or the combination of NA/AII
(table 6.1). Heart rate and mean blood pressure also did not change on any
study day (table 6.1). Plasma All, aldosterone and NA levels are shown in
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table 6.2. Plasma AN rose significantly during exogenous All infusion on
both the P/AII study day and on the NA/AII study day. There was no
significant difference in the plasma All data between the P/AII and the
NA/AII days. Plasma NA rose significantly during NA infusion, with no
significant difference between the NA/P and the NA/AII days. Plasma NA
did not change significantly on P/P or P/AII days. Plasma aldosterone rose
significantly on P/AII and NA/AII days, reaching highest levels in period D,
after All infusion had finished (period C). There was no significant
difference between P/AII and NA/AII days and no significant change on
P/P and NA/P days.
Changes in absolute sodium excretion (U]\jaV) are shown in figure 6.1.
The results of time trend analysis for change over time (placebo day) and
effect of NA over time with respect to Uj^gV, urinary flow rate (UV),
fractional sodium excretion (FE^g) and absolute potassium excretion (U^-V)
are shown in table 6.3(a). The changes in U^gV, UV, FE^g and Uj^V
caused by All infusion are shown in table 6.3(b).
There was a small fall in UV with time on the P/P study day
(p<0.02). U^gV, FEj^g and Uj^V did not change significantly on the P/P
study day. NA infusion (P/NA study day) caused reductions in Uj^gV
(p<0.02), FE^g (p<0.01), UV (p<0.02) and a small but non significant fall in
Uj^V. All caused a 37% reduction in UjvjaV on the P/AII study day and 32%
reduction during concomitant NA infusion (NA/AII day). All also caused
significant falls in UV and FEj^g on both study days with no difference in
the presence of NA infusion. There was no significant effect of All on








































Legend to figure 6.1
Mean change in absolute sodium excretion +/- s.e.m. (pmol/min).
(a) Placebo/Placebo (b) Placebo/Noradrenaline (c) Placebo/Angiotensin II and
(d) Noradrenaline/Angiotensin II, where placebo = 5% dextrose infusion,
Angiotensin II = infusion at lng/kg/min and Noradrenaline = infusion at
25ng/kg/min. The horizontal bar represents the period over which placebo
or noradrenaline was infused. The vertical broken-line box the period in
which placebo was given and the hatched vertical box represents the period
in which All was given, as the second infusion.
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TABLE 6.1
INFUSION URINARY COLLECTION PERIOD
COMBINATION A B C D E
MEAN BP P / P 88+/-4 86+/-4 86+/-4 84+/-4 89+/-4
(mmllg) NA/ P 88+/-3 87+/-4 86+/-3 89+/-3 85+/-4
P /All 82+/-3 87+/-3 87+/-4 85+/-2 87+/-3
NA/AII 86+/-3 91+/-5 91+/-3 90+/-3 94+/-3
HEART RATE P / P 65+/-3 64+/-3 66+/-4 68+/-3 69+/-4
(beats/min) NA/ P 61+/-3 61+/-3 61+/-2 62+1-2 62+/-3
P /AN 64+/-4 62+/-4 63+/-4 68+/-5 65+/-6
NA/AII 65+/-4 64+/-2 62+/-2 64+/-2 66+/-3
CREATININE P / P 113+/-6 109+/-4 113+/-3 108+/-6 109+/-3
CLEARANCE NA/ P 112+/-5 111+/-4 111+/-3 108+/-4 109+/-3
(mls/min) P /All 101+/-3 107+/-3 110+/-4 107+/-4 107+/-4
NA/AII 109+/-5 109+/-2 112+/-4 106+/-3 109+/-7
Table legend
Mean blood pressure (BP), heart rate and creatinine clearance for consecutive
collection periods A-E. All results are expressed as mean +/- standard error. P =
Placebo infusion (5% dextrose), All = Angiotensin II infusion (1 ng/kg/min) and
NA = noradrenaline infusion (25 ng/kg/min).
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TABLE 6.2
INFUSION URINARY COLLECTION PERIOD
COMBINATION A B C D
An P / P 31+/-3 31+/-3 31+/-3 35+/-3
(pg/ml) NA/ P 34+/-5 31+/-4 29+/-3 30+/-4



















Noradrenaline P / P 495+/-71 533+/-84 530+/-64 577+/-109
(pg/ml) NA/ P 552+/-27 821+/-77++ 616+/-59+ 826+/-52++
p /An 469+/-66 491+/-74 482+/-52 529+/-44
NA/AII 536+/-63 898+/-106++ 845+/-121+ 845+/-109++
Table legend
Plasma angiotensin II, aldosterone and noradrenaline levels during urinary
collection periods A-D. All results are expressed as mean +/- standard error. P
= Placebo infusion (5% dextrose), All = Angiotensin II infusion (1 ng/kg/min) and
NA = noradrenaline infusion (25 ng/kg/min). * = p<0.05, ** = p<0.01, + = P<0.005
and ++ = p<0.001 (by paired t-testing with period A for any given study day in
which a significant treatment by time effect was shown by MANOVA)
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TABLE 6.3(a) Results of time trend analysis.
UNaV UV FENa uKv
Slope P< Slope P< Slope P< Slope P<
P / P -3.40 NS -0.29 0.02 -0.12 NS +0.37 NS
NA/ P -8.74 0.02 -0.54 0.01 -0.54 0.02 -2.36 NS
Mean slope of regression analysis (see Methods for description of
analysis).
TABLE 6.3(b) Effect of Angiotensin II
UNaV UV FENa UKV
P /All -37 -10 -20 -11
(-24 to-50) (-2 to -18) (-2 to -38) (0 to -21)
NA/AII -32 -9 -17 -6
(-23 to-41) (-3 to -15) (-5 to -30) (+5 to -17)
Mean change as percentage and 95% confidence interval
Table legend: (a) Results of regression analysis and (b) effect of Angiotensin II.
P = Placebo infusion (5% dextrose), All = Angiotensin II infusion (1 ng/kg/min)
and NA = noradrenaline infusion (25 ng/kg/min), Uj\jaV= absolute sodium
excretion, UV= urinary flow rate, FEjSja= fractional sodium excretion and UKV=
absolute potassium excretion. NS = non-significant.
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Summary
This study sought to investigate the possible interaction of
physiological doses of All and NA on sodium excretion in man. Seven
normal volunteers were studied on four occasions during maximum water
diuresis sustained by oral hydration. Samples were obtained during a
baseline and four subsequent 20 minute periods (A-E). Placebo or NA was
infused over periods B-E, and placebo or All infused over period C.
There was no change in systemic blood pressure, heart rate or
creatinine clearance caused by infusion of either All, NA or both in
combination. Noradrenaline alone caused a significant fall in absolute and
fractional sodium excretion. All when infused with placebo caused a 37%
fall in absolute sodium excretion and a 32% fall when infused with NA (no
significant difference between the two days). Similar changes were seen for
urinary flow and fractional sodium excretion.
We have therefore found no evidence to support a postsynaptic






The effect of angiotensin II on the stroke volume response to beta-agonism
in man
Introduction
The data described in chapter three show that when NA and All are
infused coincidentally into normal man, there is a synergistic augmentation
of the systolic blood pressure response but this did not occur with diastolic
blood pressure. The fact that this was limited to systolic pressure suggests
that this NA/AII interaction occurs at an intrathoracic or myocardial level
rather than in the peripheral vasculature.
Recently Stokland et al (1986) have described an animal experiment
which may explain the mechanism for this effect. In dogs, during
isoprenaline (ISO) infusion All was found to relocate venous blood from the
liver and spleen to the heart hence increasing filling pressure and therefore
cardiac output (CO). We were interested to perform the analogous human
experiment including a non-invasive measure of stroke volume to seek
evidence for a similar effect in man.
Methods
Ten normal volunteers (8 male and 2 female, mean age 24 years,
range 20-33 and mean weight 70 kg, range 56-87.5 kg) were studied on
four separate occasions a minimum of 5 days apart. Subjects attended the
clinical laboratory at 08.30 hours or 13.00 hours and were studied at the
same time on all four days. They were positioned supine and intravenous
cannulae placed in veins in both forearms. After 30 minutes of supine rest
an infusion of either All (2ng/kg/min) or placebo (PL, 5% dextrose) was
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commenced and infused in a volume of 0.5 mls/min throughout the rest of
the study. After a further 15 minutes an incremental infusion of placebo
(PL, 5% dextrose) or ISO (Saventrine, Pharmax Ltd., Kent, UK.) was
commenced at 0.25 mcg/min and increased at 10 minute intervals to 0.5,
1.0 and 2.0 mcg/min. The infusions were given in randomised single blind
fashion. Blood pressure and heart rate were recorded semi-automatically
every five minutes throughout each experiment. The values recorded at the
end of the rest period, at the end of the All or placebo alone period and
at the end of each ISO infusion period were used for statistical analysis.
The ECG was monitored continuously on an ECG oscilloscope. Cardiac
output was measured at the end of the rest period, at the end of the All
or placebo alone period and at the end of each ISO infusion period by a
non-invasive acetylene rebreathing technique. Blood samples were taken and
divided into three aliquots for later analysis of plasma All, plasma NA and
plasma atrial natriuretic peptide (ANP).
Results were analysed by repeated measures analysis of variance
(MANOVA, SPSS/PC+) to examine the effect of dual placebo infusion,
treatment (dual placebo vs. All and dual placebo vs. ISO) and for an
interaction between treatments. In considering the interaction term the
change due to ISO in the presence of PL or All infusion was obtained by
using each subjects responses on the dual PL and PL/AII days respectively
as control. The data were thus considered as change produced by ISO (a) in
the presence of placebo as [ISO/PL - PL/PL] and (b) in the presence of All
as [All/ISO - AII/PL] for all parameters in each individual. These two
changes (a) and (b) were then compared by ANOVA for repeated measures.
A p-value of <0.05 was considered significant.
All subjects noticed tachycardia during ISO infusion regardless of
whether PL or All was being infused simultaneously. No subject reported
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any unpleasant side effect during any infusion or combination of infusions.
One subject developed asymptomatic ventricular premature beats at the
highest dose of ISO on the PL/ISO day.
Results
The data for SV are shown in figure 7.1 and Table 7.1. There was no
significant change in SV over the dual placebo day nor with All infusion
alone (ANOVA). ISO caused an 11-20% rise in SV which did not reach
significance. But of major interest is that the combination of All and ISO
caused a significant 31-55% rise in SV (p<0.01), and considering the
interaction term (see methods) this rise in SV was significantly greater
than with ISO confirming an All/ISO interaction with regard to increase in
SV (p<0.02).
Figure 7.2 shows the data for TPR. This contrasts with the SV data.
There was no effect of infusion with dual placebo, but All alone caused a
significant rise in TPR (p<0.05, figure 7.2 and table 7.2). ISO alone caused
a dose dependent fall in TPR (p<0.001). Of interest, however, with the
combination of All/ISO is that the expected dose dependent fall in TPR
with ISO was unaffected by concomitant AII infusion. Considering the
interaction term (see methods) the difference in response to ISO and the
All/ISO combination (illustrated in figure 7.2) was highly significant
(p<0.01).
The CO data are given in Table 7.1. Neither dual placebo nor AII
alone caused significant change in CO. ISO produced a dose dependent
increase in CO (p<0.001), and the combination of All and ISO produced a
further increase in CO that just failed to reach significance (p=0.065). The
HR data is given in table 7.1. Neither dual placebo nor All alone caused
significant change in HR. ISO produced a dose dependent increase in HR
(p<0.001), but there was no significant interaction between All and ISO.
The blood pressure data are given in Table 7.2. There was no effect
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of dual placebo Infusion, but All alone produced a significant rise in SBP
(p<0.01) which did not change with time. ISO produced a significant dose
dependent rise in SBP (p<0.001). However there was no interaction between
All and ISO in the SBP data. There was no effect of dual placebo infusion
on DBP, but All alone caused a significant rise in DBP (P<0.002). ISO
caused a significant fall in DBP (p<0.001). There was, however, no
interaction between All and ISO in the DBP data.
The results of plasma All analysis are given in Table 7.3(a). There
was no significant change in plasma All with time on the dual placebo day.
Infusion of All caused a significant rise in plasma All (p<0.001). ISO alone
had no significant effect on plasma All and there was no interaction
between All and ISO in the plasma All data. The results of plasma NA
analysis are given in Table 7.3(b). There was no significant change on the
dual placebo day. The mean resting supine plasma NA levels for the four
study days varied between 395 to 440 pg/ml which is in the normal range
for our assay and are the same as in many previous studies with this assay
(chapter three; Brown et al, 1985; Becker et al, 1986; Struthers et al,
1986). All infusion did not affect plasma NA levels. ISO produced a small
rise in plasma NA levels, but there was no significant interaction between
All and ISO in the NA data. ISO induced increases in plasma NA have
been reported before and are thought to be due either to baroreflex
activation or to ISO stimulating presynaptic beta-adrenoceptors (Vincent et
al, 1982). The results of plasma ANP analysis are given in table 7.3(c).
ANP levels did not change on the dual placebo day, nor during infusion of
All alone or ISO alone. There was a rise in plasma ANP when both All and


























Legend to figure 7.1
Stroke volume in mis. All = angiotensin II (2ng/kg/min), PL = placebo (5%
dextrose) and ISO = isoprenaline (0.25-2 mcg/min). Horizontal axis
represents dose of isoprenaline or placebo as indicated. Results expressed




















Dose of Isoprenaline (/jg/min)
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Legend to figure 7.2
Total peripheral resistance in dyne.sec.cm"^. All = angiotensin II
(2ng/kg/min), PL = placebo (5% dextrose) and ISO = isoprenaline (0.25-2
mcg/min). Horizontal axis represents dose of isoprenaline or placebo as




HAEMODYNAMIC RESPONSES TO ISOPRENALINE INFUSION IN THE PRESENCE OF
ANGIOTENSIN II OR PLACEBO INFUSION
Resting 0





All/ISO 94+/-10 108+/-11 141+/-18 144+/-19 147+/-14 134+/-16 p<0.01
AII/PL 106+/-11 107+/-11 107+/-11 98+/-10 95+/-10 94+/-7 NS
PL/ISO 108+/-12 113+/-11 127+/-9 130+/-11 133+/-10 118+/-11 NS
PL/PL 109+/-9 110+/-8 109+/-8 108+/-8 117+/-10 106+/-11 NS
Cardiac Output (1/min)
All/ISO 6.0+/-0.5 6.1+/-0.4 8.3+/-0.8 9.0+/-0.9 10.6+/-0.7 11.3+/-0.8 p<0.001
AII/PL 6.1+/-0.7 6.1+/-0.5 5.9+/-0.5 5.6+/-0.4 5.3+/-0.3 5.5+/-0.3 NS
PL/ISO 6.3+/-0.7 6.4+/-0.6 7.9+/-0.5 8.9+/-0.6 10.1+/-0.8 10.9+/-0.8 p<0.001
PL/PL 6.5+/-0.6 6.6+/-0.5 6.5+/-0.5 6.4+/-0.5 6.5+/-0.5 6.2+/-0.7 NS
Heart Rate (beats/mln)
All/ISO 59+/-2 59+/-3 62+/-3 65+/-3 74+/-3 89+/-5 p<0.001
AII/PL 58+/-2 58+/-2 56+/-2 59+/-3 57+/-2 60+/-3 NS
PL/ISO 60+/-3 58+/-2 63+/-2 69+/-3 77+/-3 94+/-3 p<0.001
PL/PL 60+/-3 60+/-2 60+/-2 59+/-2 56+/-2 58+/-2 NS
All = angiotensin II infusion (2ng/kg/min), ISO = isoprenaline infusion,
PL = placebo infusion (5% dextrose).
All results are expressed as mean +/- s.e.m. NS = not significant.
Sign, by ANOVA = significance by ANOVA for repeated measures within study day
for dual placebo (PL/PL) and for each other study day vs. dual placebo (see Methods)
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Table 7.2
HAEMODYNAMIC RESPONSES TO ISOPRENALINE INFUSION IN THE PRESENCE
OF ANGIOTENSIN II OR PLACEBO INFUSION
Resting 0
























Systolic Blood Pressure (mmHg)
120+/-3 126+/-3 130+/-3 136+/-4
126+/-2 124+/-3 128+/-3 126+/-3
118+/-3 121+/-2 127+/-3 134+/-3
120+/-1 118+/-2 119+/-2 116+/-2
Diastolic Blood Pressure (mmHg)
10+1-2 66+/-2 65+/-2 61+/-2
71+/-1 12+1-2 73+/-1 70+/-1
65+/-2 63+/-3 60+/-2 60+/-2
64+/-2 63+/-2 63+/-2 63+/-2
Total Peripheral Resistance (dyn.s/cm^)
1170+/-70 925+/-120 834+/-88 679+/-57
1231+/-85 1293+/-109 1361+/-97 1400+/-87
1115+/-108 861+/-57 770+/-56 697+/-54
























All = angiotensin II infusion (2ng/kg/min), ISO = isoprenaline infusion,
PL = placebo infusion (5% dextrose).
All results are expressed as mean +/- s.e.m. NS = not significant.
Sign, by ANOVA = significance by ANOVA for repeated measures within study day
for dual placebo (PL/PL) and for each other study day vs. dual placebo (see Methods)
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Table 7.3(a) PLASMA ANGIOTENSIN II (pg/ml)
Study day Dose of isoprenaline (mcg/ml)
Baseline 0 0.5 2
All/ISO 17+/-3 64+/-6 50+/-7 50+/-7
AII/PL 19+/-2 78+/-8 68+/-7 50+/-7
PL/ISO 18+/-1 19+/-2 18+/-2 27+/-2
PL/PL 19+/-4 18+/-2 18+/-2 20+/-2
Table 7.3(b) PLASMA NORADRENALINE (pg/ml)
Study day Dose of isoprenaline (mcg/ml)
Baseline 0 L0 2.0
All/ISO 429+/-28 432+/-23 487+/-34* 480+/-35
AII/PL 398+/-38 ND ND 397+/-26
PL/ISO 395+/-32 408+/-23 408+/-37 520+/-48't*
PL/PL 440+/-21 ND ND 430+/-20
Table 7.3(c) ATRIAL NATRIURETIC PEPTIDE (pmol/1)
Study day Dose of isoprenaline (mcg/ml)
Baseline 0 0.5 2.0
All/ISO 14+/-2 15+/-2 17+/-4 16+/-4
AII/PL 15+/-2 14+/-2 14+/-2 12+/-2
PL/ISO 14+/-1 13+/-2 13+/-2 13+/-2
PL/PL 14+/-2 15+/-2 14+/-2 14+/-2
All = angiotensin II infusion (2ng/kg/min), ISO = isoprenaline infusion, PL
= placebo Infusion (5% dextrose). ND = not done.
All results are expressed as mean +/- s.e.m.
* = p<0.05 and ** = p<0.01 by paired t-testing after MANOVA revealed a
significant effect of ISO (p<0.001, MANOVA).
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Summary
In this study evidence was sought for an RAS/SNS interaction using
All and beta-adrenoceptor stimulation with ISO. Ten normal volunteers
were infused with placebo/placebo, placebo/AII, placebo/ISO and All/ISO in
a randomised single-blind fashion. ISO alone caused a non-significant 11-
20% rise in SV. All alone caused no significant change in SV. However the
combination of All/ISO caused a significant increase in SV of 31-55%
(p<0.01), and this increase was significantly greater than with ISO alone
(p<0.02 by repeated measures ANOVA). This occurred with no difference in
change of heart rate. ISO significantly reduced total peripheral resistance
and this reduction was not affected by concomitant infusion of AIL This
study provides evidence that a physiological dose of All can synergistically






The effect of angiotensin II on endogenous noradrenaline release in man
Introduction
( ^
In chapter three data was presented supporting a possible post¬
synaptic AII/NA interaction in that All synergistically augments the systolic
blood pressure response to NA. In this study we have now sought evidence
for a presynaptic AII/NA interaction by examining whether exogenous All is
able to enhance the presynaptic release of endogenous NA in response to
physiological stimuli in man. The stimuli were chosen to produce a wide
range of different levels of sympathetic activation.
Methods
Nine normotensive volunteer males were studied (mean age 26 years,
range 19-38 years and mean weight 80 kg, range 67-109 kg). They were
studied on three occasions, the first a pre-study assessment as described
below and two formal study days at least one week apart. The subjects
attended at 09.30 hours after a light breakfast or at 13.30 hours after a
light luncheon. Each individual was investigated at the same time of day
on both study days.
Pre-study assessment: An initial assessment of bicycle workload and
hand dynomanometry was made 7 days before the first study day. Each
subject commenced cycling on a bicycle ergometer (Tunturi, Finland) at a
load of 50 kilopunds and the workload was then increased at one minute
intervals until a heart rate of 130-140 beats per minute was achieved as
recorded by ECG monitor. After a period of 15 minutes rest maximal
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voluntary contraction of handgrip was measured using a hand
dynomanometer.
Formal study days: At the start of the study intravenous cannulae
were inserted into the antecubital vein of each arm, one for infusion and
the other for blood sampling. After 20 minutes supine rest, baseline
recordings of heart rate and blood pressure and blood samples were taken.
Infusion was commenced with either a subpressor dose of All (1.5
ng/kg/min) or placebo (5% dextrose) in a randomised single-blind fashion.
After a further 15 minutes supine rest blood pressure and heart rate
recordings and blood sampling were repeated. Thereafter each subject
underwent a series of standard tests to endogenously stimulate the
sympathetic nervous system. These tests were always administered in the
same order as described below and illustrated in figure 8.1.
Cold pressor test: The subject immersed one foot to the ankle in
melting ice for two minutes. Blood pressure and heart rate were recorded
at 0, 1 and 2 minutes and a blood sample taken at 2 minutes. The subject
then rested in the supine position for a further 15 minutes during which
blood pressure and heart rate were measured every 5 minutes and at the
end of which a blood sample was taken.
Response to standing: Blood pressure and heart rate were recorded
and blood samples taken after two minutes standing erect.
Bicycle exercise: The subject then sat on a bicycle ergometer and
after baseline haemodynamic recordings performed five minutes exercise
at a workload predetermined in each individual at the pre-study assessment
to cause a rise in heart rate to 130-140 beats per minute. The same
workload was used on both study days. Blood pressure and heart rate were
recorded at 2 and 5 minutes of exercise and 1, 2 and 3 minutes after
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exercise. Blood samples were taken during the fifth minute of exercise.
Forearm isometric exercise: Following a further rest period of 15
minutes, baseline haemodynamic recordings and blood samples were taken.
The subject then undertook 3 minutes of forearm isometric exercise when
they maintained 30% of their maximal voluntary handgrip which had
previously been determined at the pre-study assessment. The same workload
was used on both study days. Blood pressure and heart rate were recorded
at one minute intervals during handgrip and blood samples taken after
three minutes.
The results were analysed by two way analysis of variance
comparing responses during placebo infusion with those during All infusion
(Statistical package for the social sciences - Nie et al, 1975). The Duncan
procedure was then used to compare each stimulus pair wise with every
other stimulus (SPSS - Nie et al, 1975).
Results
Table 8.1 shows the initial recordings of blood pressure, heart rate
and plasma NA before and 15 minutes after the start of an All (1.5
ng/kg/min) or a placebo infusion. There were no changes in any of these
observations in response to AII.
The haemodynamic and plasma NA responses to two minutes cold
pressor testing, after two minutes standing from lying, at five minutes
bicycle exercise and at three minutes isometric handgrip are shown in
figure 8.1 and figure 8.2. Two way analysis of variance showed that there
was no overall effect of infusion of AN compared with a placebo infusion
on haemodynamic or plasma NA responses to the physiological stimuli
investigated.
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Since the All study day was not significantly different from the
placebo study day, the Duncan procedure was applied to the data from
both study days to compare the results of each test. The results of this
analysis of haemodynamic and plasma NA responses are shown in Table 8.2.
The haemodynamic data show a significant pressor response to cold
pressor testing, bicycle exercise and forearm isometric exercise and
significant rises in heart rate during standing, bicycle exercise and forearm
isometric exercise. There were significant rises in plasma NA after cold
pressor testing, standing and bicycle exercise. The changes in plasma NA
demonstrated in our study are similar to those shown by other groups
(Robertson et al, 1979; Struthers et al, 1986).
The mean +/- s.e.m. 24 hour urinary sodium excretion (mmol/24 hr)
was 174+/-16 prior to the placebo study day and 201+/-20 prior to the All
infusion study day, which was not significantly different by paired t-
testing. The plasma All levels (Table 8.3) show that there was no
significant difference between the resting levels on the two study days and
no change during placebo infusion but there was a 312% rise in plasma All
levels during the All infusion.
Figure 8.1
PROTOCOL : PRESYNAPTIC STUDY







Legend to figure 8.1
Subjects received an infusion of either a subpressor dose of All (1.5
ng/kg/min) or placebo (5% dextrose) in a randomised single-blind fashion on
either of two separate study days. After a period of rest the subjects
performed a series of standard tests in the following order:
1. Cold pressor test
2. Response to standing
3. Bicycle exercise
4. Forearm isometric exercise


















Legend to figure 8.2
Systolic and diastolic blood pressure responses to physiological stimuli in










Legend to figure 8.3
Heart rate and plasma noradrenaline responses to physiological stimuli in




Systolic and diastolic pressure, heart rate and plasma noradrenaline before and 15
minutes after angiotensin II (1.5 ng/Kg/min) or placebo infusion.
Results are expressed as mean +/- s.e.m. (n=9).
SBP(mmHg) DBP(mmHg) HR(beats/min) NA(pg/ml)
PL All PL All PL All PL All
Before 125+/-4 127+/-4 65+/-3 67+/-3 64+/-3 65+/-4 560+/-60 510+/-20
After 124+/-4 126+/-4 66+/-3 66+/-3 64+/-4 63+/-4 510+/-50 480+/-20
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate,
NA = Noradrenaline. None of the above data are significantly different between
placebo and angiotensin II by ANOVA.
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Table 8.2
Haemodynamic and plasma noradrenaline response to physiological stimuli.
(Mean data only are displayed for clarity. This table includes All pretreatment
and placebo pretreatment days as they were not significantly different from
each other).
SBP(mmHg) DBP(mmHg) HR(beats/min) NA(ng/l)
Control 125 66 64 494
Cold pressor 140 * 79 ** 67 674 *
Standing 124 73 83 ** 654 *
Exercise 159 ** 86 i* 130 ** 1196 **
Handgrip 145 ** 84 ** 77 =t* 537
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart
NA = Noradrenaline. None of the above data are significantly different between
placebo and angiotensin II.
* p < 0.05 }
} represent significant differences from control
** p < 0.01 } values as obtained by the Duncan procedure.
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Table 8.3
Plasma angiotensin II levels (pg/ml) before and after 15 minutes
of placebo Infusion or angiotensin II infusion (1.5 ng/kg/min).
Infusion:
Placebo Angiotensin II
Before CO • CD + I • CO ►—* 0 • CO + 1 • NS




This study sought evidence for an RAS/SNS interaction in man by
examining how a subpressor dose of All (1.5 ng/kg/min) influences the
haemodynamic and plasma NA responses to physiological stimulation of the
sympathetic nervous system. The physiological stimuli investigated were a
cold pressor test, the response to standing from lying, bicycle exercise and
forearm isometric exercise.
The presence of the All infusion had no effect on the systolic blood
pressure, diastolic blood pressure, heart rate or plasma NA responses to
stimulation of the sympathetic nervous system. This study has therefore
found no evidence to support the enhancement of NA release by this low





The effect of angiotensin II on the haemodynamic and plasma noradrenaline
responses to tyramine infusion in man
Introduction
The data presented in chapter eight has shown that a subpressor
infusion of All does not alter the haemodynamic or plasma NA response to
a cold pressor test, standing from lying, bicycle exercise or forearm
isometric exercise. In case the kind of SNS stimulation is a crucial factor,
this study seeks evidence for an AII/NA interaction by examining whether
exogenous All is able to augment the presynaptic release of endogenous NA
in response to infused tyramine (TYR) in normal man.
Methods
Six normotensive volunteers (4 male and 2 female) were studied.
Their mean age was 24 years (range 18-33) and mean weight 70 kg (range
54-87.5 kg). They were studied on four separate occasions at least five
days apart. The subjects attended the clinical laboratory at 09.30 h after a
light breakfast or at 13.30 h after a light luncheon. Each individual was
investigated at the same time of day on all four study days. They were
positioned supine and intravenous cannulae were placed in veins in both
forearms. After 20 minutes of supine rest an infusion of either All
(2ng/kg/min) or placebo (5% dextrose) was commenced and infused at a
constant rate in a volume of 0.5 ml/min throughout the rest of the study.
After a further 20 min supine rest an incremental infusion of placebo (5%
dextrose) or TYR was commenced at 1.25 mcg/kg/min and increased at 10
min intervals to 2.50, 3.75, 5.00, 7.50 and 10.0 mcg/kg/min. The infusions
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were given in randomised single blind fashion. Blood samples were taken
and divided into two aliquots for later analysis of plasma All and plasma
NA.
Results were analysed by repeated measures analysis of variance
(MANOVA, SPSS/PC+) to examine the effect of time, treatments and for
an interaction between treatments. A p-value of <0.05 was considered
significant. Results are given as mean +/- s.e.m. in the figure and tables.
Results
Table 9.1 shows systolic and diastolic pressure and heart rate before
and after the start of an All or placebo infusion. Resting systolic BP,
diastolic BP and heart rate were not significantly different on all four
study days. There were no significant changes in any of these observations
in response to All infusion.
Figure 9.1(a) shows the effect of TYR infusion on systolic and
diastolic BP with concomitant placebo infusion, and figure 9.1(b) shows the
effect of TYR infusion with concomitant All infusion. All alone produced
no significant change in systolic or diastolic BP. TYR alone caused a large
dose-dependent increase in systolic BP (118+/-3 to 138+/-5, p<0.02
MANOVA) and a smaller but significant increase in diastolic BP at the two
highest doses of TYR (p<0.03). When infused together, AII/TYR produced a
similar dose-dependent increase in systolic BP (115+/-2 to 143+/-6, p<0.02)
and a small rise in diastolic BP (65+/-4 to 75+/-5, p<0.03). There was no
significant interaction between All and TYR in either the systolic BP or
the diastolic BP data.
Table 9.2 shows the heart rate data for the four study days. There
was no effect of All alone, TYR alone nor their combination seen in the
heart rate data (MANOVA). Table 9.3(a) shows the plasma All response and
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table 9.3(b) the plasma NA response to infusion. Plasma All levels were no
different at the beginning of the four study days and did not change on
the dual placebo day. Infusion of TYR alone also had no effect on plasma
All levels. Infusion of All caused a significant rise in plasma All (p<0.01)
and this rise was not altered by concomitant TYR infusion. Plasma NA
levels were not significantly different at the start of the four study days.
Neither dual placebo infusion nor All infusion alone caused significant
change in plasma NA levels. TYR alone and the combination of AII/TYR
produced a rise in plasma NA only at the highest dose (p<0.01). Whilst the
plasma NA levels at the highest dose of TYR showed considerable
interindividual variability there was no significant difference depending on
whether All was also present or not, and the plasma NA and
haemodynamic measurements are clearly the same in both TYR treated
groups at the penultimate dose.
Figure1a
Figure1b
HAEMODYNAMICEFFECTOFTYRAMINEINFUS ONHAEMODYNAMICEFFECTFTYRAMINEINFUS ON WITHCONCURRENTPLACEBOINFUSIONWITHONCURRENTA GI E SININFUSION





















Legend to figure 9.1 (a) and (b)
The haemodynamic effect of tyramlne infusion (a) with concurrent placebo
infusion and (b) with concurrent angiotensin II infusion. Angiotensin II was
infused at a constant rate of 2 ng/kg/min. Systolic blood pressure is shown
in the top half of each panel. Diastolic blood pressure is shown in the
bottom part of each panel. Bars represent mean +/- s.e.m.
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Table 9.1
Systolic and diastolic pressures and heart rate before and 20 min after
angiotensin II (2ng/kg/min) or placebo infusion.
SBP(mmHg) DBP(mmHg) HR(beats/min)
before after before after before after
Placebo (PL) 117+/-2 115+/-3 64+/-4 63+/-4 59+/-5 59+/-5
Placebo (TYR) 118+/-3 117+/-2 63+/-4 63+/-3 60+/-5 60+/-5
All (PL) 113+/-5 118+/-4 63+/-4 68+/-3 61+/-7 56+/-6
All (TYR) 115+/-2 117+/-3 65+/-4 69+/-3 57+/-7 58+7-6
SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate.
All = angiotensin II infusion. Letters in parentheses indicate the study days in
which subjects subsequently received placebo (PL) or tyramine (TYR) infusion as
described in the methods. Results are given as mean +/- s.e.m.
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Table 9.2
CHANGES IN HEART RATE (beats per min)
dose of tyramlne (mcg/kg/min)
Resting Control 1.25 2.50 3.75 5.00 7.50 10.0
PL/PL 59+/-5 59+/-5 58+/-4 58+/-4 59+/-4 57+/-4 58+/-4 59+/-5
PL/TYR 60+/-5 60+/-5 57+/-5 56+/-4 58+/-3 57+/-3 58+/-5 56+/-4
AII/PL 61+/-7 56+/-6 57+/-4 58+/-4 55+/-5 58+/-5 56+/-5 55+/-5
AII/TYR 57+/-7 58+/-6 55+/-6 55+/-7 52+/-6 55+/-6 55+/-7 57+/-5
PL = placebo infusion (5% dextrose), All = angiotensin II infusion (2ng/kg/min)
TYR = tyramine infusion (1.25 - 10.0 mcg/kg/min as indicated). Resting =
baseline measurements taken after 20 min supine rest. Control = measurements
taken after a 20 mins Infusion of either All or PL as Indicated. This was
followed by an incremental infusion of TYR in the doses indicated. Results are
given as mean +/- s.e.m.
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Table 9.3(a)
PLASMA ANGIOTENSIN II (pg/ml)
Dose of tyramine (mcg/kg/min)
Resting Control 2.50 5.00 10.0
Placebo/Placebo 21+/-7 23+/-7 - - 19+/-4
Placebo/AII 19+/-3 67+/-4* - - 61+/-6*
Tyramine/placebo 23+/-6 19+/-3 - - 18+/-3
Tyrainine/AII 23+/-8 63+/-7* - 66+/-6*
Table 9.3(b)
PLASMA NORADRENALINE (pg/ml)
Dose of tyramine (mcg/kg/min)
Resting Control 2.50 5.00 10.0
Placebo/Placebo 400+/-46 444+/-77 379+/-43 343+/-46 394+/-53
Placebo/AII 416+/-74 433+/-82 513+/-63 386+/-53 376+/-41
Tyramine/placebo 590+/-55 451+/-45 600+/-69 623+/-73 983+/-227*
Tyramine/AII 530+/-62 509+/-60 502+/-67 636+/-60 707+/-73*
Placebo = 5% dextrose, All = angiotensin II infusion (2ng/kg/min) and Tyramine =
tyramine infusion (1.25 - 10.0 mcg/kg/min as indicated). Results are given as
mean +/- s.e.m. * p<0.01
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Summary
In this study evidence was sought for an AII/NA interaction in man
by examining how an All infusion influences the haemodynamic and plasma
NA responses to endogenously released NA. TYR was infused to cause the
endogenous release of neuronal NA. Six normal volunteers were studied on
four separate occasions. On each occasion they received two concomitant
infusions which were either placebo/placebo, placebo/TYR, All/placebo or
All/ TYR. All infusion was given at a constant rate of 2ng/kg/min whereas
the TYR infusion consisted of 10 min increments at 1.25, 2.5, 3.75, 5, 7.5
and 10 mcg/kg/min.
TYR infusion caused a dose dependent increase in systolic blood
pressure with increases in diastolic blood pressure and plasma NA only at
the highest doses. These changes were not affected by concomitant All
infusion. We have therefore found no evidence to support the enhancement
of haemodynamic or plasma NA responses to tyramine infusion by low dose






The effect of angiotensin II on the forearm blood flow response to
noradrenaline
Introduction
This study and those reported in the following chapters use a second
methodology to investigate the RAS/SNS interaction further. The
methodology is that of intra-arterial infusion of hormone or placebo into
the brachial artery and simultaneous measurement of forearm blood flow
(FBF) by strain gauge plethysmography (see methods and figure 2.1).
In this study evidence was sought for a possible postsynaptic RAS/SNS
interaction. NA was infused into the brachial artery with concomitant All
or placebo infusion and the effects compared.
Methods
Eight subjects (7 male, 1 female) were studied on one occasion each.
Two infusions were given simultaneously into the brachial artery via a Y-
connector which delayed mixing until the solutions entered the arterial
cannula.
One infusion (infusion A, Table 10.1) started with saline for 20 min,
followed by two separate periods of NA infusion, each with three
sequential incremental doses (12.5, 25 and 50 ng/min), each dose being
given for 10 min. The two periods of incremental NA infusion were
separated by a washout period of 50 min of saline infusion.
The other infusion (infusion B, Table 10.1), given simultaneously,
started with saline for 10 mins followed by All (320 fmol/min) or placebo
(saline) for 40 min. This was then replaced by saline infusion for a washout
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period of 40 min, followed by a further period of All or saline placebo for
40 min. Hence All was given for 10 min before and then throughout either
the first or second period of incremental NA infusion. Whether All was
given during the first or the second NA infusion period was governed by a
balanced block design. FBF was measured for the last 5 min of each 10
min throughout the study.
Analysis of results.
Results within the text are presented as mean +/- sem for each
measurement. The data were transformed to the ratios of blood flow in
the infused and non-infused forearm as described in chapter two (Methods).
These data were subjected to analysis of variance for repeated measures
(MANOVA, SPSS/PC+), to look for an effect of NA by time and an effect
of All versus placebo. The data are illustrated in the figure as
"cannulated" (C) to "non-cannulated" (NC) ratios, were C represents the
recorded blood flow in the cannulated arm and NC represents the recorded
blood flow in the non-cannulated arm (see chapter two for details).
Results
The effect of local infusion of All (320 fmol/min) on the response to
local NA infusion is shown in Table 10.1 and figure 10.1. There was no
significant difference between the absolute resting blood flow in the
infused forearm before placebo or All infusion. Blood flow in the infused
arm was 3.4+/-0.8 ml/min/lOOml before placebo infusion, and 3.0+/-0.4
ml/min/lOOml before All infusion. Nor was there a significant change in
blood flow associated with infusion of All or placebo alone. Forearm blood
flow went from 3.4 +/- 0.8 to 3.4 +/- 0.6 ml/min/lOOml during placebo
infusion alone, and from 3.0 +/- 0.4 to 2.8 +/- 0.4 ml/min/lOOml during All
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infusion alone.
NA caused a significant dose-dependent reduction in blood flow in the
infused forearm (p<0.001 MANOVA, fig 13.1), whether given during placebo
or All infusion. There was, however, no difference between the responses
to NA in these circumstances (P=0.86). There were also no significant
changes in blood flow in the non-infused forearm during these experiments.
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Table 10.1
The effect of angiotensin II (All; 320 fmol/min) on resting blood flow and
the response of forearm blood flow to Incremental infusion of noradrenaline
(NA).
Mean +/- s.e.m. For details of infusions A and B see Methods
Blood flow (ml/min/lOOml)
Infusion Infused arm Non-Infused arm
A B
Saline Saline 3.4+/-0.8 3.7+/-0.8
Saline Saline 3.4+/-0.6 3.6+/-0.7
NA (12.5 ng/min) Saline 2.1+/-0.4 3.1+/-0.6
NA (25 ng/min) Saline 2.1+/-0.5 3.3+/-0.7
NA (50 ng/min) Saline 2.2+1-0.4 3.5+/-0.8
Saline Saline 3.0+/-0.4 3.1+/-0.5
Saline All 2.8+/-0.4 3.4+/-0.5
NA (12.5 ng/min) All 2.1+/-0.4 3.2+/-0.6
NA (25 ng/min) All 1.8+/-0.4 3.4+/-0.6
NA (50 ng/min) All 1.8+/-0.3 3.6+/-0.6
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Figure 10.1




































Legend to figure 10.1
Ratio of flows in the infused arm / non-infused arm during incremental
infusion of noradrenaline (12.5-50 ng/min) with concomitant placebo (saline;
open bars) or with concomitant angiotensin II infusion (320 fmol/min;
hatched bars) in 8 supine subjects (mean +/- sem)
143
Summary
The effect of All on the response of forearm blood flow (FBF)
exogenous NA (12.5-50 ng/min) was studied in eight subjects. All had
effect on the reduction in FBF in response to incremental NA infusion.






The effect of local angiotensin II on the forearm blood flow response to
lower body negative pressure.
Introduction
In this study evidence was sought for an AII/SNS interaction by intra¬
arterial infusion of All or placebo (saline) and SNS stimulation by lower
body negative pressure (LBNP). Forearm blood flow was measured in both
forearms and compared to look for an effect of All or placebo on the
reduction in forearm blood flow caused by LBNP.
Methods
Six male subjects were studied on one occasion each. Prior to
brachial artery cannulation blood pressure and heart rate were recorded
every 2 min for 18 min with LBNP being applied for 3 min, between 11
and 14 min. This was followed by brachial artery cannulation and
sequential infusion of saline, All (320 fmol/min), and then further saline.
Each infusion was given for 15 min. FBF was recorded for the last 9 min
of each infusion period, with LBNP (15 mmHg; see chapter two: Methods)
being applied for the middle 3 min of FBF measurement.
Analysis of results.
Results within the text are presented as mean +/- sem for each
measurement. The effect of LBNP on blood pressure and heart rate was
subjected to analysis of variance for repeated measures (SPSS/PC+) using
the two measures during, and the two measures immediately preceding and
following LBNP. Where a significant F ratio was obtained, Student's t-test
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was performed using the Bonferroni correction. The effect of All on
responses to LBNP were analysed using Wilcoxon's signed rank test, with
the percentage changes in blood flow in the infused and non-infused
forearm calculated by the formula given below:
F(t) " F(0) x 100 %
F(0)
where F^ and F^tj represent measured forearm blood flows (F) before (0)
and during (t) intervention.
Results
The effect of LBNP on systemic BP and heart rate are shown in
figure 11.1 and figure 11.2. LBNP caused an initial 5 mmHg fall in systolic
BP (p<0.01) which returned to baseline within a further 2 min of LBNP.
Neither diastolic BP nor heart rate were affected by this degree of LBNP,
and blood pressure and heart rate after LBNP was similar to that before
its institution.
The changes in forearm blood flow in response to LBNP are shown in
table 11.1 and figure 11.3. Absolute resting blood flows during saline
infusion were similar in the infused and non-infused arms at 5.8+/-1.1 vs.
6.9+/-1.5 ml/min/lOOml tissue respectively, and blood flow was reduced to
a similar degree in both arms by LBNP (21 +/- 6% in each forearm). At
the dose of All given (320 fmol/min) there was no alteration in forearm
blood flow, with flows in the infused and non-infused arms of 5.9-+-/-1.6 and
6.7+/-1.4 ml/min/lOOml respectively. However of major importance is the
finding that, during All infusion at this dose, there was a marked
difference in response to LBNP, with blood flow reduced by 40 +/- 7% in
the All infused arm but only by 21 +/- 4% in the non-infused arm (p<0.05).
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Table 11.1
The effect of angiotensin II (All) on resting blood flow and the
response of forearm blood flow to lower body negative pressure (LBNP).
Mean +/- s.e.m.
Blood flow (ml/min/lOOml)
Infused arm Non-Infused arm
Saline Resting 5.8+/-1.1 6.9+/-1.5
LBNP 4.8+/-1.3 5.5+/-1.4
All Resting 5.9+/-1.6 6.7+/-1.4
(320 fmol/min)
LBNP 3.6+/-1.0 5.2+/-1.1





























Legend to figure 11.1
Effect of 3 min application of lower body negative pressure (LBNP) on












Legend to figure 11.2
Effect of 3 mln application of lower body negative pressure (LBNP) on
heart rate (beats/min) in 6 supine subjects (mean +/- sem).
Figure 11.3
EFFECT OF ANG II ON FOREARM BLOOD FLOW




























Legend to figure 11.3
Percentage changes (from control) in forearm blood flow with LBNP (mean
+/- sem) in the infused (hatched bars) and the non-infused arm (open bars)
of 6 subjects during sequential infusion of saline (control period),
angiotensin II (ANG-II 320 fmol/min; upper section of figure) and further
saline (Resting; lower section of figure). * P<0.05
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Summary
The effect of brachial arterial infusion of All on the response to
sympathetic vasoconstriction produced by LBNP (15 mmHg) was studied in
6 subjects.
All itself caused no change in resting forearm blood flow. LBNP
produced no change in heart rate or diastolic BP, but caused an early 5
mmHg fall in systolic BP (p<0.01) which rapidly returned to baseline.
Before All infusion LBNP caused a 21+/-6% fall in forearm blood flow in
the infused arm and a 21+/-6% fall in the non-infused arm. In contrast
during All infusion LBNP caused a 40+/-7% fall in forearm blood flow in
the infused arm and a 21+/-4% fall in the non-infused arm (p<0.05).
This study provides evidence that a significant haemodynamic All/





Studies employing pharmacological interruption of the renin-angiotensin
system.
Four experiments were undertaken to investigate the value of
pharmacological interruption of the RAS as a tool for studying the
interaction between the RAS and SNS. The forearm circulation of normal
volunteers was studied and LBNP was employed as the stimulus to activate
the SNS in all studies. The first approach (a) was the local intra-arterial
infusion of enalaprilat (the active metabolite of the prodrug enalapril, an
ACE inhibitor). The second approach (b) was to pretreat all subjects with
enalapril, and subsequently infuse All intra-arterially in an incremental
fashion. The third approach (c) was to infuse saralasin (an All antagonist)
intra-arterially in salt replete subjects. The fourth approach (d) was to
infuse saralasin intra-arterially in sodium deplete subjects. The results of
these four studies are given in this chapter.
(a) The effect of local angiotensin converting enzyme inhibition on the
forearm blood flow response to lower body negative pressure
Introduction
In chapter eleven All was shown to augment the LBNP induced
sympathetic vasoconstriction in the forearm resistance vessels. In this study
evidence was sought for an effect of endogenous All generation in the
forearm vasculature on sympathetic vasoconstriction. The forearm blood
flow responses to blockade of local forearm ACE activity by infusion of
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enalaprilat were examined at rest and during sympathetic stimulation with
LBNP.
Methods
Six male subjects were studied on one occasion each. Subjects were
sequentially infused via the brachial artery with saline for 15 min,
enalaprilat (5 mcg/min: low dose) for 19 min, and enalaprilat (50 mcg/min:
high dose) for 19 min. [enalaprilat is the active form of the prodrug
enalapril: Merck Sharp and Dohme Ltd, UK]. Enalaprilat was prepared for
infusion diluted in saline immediately prior to infusion. FBF was measured
for the last 9 min of each infusion period, with LBNP (15 mmHg) being
applied for the middle 3 min of recording.
Analysis of results.
Results are presented as mean +/- sem for each measurement. The
data were transformed to the ratios of blood flow in the infused and non-
infused forearm as described in chapter two. These data were subjected to
analysis of variance for repeated measures (MANOVA, SPSS/PC+), to look
for an effect of enalaprilat and an effect of LBNP.
Results
The results of resting forearm blood flow are given in table 12(a).l.
Resting blood flow in the infused arm was not altered by infusion of either
low dose or high dose of enalaprilat (Saline, 4.7+/-1.0; low dose, 4.7+/-1.2;
high dose, 5.5+/-1.1 ml/min/lOOml). The small rise noted at the high dose
was matched by a similar rise in the non-infused arm and the C/NC ratio
was unchanged (figure 12(a). 1).
LBNP caused reductions in blood flow in both infused and non-infused
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forearms of the same magnitude and these were unaltered by infusion of
enalaprilat. These results are given in table 12(a). 1 and are illustrated by
unchanged C/NC ratios in figure 12(a).l
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Table 12(a).l
Effect of local ACE inhibition on the forearm blood flow response to lower
body negative pressure
Forearm blood flow in infused arm and non-infused arm at rest and with
lower body negative pressure (LBNP) in ml/min/lOOml tissue during infusion
of saline and enalaprilat (5 and 50 mcg/min)
Infused forearm Non-infused forearm
Infusion Resting LBNP Resting LBNP
Saline 4.7+/-1.0 2.8+/-0.8 4.5+/-1.3 2.8+/-0.9
Low dose 4.7+/-1.2 2.9+/-0.9 4.2+/-1.4 2.7+/-1.0
High dose 5.5+/-1.1 3.7+/-0.9 5.1+/-1.2 3.8+/-1.1
Low dose infusion = enalaprilat 5 mcg/min.
High dose infusion = enalaprilat 50 mcg/min.
Results are presented as mean +/- sem for each measurement.
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Figure 12(a).l
EFFECT OF LOCAL ACE INHIBITION ON THE FOREARM
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Legend to figure 12(a).l
Changes In forearm blood flow shown as flow ratios (C/NC ratios
where C represents flow in the infused forearm and NC represents flow in
the non-infused arm) caused by LBNP during sequential infusion of saline,
low dose enalaprilat (5 mcg/min) and high dose enalaprilat (50 mcg/min).
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Summary
Evidence was sought for an effect of endogenous All generation in
the forearm vasculature on sympathetic vasoconstriction by examining the
forearm blood flow responses to blockade of local forearm ACE activity by
infusion of enalaprilat at rest and during sympathetic stimulation with
LBNP.
Neither resting forearm blood flow, nor responses to sympathetic
stimulation with LBNP were altered by local ACE inhibition with
enalaprilat infusion.
These results suggest that local generation of All may play a lesser




(b) The effect of systemic angiotensin converting enzyme inhibition and
reinfusion of angiotensin II on the forearm blood flow response to lower
body negative pressure
Introduction
In chapter eleven All was shown to augment the LBNP induced
sympathetic vasoconstriction in the forearm resistance vessels. In this study
evidence was sought for an effect of circulating All by examining the
forearm blood flow responses at rest and in response to LBNP during
systemic ACE inhibition with oral enalapril and also studying the effect of
re-infusion of an incremental infusion of AIL
Methods
Six male subjects were studied on one occasion each. Subjects were
pretreated with enalapril 20 mg twice daily for the two days preceding the
study, and received a final dose of enalapril 20 mg on the morning of the
study, five hours before the experiment began. Before brachial artery
cannulation blood pressure and heart rate were recorded every 2 min for
12 min with LBNP being applied for 3 min, between 5 and 8 min. This was
followed by sequential infusion via the brachial artery of saline, All (160
fmol/min), All (320 fmol/min), All (640 fmol/min) and All (1280 fmol/min),
each given for 15 min. Forearm blood flow was recorded for the last 9
min of each infusion, with LBNP being applied for the middle 3 min of
forearm blood flow measurement.
Analysis of results.
Results are presented as mean +/- sem for each measurement. The
effect of LBNP on blood pressure and heart rate was subjected to analysis
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of variance for repeated measures (SPSS/PC+) using the two measures
during, and the two measures immediately preceding and following LBNP.
These were also compared with the same data from the group studied in
chapter eleven, who had not received Enalapril. The forearm blood flow
data were transformed to the ratios of blood flow in the infused and non-
infused forearm as described in chapter two. These data were subjected to
analysis of variance, to look for an effect of All versus placebo and an
effect of LBNP. Where ANOVA revealed significant differences subsequent
paired t-testing was undertaken.
Results
The effect of LBNP on systolic and diastolic BP and heart rate are
shown in table 12(b). 1. In subjects treated with enalapril systolic BP and
diastolic BP and heart rate were significantly lower than in untreated
subjects (p<0.001 and p<0.005 by ANOVA, see table 12(b). 1). There was no
significant change in any haemodynamic parameter during LBNP in the
enalapril treated group and a small non-sustained fall in systolic blood
pressure only in the untreated group as noted earlier (chapter 11 and
figure 11.1).
The results of resting forearm blood flow and blood flow during LBNP
are given in table 12(b).2. All produced a dose dependent reduction in the
infused arm compared with the non-infused arm (P<0.001, ANOVA)
illustrated in figure 12(b). 1 as reductions in consecutive flow ratios.
Significance of reduction of blood flow in the infused forearm at individual
doses of All compared with control (saline) is given in table 12(b).2.
LBNP produced further reductions in forearm blood flow which were
more marked in the infused forearm (illustrated by reductions in C/NC
flow ratios, figure 12(b). 1). Overall the responses to LBNP were not
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significantly altered by All infusion. However a significant dose related
difference was revealed (p<0.05, ANOVA). Subsequent t-testing showed that
at a dose of All 320 fmol/min the response to LBNP was significantly
enhanced, with blood flow in the infused arm being reduced by 20+/-7%
during saline infusion period and by 33+/-6% during the All infusion period,
compared with blood flow in the control arm which was reduced 16+/-8%
during saline infusion period and by ll+/-8% during the All infusion period
(p<0.05). This result is indicated in figure 12(b). 1.
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Table 12(b).l
Haemodynamic effects of lower body negative pressure in untreated
subjects and subjects pretreated with enalapril
LBNP
Baseline 1 min 3 min
SBP 114+/-5 109+/-4* 114+/-5
Untreated DBP 65+/-4 64+/-5 63+/-5
HR 73+/-6 70+/-6 71+/-7







SBP and DBP = systolic and diastolic blood pressure (mmHg).
HR = heart rate (beats/min). LBNP = lower body negative pressure.
Enalapril dosage as described in the methods.
Significance: * p<0.02 by paired t-testing with Bonferroni correction
after ANOVA; # p<0.005 and *** p<0.001 (ANOVA)
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Table 12(b).2
Effect of systemic ACE inhibition and re-infusion of angiotensin II on the
forearm blood flow response to lower body negative pressure
Forearm blood flow in infused arm and non-infused arm at rest and with
lower body negative pressure (LBNP) in ml/min/lOOml tissue during infusion
of saline and angiotensin II (160-1280 fmol/min)
Infused forearm Non-infused forearm
Infusion Resting LBNP Resting LBNP
Saline 4.1+/-0.7 3.2+/-0.6 3.0+/-0.3 2.4+/-0.2
All (160) 3.2+/-0.6** 2.5+/-0.5 2.8+/-0.3 2.4+/-0.3
All (320) 3.3+/-0.6** 2.2+/-0.5 3.1+/-0.4 2.7+/-0.4
All (640) 2.6+/-0.3* 2.5+/-0.4 2.9+/-0.2 2.8+/-0.2
All (1280) 2.5+/-0.2* 2.0+/-0.4 3.0+/-0.2 2.7+/-0.3
Numbers in parentheses indicate dose of All in fmol/min.
Results are presented as mean +/- sem for each measurement.
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Legend to figure 12(b).l
Changes In forearm blood flow shown as flow ratios (C/NC ratios where C
represents flow In the Infused forearm and NC represents flow in the non-
Infused arm) caused by LBNP during sequential infusion of saline and




In this study evidence was sought for an effect of circulating AN by
examining the forearm blood flow responses at rest and in response to
LBNP during systemic ACE inhibition with oral enalapril and also studying
the effect of re-infusion of an incremental infusion of AIL
Resting blood pressure and heart rate were significantly reduced by
treatment with enalapril. Infusion of AN caused a significant reduction in
flow in the infused arm (p<0.001, ANOVA).
In addition AII (at a dose of 320 fmol/min) significantly enhanced the
response to LBNP (p<0.05). This finding provides further evidence for AII
enhancing sympathetic vasoconstriction in the human forearm and suggests




(c) The effect of saralasin on the forearm blood flow responses to lower
body negative pressure in sodium replete subjects
Introduction
This study sought to investigate whether circulating All plays a role
in peripheral sympathetic neurotransmission by examining the effect of
blockade of AN by saralasin infusion into the brachial artery at rest and
during sympathetic stimulation with LBNP. Subjects were on free diet and
were considered sodium replete.
Methods
Eight male subjects were studied on one occasion each. The brachial
artery was cannulated followed by sequential infusion of saline, saralasin
(10 ng/min), saralasin (100 ng/min) and saralasin (1000 ng/min). Each
infusion was given for 15 min. FBF was recorded for the last 9 min of
each infusion period, with LBNP being applied for the middle 3 min of
FBF measurement.
Analysis of results
Results are presented as mean +/- sem for each measurement. The
data were transformed to the ratios of blood flow in the infused and non-
infused forearm as described in chapter two. These data were subjected to
analysis of variance for repeated measures (MANOVA, SPSS/PC+) to look
for an effect of saralasin and an effect of LBNP. Paired t-testing was
performed where a significant effect was revealed by ANOVA.
Results
The results of resting forearm blood flow and blood flow during LBNP
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are given in table 12(c). 1. There were no significant differences in resting
blood flow between the infused and non-infused arms.
Saralasin had a small but highly significant dose dependent effect
reducing blood flow in the infused arm (p<0.001, ANOVA) reflected in
falling C/NC flow ratios as illustrated in figure 12(c). 1. Significance by
paired t-testing for individual doses (compared with control, saline) is given
in figure 12(c). 1.
The responses to sympathetic stimulation with LBNP were not
affected by saralasin (p=0.6, ANOVA).
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Table 12(c).l
Effect of saralasin on the forearm blood flow response to lower body
negative pressure in sodium replete subjects
Forearm blood flow in infused arm and non-infused arm at rest and with
lower body negative pressure (LBNP) in ml/min/lOOml tissue during infusion
of saline and saralasin (10-1000 ng/min)
Infused forearm Non-infused forearm
Infusion Resting LBNP Resting LBNP
Saline 5.0+/-1.0 3.3+/-0.7 4.3+/-0.8 3.0+/-0.6
SAR (10) 4.9+/-1.1 3.3+/-0.8 4.6+/-1.0 3.1+/-0.7
SAR (100) 4.4+/-1.1 3.0+/-0.8 4.8+/-1.2 3.3+/-0.9
SAR (1000) 4.0+/-0.8 2.5+/-0.5 4.6+/-1.0 3.2+/-0.7
SAR = saralasin infusion. Numbers in parentheses indicate dose of saralasin
infused in ng/min.
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Legend to figure 12(c).l
Effect of saralasin (10-1000 ng/min) on the forearm blood flow response to
LBNP in sodium replete subjects. Results are given as mean +/- sem of
C/NC flow ratios (see chapter two for details of analysis). Plain bars
represent flow ratios at rest and hatched bars represent flow ratios 3 min
after the application of LBNP. Significance: * p<0.02, ** p<0.01
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Summary
This study sought to investigate whether circulating All plays a role
in peripheral sympathetic neurotransmission by examining the effect of
blockade of All by saralasin infusion into the brachial artery at rest and
during sympathetic stimulation with LBNP. Subjects were on free diet and
were considered sodium replete.
Saralasin was shown to have a dose dependent effect on reducing
forearm blood flow, but had no effect on the responses to LBNP.




(d) The effect of saralasin on the forearm blood flow responses to lower
body negative pressure in sodium deplete subjects
Introduction
This study sought to investigate whether circulating All plays a
role in peripheral sympathetic neurotransmission by examining the effect of
blockade of All by saralasin infusion into the brachial artery at rest and
during sympathetic stimulation with LBNP. Subjects were salt deplete on
this occasion.
Methods
Eight male subjects were studied on one occasion each. Prior to
investigation subjects were rendered sodium deplete by giving a single oral
dose of frusemide 40mg taken on the first morning, followed by three days
of a diet providing 12 to 15 mmol sodium, and 40 to 60 mmol potassium
daily. Studies were performed on the morning of the fourth day after an
overnight fast from 22.00 h. This method usually produces an external
sodium deficit of approximately 180 mmol (Webb et al, 1985). The brachial
artery was cannulated followed by sequential infusion of saline, saralasin
(10 ng/min), saralasin (100 ng/min) and saralasin (1000 ng/min). Each
infusion was given for 15 min. FBF was recorded for the last 9 min of
each infusion period, with LBNP being applied for the middle 3 min of
FBF measurement.
Analysis of results
Results are presented as mean +/- sem for each measurement. The
data were transformed to the ratios of blood flow in the infused and non-
infused forearm as described in chapter two. These data were subjected to
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analysis of variance for repeated measures (MANOVA, SPSS/PC+) to look
for an effect of saralasin and an effect of LBNP. Paired t-testing was
performed where a significant effect was revealed by ANOVA.
Results
The results of resting forearm blood flow and blood flow during LBNP
are given in table 12(d).1. There were no significant differences in resting
blood flow between the infused and non-infused arms.
Saralasin did not effect resting blood flow on this occasion (p=0.6,
ANOVA). However saralasin caused significant enhancement of the response
to sympathetic stimulation with LBNP (p<0.02, ANOVA). These results are
reflected in the fall in C/NC flow ratios illustrated in figure 12(d).1.
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Table 12(d). 1
Effect of saralasin on the forearm blood flow response to lower body
negative pressure in sodium deplete subjects
Forearm blood flow in infused arm and non-infused arm at rest and with
lower body negative pressure (LBNP) in ml/min/lOOml tissue during infusion
of saline and saralasin (10-1000 ng/min)
Infused forearm Non-infused forearm
Infusion Resting LBNP Resting LBNP
Saline 4.1+/-0.4 2.9+/-0.3 3.0+/-0.3 2.0+/-0.2
SAR (10) 4.0+/-0.5 2.7+/-0.5 3.3+/-0.4 2.6+/-0.3
SAR (100) 4.0+/-0.5 2.8+/-0.5 3.1+/-0.4 2.4+/-0.3
SAR (1000) 4.0+/-0.6 2.7+/-0.5 3.4+/-0.5 2.4+/-0.2
SAR = saralasin infusion. Numbers in parentheses indicate dose of saralasin
infused in ng/min.
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Legend to figure 12(d).l
Effect of saralasin (10-1000 ng/mln) on the forearm blood flow response to
LBNP in sodium replete subjects. Results are given as mean +/- sem of
C/NC flow ratios (see chapter two for details of analysis). Plain bars
represent flow ratios at rest and hatched bars represent flow ratios 3 min
after the application of LBNP. Significance: * p<0.05, ** p<0.02
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Summary
This study sought to investigate whether circulating All plays a role
in peripheral sympathetic neurotransmission by examining the effect of
blockade of All by saralasin infusion into the brachial artery at rest and
during sympathetic stimulation with LBNP. Subjects were salt deplete.
In contrast to the previous study (chapter 12(c)) saralasin had no
effect on resting forearm blood flow, but caused significant enhancement
of the responses to LBNP.
These findings are also likely to represent an agonist effect of







3. The effect of intravenous infusion of angiotensin II and noradrenaline
alone and in combination on blood pressure, heart rate and plasma
noradrenaline.
[Systemic: Raised All: NA infusion: Postsynaptic]
4. The effect of angiotensin II on renal sodium excretion.
[Systemic: Raised All: None: Direct All action]
5. The effect of noradrenaline on renal sodium excretion.
[Systemic: None: NA infusion: Direct NA action]
6. The effect of angiotensin II and noradrenaline alone and in
combination on renal sodium excretion.
[Systemic: Raised All: NA infusion: Postsynaptic]
7. The effect of angiotensin II on the stroke volume response to beta
agonism.
[Systemic: Raised All: Beta-agonist infusion: Postsynaptic]
8. The effect of angiotensin II on endogenous noradrenaline release.
[Systemic: Raised All: Physiological stimuli of SNS: Presynaptic]
9. The effect of angiotensin II on the haemodynamic and plasma
noradrenaline responses to tyramine infusion.
[Systemic: Raised All: NA release by tyramine infusion: Presynaptic]
10. The effect of local angiotensin II on the forearm blood flow response
to noradrenaline.
[Local: Raised All: NA infusion: Postsynaptic]
11. The effect of local angiotensin II on the forearm blood flow response
to lower body negative pressure.
[Local: Raised All: Physiological stimulus (LBNP): Presynaptic]
12. Studies employing pharmacological interruption of the renin-
angiotensin system.
(a) The effect of local angiotensin converting enzyme inhibition on
the forearm blood flow response to lower body negative pressure.
[Local: Low All: Physiological stimulus (LBNP): Role of local ACE activity]
(b) The effect of systemic angiotensin converting enzyme inhibition
and reinfusion of angiotensin II on the forearm blood flow response to
lower body negative pressure
[Local: Low All: Physiological stimulus (LBNP): Role of circulating ACE]
(c) The effect of saralasin on the forearm blood flow responses to
lower body negative pressure in sodium replete subjects.
[Local: Low All: Physiological stimulus (LBNP): Presynaptic]
(d) The effect of saralasin on the forearm blood flow responses to
lower body negative pressure in sodium deplete subjects.




13.1 The effect of intravenous infusion of angiotensin II and noradrenaline
alone and in combination on blood pressure, heart rate and plasma
noradrenaline (chapter three).
In designing this study, there were two opposing considerations with
regard to the All infusion rate. The first requirement was to infuse enough
All so that any AII/NA interaction would be detectable by non-invasive
haemodynamic parameters. The second requirement was to use as low a
dose of All as possible so that the baroreflex would not be activated as
this would further complicate interpretation of the results. As a
compromise we chose 2 ng/kg/min (Nicholls et al, 1981). This dose fulfilled
most of these aims in that it was a high enough dose to demonstrate a
systolic AII/NA interaction but was also low enough to cause no significant
change in systolic pressure or in baroreflex activity, as judged by reflex
HR changes. Unfortunately, it did increase diastolic pressure. This does not
however, detract from the main findings of this study since the
synergistic AII/NA Interaction was limited to systolic pressure, mean
pressure and reflex bradycardia while All alone had no effect on any of
these parameters. It is worth noting from fig. 3.1, that at several time
points when a subpressor systolic dose of NA was infused in the
coincidental presence of a subpressor systolic dose of All, then together a
pressor effect was evident. In addition, plasma NA and All were within the
physiological range at this stage where the AII/NA interaction was most
prominent. Furthermore, the fact that the reflex changes in HR followed
the same synergistic pattern, suggests that the results were not a chance
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phenomenon. On examining individual data in this study, it is evident that
the augmentation of the systolic effect of NA is variable from one
individual to another. However, no individual characteristics seemed to
contribute to this variability, including baseline haemodynamics, plasma
levels of NA or All or urinary sodium excretion. With regard to diastolic
pressure, All alone did produce a significant increase but when All and NA
were given together, there was only an additive effect. This suggests that
there was indeed no AII/NA interaction whatever with diastolic pressure.
It is not possible from this study to identify the precise location of
this AII/NA interaction or to fully explain why this interaction was limited
to systolic pressure. In considering possible interpretations, however, it is
worth remembering that blood pressure is a combination of stroke volume,
and peripheral resistance. Although there is much overlap, systolic pressure
tends to preferentially reflect stroke volume, left ventricular ejection
velocity and aortic compliance while diastolic pressure tends to
preferentially reflect tone in the peripheral resistance vessels. In vitro, All
produces a consistent, concentration dependent, direct inotropic effect on
myocardial ventricular contraction (Koch-Weser, 1964; Koch-Weser, 1965).
Yet in vivo, this positive inotropic effect of All is normally masked by
peripheral vasoconstriction, so that in a human volunteer, infused All tends
to increase diastolic pressure more than systolic pressure and cardiac
output is usually little altered by All (Yu et al, 1961). Interestingly
however, there are two other experimental situations apart from this study
in which a link between All and systolic pressure is unmasked so that All
becomes more closely associated with the systolic pressure than with
diastolic pressure. Firstly, during the infusion of sodium nitroprusside in the
presence of captopril, the withdrawl of All augments the fall in systolic
pressure but not that of diastolic pressure (Becker et al, 1986). Secondly,
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in essential hypertension, when ACE inhibitors have been directly compared
with beta-blockers, one repeated and surprising observation is that, while
both groups of drugs reduced diastolic pressure equally, the fall in systolic
pressure is normally greater with ACE inhibitors (Enalapril in hypertension
study group, 1986; Lichter et al, 1986; Webster et al, 1986).
The mechanism for this link between All and systolic inotropic
activity may be twofold. Firstly, Stokland et al (1986) have shown in dogs
that during isoprenaline infusion All relocates central venous blood from
the liver and spleen to the heart, hence increasing filling pressure and
therefore cardiac output. Secondly, Peach et al (1969) showed that in vitro,
All is a potent inhibitor of NA uptake in ventricular muscle. Such a
mechanism could explain why All increases cardiac contractility in response
to adrenergic nerve stimulation (Ackerly et al, 1976). It could also be
relevant to this study where the systolic inotropic effect of the infused
NA might have been augmented locally within the myocardium by All,
preventing NA re-uptake. If this uptake inhibition were to have occurred
only within myocardial tissue, then it is most unlikely that our plasma NA
levels would have been altered by All, since myocardial tissue contributes
only a small amount to overall NA clearance. Our plasma NA and All
levels really only exclude a global pharmacokinetic interaction. Overall,
therefore, our results are consistent with either a localised pharmacokinetic
AII/NA interaction as described above or a true pharmacodynamic AII/NA
interaction which would have occurred either within the central veins, the
myocardium or even the aorta.
Four other possible interpretations of our data are worthy of
consideration. Firstly, it is possible that a subpressor infusion of All could
cause peripheral venous constriction so increasing venous return and hence
myocardial contractility. A generalised increase in peripheral venous tone is
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however, unlikely since All has a much lesser effect on peripheral venous
tone than NA so that the low dose of All used in this study would be
unlikely to to cause any such changes (McQueen and Morrison 1961; Collier
et al, 1972). In addition, there is rapid tachyphlaxis to the peripheral
venous effect of All so that any initial effect would be liable to have
waned by the later stages of our infusions. Secondly, although the HR
changes are generally considered to be secondary to pressor responses, it is
conceivable that the opposite is true in some cases (Mace et al, 1985). If
so, the augmented bradycardia due to AII/NA might be compensated for by
an increase in stroke volume leading to an augmentation of systolic
pressure, as was observed. This seems possible but unlikely because it
requires that the baroreflex works in the opposite direction to that which
is generally accepted. Thirdly, it is often although not universally true that
any vasodilator drug will non-specifically reduce the pressor response to
NA and All (Millar et al, 1983; Murphy et al, 1984). It is conceivable that
the opposite is also true of pressor substances so that All could render the
peripheral vascular tree more responsive to other pressor agents such as
NA. There is no corresponding human data yet on the effect of vasopressin
on the pressor response to NA but there i^ in vitro animal data to suggest
that vasopressin potentiates NA induced vasoconstriction and that NA
potentiates vasoconstriction due to vasopressin (Bartelstone and Naysmith,
1965; Sueta et al, 1983). This attractive explanation does not however,
fully explain the data because the changes in peripheral vascular tone are
best detected by the parameter of diastolic pressure and yet in this study,
a synergistic AII/NA interaction occurred with systolic pressure only and
not diastolic pressure. Fourthly, it is conceivable that All releases
vasodilatory prostaglandins in small, but not in large arteries and that
these prostaglandins conceal an AII/NA interaction on diastolic pressure.
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Again this is possible but unlikely since All infusions produce no overall
systemic effect on prostacyclin release in humans (Barrow et al, 1986).
In this study therefore evidence is presented for a synergistic AII/NA
interaction with regard to systolic but not to diastolic pressure. As we
have seen one explanation of this may be an increase in stroke volume.
One way in which stroke volume may be affected is by an increase in
intravascular volume. The possible effect of an AII/SNS interaction on
intravascular volume was explored by considering the possible intrarenal
interaction to retain sodium and water. This was investigated first by
defining the effects of All and NA on renal sodium excretion and then
investigating the effects of the combination of All and NA infused
concurrently.
13.2 The effect of angiotensin II on renal sodium excretion In man
(chapter four)
The results of this study show that small ('physiological') increments
in All have a significant antinatriuretic action in man. The data also
suggest that this effect on sodium excretion could be a direct one,
independent of the actions of aldosterone. Though aldosterone levels did
rise after infusion of AII, the peak was delayed beyond the nadir in sodium
excretion, actually occurring at a time when sodium excretion was
returning towards baseline. In support of this, previous evidence suggests
that the action of intravenous aldosterone in man is delayed for over 40
min (this delayed onset of effect could explain the lack of immediate
antinatriuresis with rising aldosterone levels during period D) [Sonnenblick
et al, 1961]. In addition, potassium excretion in our study tended to fall, a
directional change also arguing against an aldosterone-mediated
antinatriuretic effect. Our results have also demonstrated, for the first
190
time in man, that All decreases FEjj. There is evidence that lithium is a
specific marker for proximal tubular sodium handling in salt replete
experimental animals and man, although not all authors accept the validity
of this technique (Thomsen, 1984; Navar and Schafer, 1987). In our study
subjects were salt-replete and fell during All infusion, suggesting that
whole kidney proximal tubular reabsorption was increased (this would also
argue against the major effect being due to aldosterone). We also measured
FDD, a conventional clearance parameter believed to give some measure of
proximal tubular outflow. This parameter relies on the concept of 'solute
free water' generation, i.e. that sodium exiting the proximal tubule will be
reabsorbed independently of water in the ascending limb of the loop of
Henle generating 'solute free water', which in the absence of antidiuretic
hormone, is excreted in the urine. In this study Uosm was reduced to less
than 65 mosmol/kg, implying complete suppression of antidiuretic hormone.
There is some evidence that All can increase antidiuretic hormone
levels in man, although this is conflicting, and in this study there was no
increase in UOS]m during or after All infusion. FDD fell in this study during
All infusion exhibiting a similar response to FE^j. Though this method too
has been criticized, on the basis that back diffusion of water can occur in
the distal nephron, even in the absence of antidiuretic hormone, the fact
that two separate measures of proximal tubular function showed an almost
identical response to All infusion suggests that this is a genuine effect.
This is compatible with a wealth of evidence from animal experimentation
where a variety of methods, including lithium clearance, have all suggested
a proximal tubular effect of All (Johnson and Malvin, 1977; Olsen et al,
1985).
A further interesting finding in this study was that distal reabsorption
of sodium fell significantly during infusion of All. Little is known about
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the effects of All on distal nephron function in either experimental animals
or man and conflicting reports have been published (Olsen et al, 1985;
Vander, 1963). One possible explanation for a reduction in RDj^a would
simply be that enhanced proximal tubular sodium reabsorption reduces
distal delivery of sodium to the extent that falls. This view is
supported by the observation that FRD^ did not change significantly
during All infusion. These findings again support previous data obtained in
animal studies and are a further argument against aldosterone contributing
significantly to the observed reduction in sodium excretion (Olsen et al,
1985).
A recent study also supports our current findings. Brown (1988) has
shown that captopril, an ACE inhibitor, increased FEjj in salt-replete
normal volunteers without changing inulin clearance. The effects of
captopril during maximal water diuresis were also measured to assess
segmental function by the free water clearance method; here too a
proximal effect was demonstrated. While it is likely that the results of the
study by Brown (1988) reflect removal of the effect of All, a role for
natriuretic prostaglandins cannot be excluded. In fact, Usberti et al (1986)
have recently shown that the natriuretic action of captopril in normal
subjects can be blocked by aspirin. The current results, however, are free
from this difficulty in interpretation related to the use of captopril.
Our findings do not, however, allow any further interpretation of the
mechanism by which All might mediate the observed effects. We found no
significant change in Cq. in keeping with previous studies that have shown
no change in GFR during infusion of low-dose All (Johnson and Malvin,
1977; Olsen et al, 1985). We did not measure renal blood flow but the bulk
of previous evidence suggests that renal blood flow falls and filtration
fraction rises during All infusion (Finnerty et al, 1961; Hollenberg et al,
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1976; Johnson and Malvin, 1977; Olsen et al, 1985). The resultant changes
in peritubular physical forces would be expected to enhance proximal
tubular transport of sodium. Nevertheless it has been demonstrated that
lower doses of All can decrease sodium excretion in animals and man
without changes in GFR or renal plasma flow (Johnson and Malvin, 1977;
0.1 and 0.5 ng/kg/min intra-renal artery infusion in dogs: Ljungman et al,
1983; 0.1 and 0.5 ng/kg/min intravenously in man), and without changing
the intrarenal distribution of blood flow in animals (Johnson and Malvin,
1977). A direct effect of All on proximal tubular sodium handling has also
been suggested and the presence of specific proximal tubular All receptors
supports this possibility (Brown and Douglas, 1983; Schuster et al, 1984).
Our results, however, do not enable a distinction to be made between an
indirect haemodynamic mechanism of action or a direct tubular action. A
further limitation of this study is that systemic infusion of All may have
different physiological effects than endogenous renal generation of All.
There is some evidence to suggest that components of the RAS (e.g. renin
and angiotensin converting enzyme) are localised within the kidney, in
different nephron subpopulations and within different parts of the nephron
(Levens et al, 1981; Hollenberg, 1984). Physiological enhancement of
endogenous All production may, for example, produce local concentrations
of All sufficient to constrict the efferent arteriole or directly stimulate
proximal tubular reabsorption of sodium. Only more sustained and intense
stimulation might be necessary to cause sufficient intrarenal All to be
generated to affect nephron sites with a higher threshold for All effect or
to spill over into the systemic circulation (Levens et al, 1981). Viewed in
this way systemic administration of All might cause an abnormal pattern
of response. Nevertheless it would seem from this study that the
circulating levels of All formed under certain physiological and
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pathophysiological conditions could have a significant renal effect in their
own right, albeit combined with the effects of local intrarenal production
of AIL For example, the All levels produced by infusion in this study
(49+/-9 pg/ml) are similar to those produced by moderate salt restriction
(Hollenberg et al, 1974), renovascular and accelerated hypertension
(Robertson et al, 1986) and are at the lower end of the range found in
compensated chronic heart failure (Fitzpatrick et al, 1985).
In summary, therefore, we have shown that physiological increments
of All are antinatriuretic in man, confirming previous observations. We
have also attempted to elucidate some of the mechanisms by which All
alters renal sodium handling in man, presenting evidence that it enhances
proximal tubular sodium reabsorption.
13.3 The effect of noradrenaline on renal sodium excretion in man
(chapter five)
In this study we have shown that physiological increments in plasma
NA have a significant antinatriuretic action in man. Previous investigations
have concerned only high-dose infusion of NA (140-300 ng/kg/min) though a
similar effect was observed (Werko et al, 1951; Smythe et al, 1952;
McQueen and Morrison, 1961; Laragh et al, 1963). Basal NA levels in our
study were at the upper part of the normal range because subjects were
studied sitting and stood every 20 min to void. Consequently, the
increment in NA achieved (280 pg/ml) resulted in steady state NA levels in
the region of 830 pg/ml. These levels are only slightly higher than those
found in upright salt-depleted subjects and are similar to those obtained
during low-level exercise (Romoff et al, 1978; Richards et al, 1987;
chapter eight). Further, these levels are typical of the circulating NA
levels found in certain pathological salt-retaining conditions such as chronic
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heart failure and hepatic cirrhosis (Bichet et al, 1982; Levine et al, 1982).
From this study it is clear that circulating concentrations of NA can
themselves reduce sodium excretion. This finding is particularly interesting
in view of the haemodynamic effects of low-dose NA infusion. Several
investigations have shown that exogenous infusion of NA in a dose of 20-30
ng/kg/min produces physiological plasma increments which begin to increase
systemic blood pressure and lower the heart rate, probably by acting at
extrasynaptic alph^-adrenoceptors, as well as intrasynaptic alpha j-
receptors (Izzo, 1983; Scriven et al, 1983; Jie et al, 1987 and discussion
section 13.5). It is now clear, however, that circulating NA is not an inert
neurotransmitter which has simply spilled over into the circulation. Rather,
circulating NA appears to be a vasoactive hormone, which, at physiological
concentrations, influences both renal function and the peripheral
vasculature.
We also observed that the antinatriuretic effect of low-dose NA
occurred without any change in creatinine clearance. This indicates that
NA has a tubular action. Clearance of lithium was again used as a marker
of proximal tubular sodium outflow in salt-replete subjects (Thomsen, 1984).
In the present study lithium clearance declined in all subjects during NA
infusion compared with placebo infusion without any concomitant change in
the glomerular filtration rate. It appears, therefore, that NA enhances
fractional proximal tubular sodium reabsorption in man, which is in keeping
with animal experiments showing the presence of proximal tubular
adrenergic receptors and demonstrating that synaptically released NA
increases proximal tubular sodium reabsorption (DiBona, 1977; Gill, 1979).
These experiments, however, only investigated neuronally released, rather
than circulating, NA. It is probable that the effects of NA differ
depending on whether the hormone is circulating or synaptically released,
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as Its access to different receptor subtypes differs in these two situations.
Most authorities have suggested that post-synaptic alphaj-receptors mediate
the effects of catecholamines on renal tubular function. Peripherally
infused NA may, however, have more access to extrasynaptic alpl^-
receptors (Jie et al, 1987). Alph^-receptors have recently been identified
in both animal and human kidneys (Young and Kuhar, 1980; Umemura et al,
1986). Indeed, in certain species they may be the predominant alpha-
adrenoceptor subtype found on the proximal tubules (Young and Kuhar,
1980; Nord et al, 1987). Furthermore, there is accumulating evidence that
alpl^-receptors may mediate catecholamine-induced proximal tubular fluid
reabsorption in animals, as measured by micropuncture techniques or the
lithium clearance technique (Baines, 1987; Nord et al, 1987). A further
consideration is the possibility of presynaptic 'autoreceptor' activation by
NA infusion. Presynaptic beta-receptors may augment neurotransmitter
release while alpf^-receptors in this location mediate negative feedback
inhibition of NA release (Jie et al, 1987). With NA infusion, activation of
the latter receptors is likely, though there is some evidence that this type
of receptor mechanism is absent, or of only minor importance, in the
kidney compared to the muscular bed (Robie, 1980; Insel et al, 1985).
A further observation in the present study was that the
antinatriuretic effect of NA appeared to take time to develop in contrast
to, for example, that of All which reduces sodium excretion almost
immediately (chapter four). This suggests an alternative view that the
effect of circulating NA could be an indirect one, possibly due to
intrarenal generation of AIL There is considerable evidence from animal
experiments that the renal effects of sympathetic nerve stimulation may,
at least in part, be mediated by the intrarenal RAS (Pelayo and Blantz,
1984; Johns, 1987a; Johns, 1987b). In the present study systemic All and
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aldosterone did not change significantly, though this does not exclude the
possibility of an intrarenal effect. The theory that the intrarenal RAS
could be important in explaining our findings will only be fully tested by
studying the effects of ACE inhibition on the renal responses to low-dose
NA infusion.
We did not detect any significant change in the sitting heart rate or
blood pressure in this study. Our volunteers were seated and stood every
20 min to void. These changes in posture may have obscured the minor
haemodynamic changes predicted by previous investigations performed in
quietly resting, supine, subjects. Indeed, the dose of NA used (25
ng/kg/min) was a threshold one for detectable haemodynamic effects in
man.
We did not measure renal blood flow in this study. High doses of NA
consistently reduce renal blood flow in animals and man (Werko et al,
1951; Smythe et al, 1952; McQueen and Morrison, 1961; Laragh et al,
1963). However, low dose infusion of NA and low frequency renal SNS
stimulation in animals can reduce sodium excretion without affecting
glomerular filtration rate, renal blood flow or distribution of intrarenal
blood flow (Slick et al, 1975; DiBona, 1978; DiBona, 1977; Gill 1979;
Johnson and Barger, 1981). It is therefore possible that the decrease in
sodium excretion measured in this study occurred independently of any
change in renal blood flow; this requires further investigation. Another
limitation of the present study is that we only studied the effects of
increased circulating NA alone, as opposed to its combination with
increased sympathetic nerve transmission. Clearly, the latter is the
'physiological' situation, and it is possible that the effects of a given level
of plasma NA could differ when there is concomitant enhancement of
intrasynaptic NA release.
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In summary, we have shown that physiological increases in circulating
NA reduce sodium excretion in man, at least partly by enhancing proximal
tubular reabsorption. Circulating NA, per se, may therefore influence renal
function under certain physiological conditions and pathological states
associated with high plasma levels of this hormone.
13.4 The effect of angiotensin II and noradrenaline alone and in
combination on renal sodium excretion in man (chapter six).
In studying the interaction between the RAS and SNS in the kidney,
it is important to restate that the experimental evidence which supports
such an interaction has shown that it occurs only when the RAS is
activated (Zimmerman et al, 1984). In our study we increased "RAS"
activity by infusion of exogenous All and also altered "SNS" activity by
infusion of NA, both at doses chosen to produce increments in hormone
level and final hormone concentration of physiological and/or
pathophysiological relevance in man. The baseline All and aldosterone levels
are higher than those reported for resting supine subjects and as noted in
the last study basal plasma NA was also in the upper part of the normal
range. These findings may be explained by posture as our subjects were
studied in the seated position and stood every 20 minutes to pass urine.
The increase in plasma All (mean 19+/-5 pg/ml for all 14 infusions) and
the final levels achieved by infusion (table 6.2) are similar to those that
would be expected in normal subjects on a low salt diet (Oelkers et al,
1974), or in some groups of patients with heart failure (Dzau et al, 1981;
Fitzpatrick et al, 1985). The increase in plasma NA (mean 316+/-51 pg/ml)
and final levels achieved (table 6.2) are slightly higher than those that
might be expected in upright salt depleted subjects and are similar to
those seen during submaximal exercise (Robertson et al, 1979; Romoff et
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al, 1979; chapter eight). These levels are also comparable to those found in
patients with heart failure (Levine et al, 1982; Fitzpatrlck et al, 1985).
The results of our study show that these small increments of All, or
NA, alone produce a significant reduction in sodium excretion (figure 6.1
and table 6.3). These decreases in sodium excretion due to All and NA
occurred without any change in creatinine clearance. Thus in our study the
principal effect of All and NA is most likely to have occurred at a tubular
level. Our results in man therefore support earlier experimental work that
suggests low doses of All have a direct effect on the proximal tubule to
increase sodium reabsorption (Harris and Young, 1977; chapter four), as do
low doses of NA or low frequency renal SNS stimulation (DiBona, 1978;
Bello-Reuss, 1980; chapter five). However we found no evidence to suggest
that low doses of AII and NA given concomitantly in man act to further
alter sodium excretion. The decrease in sodium excretion seen in our study
again occurred without any change in systemic blood pressure and heart
rate. This is important since changes in systemic pressure would have
clearly altered the normal relationship between pressure and natriuresis. I
have discussed above that low doses of All and NA alone have been shown
to cause reductions in sodium excretion without affecting glomerular
filtration rate or renal haemodynamics. The corresponding information
concerning infusions of both agents together is not available. It remains
likely that the decreases in sodium excretion measured in this study
occurred independently of any change in renal blood flow, though this
requires further investigation (this limitation is discussed more fully below
in section 13.6(a)). I have concentrated the present discussion on the
evidence for a tubular RAS/SNS interaction from animal studies and the
interpretation of the present results.
Experimental evidence for a renal tubular RAS/SNS interaction. In the
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early 1970's It was recognised that low levels of renal nerve stimulation
caused an antinatriuresis without change in GFR or renal blood flow (see
references cited in section 13.3 and reviews DiBona, 1977 and Thames,
1984). The first studies of tubular interactions of the RAS and the SNS
were undertaken at that time and were designed to investigate whether the
antinatriuretic effect of low level renal nerve stimulation was mediated via
the RAS. Saralasin was used as an All antagonist and had no effect on the
antinatriuretic effect of low level renal nerve stimulation (Zambraski and
DiBona, 1976). This was interpreted as evidence against an All involvement
in the antinatriuretic effect of low level renal nerve stimulation. However
this experiment is confounded as saralasin alone caused significant
attenuation in blood pressure, renal plasma flow and U^gV prior to renal
nerve stimulation.
The alternative approach to the interaction, whether the anti¬
natriuretic effect of All is mediated by or requires the activity of the
renal SNS, has also been studied. Pelayo and Blantz (1984) showed that
saralasin caused a reduction in absolute proximal reabsorption in both
innervated (sham operated) and renal denervated rats, suggesting that the
effects of All and denervation are separate. However infusion of captopril
in the renal denervated rats did not cause a reduction in absolute proximal
reabsorption which is against that conclusion. Again in these experiments
saralasin and captopril had significant effects on systemic and renal
haemodynamics and indirect actions cannot be excluded.
Recent investigations by Johns and coworkers have studied this area
further. Handa and Johns (1985) demonstrated that the action of low level
renal nerve stimulation to decrease sodium excretion was removed by high
dose captopril and was attenuated by a lower dose. Therefore in these
experiments in the rat the action of the renal nerves to decrease sodium
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excretion was dependent on AIL Similar results were obtained by indirect
stimulation of the renal nerves in rats by brachial nerve stimulation (Handa
and Johns, 1987). They showed that pharmacological inhibition of the RAS
with saralasin and captopril attenuated the large falls in sodium and water
output seen during brachial nerve stimulation. It is possible that small
changes in renal haemodynamics may be involved in the attenuated
antinatriuresis. However captopril did not alter renal blood flow during
nerve stimulation and, whilst in the presence of saralasin there was a
small fall in renal blood flow, the attenuation of antinatriuresis and
antidiuresis was of the same magnitude. In addition a direct action of All
may have been removed by pharmacological blockade. There is some
evidence against this being the explanation. Two studies have shown that
the antinatriuresis mediated by renal nerve stimulation can be completely
blocked by alpf^-adrenoceptor antagonism with prazosin (Osborn et al,
1983: Hesse and Johns, 1985). However the rise in plasma renin was
unaffected by prazosin. If the direct tubular action of All was important in
this experiment then its effects should still have been observed (Handa and
Johns, 1987).
Further studies in rats have strengthened this argument (Johns, 1987a:
Johns, 1987b). The effect of elevating the activity of the RAS (by salt
depletion) and of decreasing RAS activity (by administration of
deoxycortone acetate (DOCA) and saline to drink) were compared. Low
level renal nerve stimulation caused decreases in sodium and water
excretion in sodium deplete rats (high basal All), but these responses were
abolished by continuous captopril infusion. In rats given DOCA and saline
to drink (low basal All) low level renal nerve stimulation had no effect on
excretion of water and sodium, however in a similar group of high salt
rats given a continuous All infusion low level renal nerve stimulation
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decreased water and sodium excretion by a similar amount to that seen in
normal, sodium replete rats. These data are therefore consistent with the
view that All can facilitate adrenergic transmission at a tubular level
(Johns, 1987b).
Interpretation of the present results. The results of the present study
showed no augmentation of antinatriuresis when All and NA were given
simultaneously in man. This study was designed to seek evidence for a
postsynaptic AII/NA interaction in man. The conclusion from the animal
evidence is that an AII/SNS interaction occurs but the exact location of
such facilitation is unclear. Studies of renal nerve stimulation cannot
differentiate between a presynaptic and a postsynaptic interaction. The
present findings argue against a postsynaptic interaction, and taken with
the animal evidence, suggests that the AII/SNS interaction demonstrated in
animal studies may be presynaptic in origin.
Another possibility is that an action of All to facilitate responses to
SNS may be fully expressed in the salt replete state. Increments of All
and NA by infusion will then have only direct additive effects as seen
rather than an augmented effect. This has not been tested in the present
study. However in rats Johns (1987b) showed that the pattern and
magnitude of the changes in water and sodium excretion in response to
renal nerve stimulation were very similar in both normal, sodium replete
rats and in sodium depleted rats. These findings support that a facilitatory
effect may be maximal in the sodium replete state.
It is also worth noting that the infusion of exogenous All and NA
does not exactly mimic the effects of endogenous All and NA, since the
latter are both produced locally and systemically. Exogenous All is able to
act on all blood vessels with which it comes in contact. However
intrarenally produced endogenous All may be produced in different amounts
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in differing parts of the kidney and not affect some parts in contact with
exogenous All (Levens et al, 1981). This is supported by the finding that
angiotensin converting enzyme in the rabbit kidney is localised to specific
parts, namely endothelial cells of renal arterioles, glomerular and
intraglomerular capillaries and epithelial cells of the proximal tubule
(Caldwell et al, 1976). Furthermore the increment in circulating NA
brought about by infusion of NA is not accompanied by high intrasynaptic
levels of NA as occurs with nerve stimulation.
Although aldosterone levels rose during All infusion the immediate
effect of AN on sodium excretion seen in our study is unlikely to be due
to these changes (see discussion 13.2 above).
In summary our results have shown that low doses of AN and NA
alone cause a significant reduction in urinary flow and sodium excretion in
man with no change in systemic blood pressure or creatinine clearance.
The concomitant infusion of AN and NA caused a simple additive but not
synergistic reduction in sodium excretion. We have therefore found no
evidence to support a postsynaptic interaction of low doses of AN and NA
on renal sodium excretion in man.
13.5 Evidence that noradrenaline acts as a circulating hormone.
In the discussion above (13.3) I introduced the concept that NA may
act as a circulating hormone as well as a neurotransmitter (Izzo, 1983;
Scriven et al, 1983). More recently Chang and coworkers (1988) have
reassesed the threshold for response to NA infusion in man using low,
"physiological" doses (0-54 ng/kg/min). In resting, supine subjects they
showed that the threshold venous plasma NA concentration for measurable
effects on arterial BP was lower than earlier studies had suggested.
Furthermore these concentrations were well within the physiological range.
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Review of the literature shows the following threshold or lowest dose
used with detectable change in blood pressure (diastolic, systolic or mean):
Fitzgerald et al, 1979 30 ng/kg/min
Grimm et al, 1980 42 ng/kg/min
Hjemdahl et al, 1983 90 ng/kg/min
Izzo, 1983 20 ng/kg/min
Scriven et al, 1983 20 ng/kg/min
Gordon et al, 1987 50 ng/kg/min
Blankestijn et al, 1988 30 ng/kg/min
Chang et al, 1988 18 ng/kg/min
The variation may by explained in part by different experimental
procedure. Chang and coworkers recorded BP intra-arterially compared with
non-invasive measurements in all other studies. Also Chang and coworkers
excluded hand blood flow by cuff occlusion at the wrist for simultaneous
measurement of forearm blood flow by strain-gauge plethysmography.
Hjemdahl and coworkers studied their subjects in the semi-supine position
and found that a higher rise in plasma NA and a higher NA infusion dose
are needed before a detectable haemodynamic change occurs. This is
important with regard to our study in seated subjects (Chapter 5, 13.3,
receiving 25 ng/kg/min), though a rise in BP would be expected to reverse
the renal effects we have demonstrated.
These studies support that NA may act as a circulating hormone as
well as a local neurotransmitter and is relevant to the design and
discussion of other studies in this thesis.
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13.6 Methodological considerations concerning the studies of urinary
sodium excretion (chapters 4-6).
(a) Measurement of creatinine clearance as a measure of glomerular
filtration. Effect of angiotensin II and noradrenaline on renal blood flow.
(b) Lithium clearance as a marker of proximal tubular sodium
handling.
13.6(a) Measurement of creatinine clearance as a measure of glomerular
filtration. Effect of angiotensin II and noradrenaline on renal blood flow.
One limitation of these studies is that creatinine clearance has been
used as a measure of glomerular filtration. A second limitation of these
studies is that renal blood flow was not measured. As GFR did not change
in any of these studies this has been taken to support that the observed
effects on sodium excretion are due to an influence on tubular sodium
handling. The experimental evidence supporting this has been cited above.
Inulin clearance and excretion of para-aminohippurate (PAH) have been
most widely used in studies to measure glomerular filtration and effective
renal plasma flow respectively in man. I now review the evidence in man
in more detail.
Effect of angiotensin II on glomerular filtration and renal plasma
flow. The renal effects of subpressor doses of All have been the subject of
few studies. Pressor doses are recognised to cause a decrease in renal
plasma flow and GFR (Finnerty et al, 1961; Vagnucci et al, 1964). Two
groups have used lower doses of AN with minor pressor effects. Ajzen and
coworkers (1968) using a dose of 2 mcg/min (approximately 2.9 ng/kg/min)
show a fall in renal plasma flow with no change in GFR (inulin clearance).
Aurell (1969) using doses between 1.1 and 1.5 ng/kg/min show a fall in
renal plasma flow (PAH method) and a fall in GFR (inulin clearance).
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Subpressor doses of All have been employed by three groups of
workers. Hollenberg and coworkers (1974) have shown that a low dose of
All (1 ng/kg/min) reduces renal blood flow assessed by *"^Xenon washout
studies in both sodium replete (intake 200 mmol/24 hr) and sodium deplete
subjects (intake 10 mmol/24 hr). Ljungman and coworkers (1983) studied
doses of AN 0.1 and 0.5 ng/kg/min and show no significant change in renal
plasma flow or GFR. In contrast Eadington and coworkers (1991) show that
a dose of 0.5 ng/kg/min causes a small change in renal plasma flow and no
change in GFR, whereas a dose of 1.0 ng/kg/min caused small changes in
both GFR and renal plasma flow.
It therefore seems likely that the "threshold" dose of AN for effect
on glomerular filtration and renal plasma flow lies between 0.5 and 1.0
ng/kg/min. The dose of AN used in these studies (1 ng/kg/min) is at upper
end of this range.
Effect of noradrenaline on glomerular filtration and renal plasma
flow. The effect of low doses of NA on glomerular filtration and renal
plasma flow in man has also been the subject of few studies.
McQueen and Morrison (1961) showed that a dose of 140 ng/kg/min
had no significant effect on GFR (inulin clearance) but significantly
reduced renal plasma flow. Similarly Baldwin et al (1963) studied the
effect of a range of doses of NA (38-440 ng/kg/min) and showed no effect
on GFR (inulin clearance) and significant reduction in renal plasma flow
(PAH method). The lowest dose used (38 ng/kg/min compared with 25
ng/kg/min used in our study) caused a small reduction in renal plasma
flow.
Using a different technique ( Xenon washout) Hollenberg and
coworkers (1972) studied the effect of intrarenal arterial infusion of NA in
healthy man. The calculated threshold increment in inflow NA
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concentration for effect on renal blood flow was 100-300 pg/ml. The
increment seen in venous plasma NA in our studies was 280 pg/ml (chapter
five) and 316 pg/ml (chapter six).
The dose of NA used in the present studies (25 ng/kg/min) therefore
has no effect on GFR and may be considered a threshold dose for effect
with regard to renal plasma flow.
As noted earlier (13.4) in the discussion, the renal vascular effects of
combined infusion of All and NA in these low doses has not been subjected
to systematic investigation. Renal plasma flow was not measured and GFR
was estimated by creatinine clearance in this study. The absence of change
in the latter argues against a major renovascular interaction. Whilst such
an interaction has not been excluded I have concentrated the discussion on
the possibility of an interaction at the tubular level.
13.6(b) Lithium clearance as a marker of proximal tubular sodium
handling.
[This has been reviewed in detail by Koomans, Boer and Dorhout Mees,
1989. The essential arguments are presented here. I have referred to the
original manuscripts of references cited and more recent findings have also
been included. For more detailed referencing the reader is referred to the
above review.]
The lithium clearance technique has recently been recommended as a
method to quantitate sodium and water delivery from the proximal tubule
by Thomsen and colleagues (1984). Conventional indirect methods do not
allow quantitative analysis and the technique has been widely embraced.
However Navar and Schafer (1987) point out that much of the evidence
supporting the techniques use is circumstantial and do not support its
207
unconditional use.
Sodium is freely filtered at the glomerulus and approximately 75% is
reabsorbed by the proximal tubule. Most of the remaining sodium is
reabsorbed distal to this and only 1% of the filtered load is excreted in
the urine. For lithium clearance to act as a marker of proximal tubule
reabsorption three main criteria must be fulfilled. (1) Lithium should exert
no influence on renal function. (2) Reabsorption of lithium should occur in
proportion to sodium and water along the entire proximal tubule (3) No
reabsorption of lithium should occur beyond the proximal tubule.
Lithium and renal function. It is recognised that high plasma lithium
levels acutely alter renal function, causing increased sodium and potassium
excretion, hydrogen ion retention and decreased water reabsorption (Singer
1981). The normal therapeutic range of plasma lithium is 0.6-1.2 mmol/1 at
12 hours post dosage. However the doses usually given to man in lithium
clearance studies (250-750 mg Lithium carbonate) give plasma levels of
0.2-0.3 mmol/1 at 12 hours. It is generally assumed that renal effects of
lithium are absent at concentrations below 0.4 mmol/1 but this has not
been studied systematically. In man recent evidence is conflicting. Jeffrey
and coworkers (1988) showed that a dose of 750mg lithium carbonate
caused a natriuresis ten hours later at a plasma level of 0.29 mmol/1 and
also that the natriuretic response to the dopamine prodrug, gludopa, was
attenuated by this dose of lithium. Since the published review further
information has become available. Schoors and Dupont (1990) investigated
the effect of lithium on the response to intravenous dopamine using the
same dose of lithium and achieving similar plasma lithium concentrations
(0.26 mmol/1). The natriuretic response to dopamine was not altered,
though in this study lithium per se also did not cause a natriuresis. Luik
(1990) found that a dose of 600mg Lithium carbonate achieving a plasma
208
lithium concentration of 0.22 mmol/1 was natriuretic. Peart and coworkers
(1988) have shown that a dose of 500mg lithium carbonate increased
sodium excretion in the 24 h post dosage and decreased sodium excretion
in the following 24h. Strazzullo and coworkers (1988) show that a dose of
300mg lithium carbonate has no effect on renal function, though no plasma
lithium concentration was given. In contrast Girbes and coworkers (1990)
show that a dose of 300mg lithium carbonate achieving a plasma lithium
concentration of 0.12 mmol/1 was natriuretic. It is possible that flameless
atomic absorption photometry may allow lithium clearance studies to follow
normal trace lithium handling and avoid the need for oral loading with
lithium altogether (Durr et al, 1990). This problem is therefore not yet
resolved.
Reabsorption of lithium in the proximal tubule, loop of Henle and
distal and collecting tubule. Evidence has been obtained principally from
micropuncture studies in animals, studies during maximal water diuresis and
pharmacological studies with diuretics.
Direct measurement of lithium delivery is possible by micropuncture
in animals. This is however limited to superficial nephrons in anaesthetised
animals. In addition only part of the nephron is accessible, up to the late
proximal tubule and subsequently the distal convoluted tubule. The pars
recta of the proximal tubule and the loop of Henle cannot therefore be
studied independently. Using this technique Hayslett and Kashgarian (1979)
show that 57% of the filtered lithium is reabsorbed before the late
proximal convoluted tubule and a further 18% is reabsorbed before the
early distal convoluted tubule. Thomsen (1984) argues that given the known
anatomy and function of the pars recta it may be assumed that absorption
occurs in the pars recta rather than the loop of Henle. Animal studies
support this interpretation except in one circumstance. In sodium deplete
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rats and dogs FEjj was found to fall disproportionately with the reduction
in sodium delivery to the proximal tubule (Kirchner, 1987). Lithium
reabsorption in these circumstances is assumed to have occurred in the
distal and collecting tubule as the disproportionate fall in FE^ could be
prevented by amiloride which acts selectively at this part of the nephron.
However no sharp fall in FE^j has been shown in man during salt
restriction (Koomans et al, 1989). In addition two groups have shown that
amiloride does not alter lithium clearance in sodium deplete man (Boer et
al, 1988; Bruun et al, 1989). Leyssac and coworkers (1990) have recently
confirmed the findings of Hayslett and Kashgarian by micropuncture
studies, but also show that during osmotic diuresis with mannitol lithium
reabsorption follows more closely the net water reabsorption rather than
net sodium reabsorption. Thus during osmotic diuresis lithium clearance
may slightly overestimate the water outflow from the proximal tubules.
Indirect evidence supporting the technique has been obtained by
studying FE^j during manoeuvres supposed to alter proximal sodium
reabsorption. In general FE^j is found to alter as well. FE^j is increased
by saline infusion, volume expansion by mineralocorticoid, hypotonic
expansion with antidiuretic hormone and decreased by volume depletion due
to thiazides, acute elevation of plasma oncotic pressure and upright
posture.
Pharmacological studies are complex. Acetazolamide, a carbonic
anhydrase inhibitor, has a major action on the proximal tubule and causes
a marked rise in FE^j. However carbonic anhydrase is not confined to the
proximal tubule. Thiazides with carbonic anhydrase inhibitor activity also
cause a rise in FEjj. The "loop" diuretic frusemide causes a large increase
in FEjj but lesser increases in some other proximal markers. This may be
due to an effect of frusemide both on the proximal tubule and to
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abolishment of pre-existing lithium transport in the loop of Henle. A
recent study by Colussi and coworkers (1989) using acetazolamide and
frusemide alone and in combination in salt replete normal volunteers, shows
that the frusemide increase in FEjj was not an action on carbonic
anhydrase. This further supports a distal effect of frusemide on lithium
transport, though an effect of frusemide on the proximal tubule
independent of carbonic anhydrase inhibition has been demonstrated.
Amiloride which acts at late distal tubule and collecting duct produces no
change in FE^j ln t^ie sa^ rePlete state. However triamterene, which also
acts at collecting tubules, causes a rise in FEjj and FEj^ but no rise in
fractional excretion of phosphate, a proximal marker (Wetzels et al, 1989).
Pharmacological studies are therefore inconclusive.
Three other findings suggest that lithium can be reabsorbed by the
loop of Henle. Firstly in humans during volume expansion with
mineralocorticoid there was an exceptionally large increase in FELj, which
was greater than the fall in maximal free water clearance, a second
method of estimating fractional proximal sodium reabsorption (Boer et al,
1987). Studies in animals suggest that this is at least partly due to reduced
reabsorption in the loop of Henle. Secondly in healthy volunteers
indomethacin, a prostaglandin synthetase inhibitor, markedly reduced FE^j
whilst FEj^a was unaltered (Galllard et al, 1987; Rabellnk et al, 1989).
Proximal solute (phosphate and uric acid) handling was not altered,
agreeing with the absence of a proximal effect. Prostaglandin synthetase
inhibitors increase medullary thick ascending limb reabsorption, diminish
papillary blood flow and thus increase the corticomedullary osmotic
gradient. Increased lithium reabsorption may therefore have occurred in the
loop of Henle. Finally in water loaded volunteers the administration of the
vasopressin analogue dDAVP reduced both FEj^ and FEjj (Boer et al,
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1988). This may be explained in the same way as for the effect of
indomethacin, by direct and indirect (increasing the corticomedullary
osmotic gradient) effects. Koomans and coworkers (1989; Boer et al, 1990)
conclude the falls in FEj j with indomethacin (9% of the filtered load) and
dDAVP (2 to 3% of the filtered load) confirm that distal lithium
reabsorption can be stimulated under certain conditions. The large rise in
FEjj during mineralocorticoid escape suggests that lithium reabsorption
may also take place in the loop of Henle under normal conditions.
Summary. Estimation of proximal tubule sodium reabsorption by the
lithium clearance technique method comes closer to direct measurement
than any other indirect method. Lithium per se may alter tubular sodium
handling. Most lithium reabsorption occurs in the proximal tubule. However
there are clearly circumstances when reabsorption in the loop of Henle or
distal nephron occurs. The known conditions invalidating the method are in
the presence of antidiuretic hormone, NSAID therapy, salt depletion
(probably not in humans) and during osmotic diuresis.
With regard to the studies presented in this thesis there are
important practical points to be made. (1) The subjects were studied
sodium replete (2) A placebo control study day with lithium alone
administered was included. (3) The observed effect of intervention (All
infusion and NA infusion) fits with the known effects on sodium excretion
when studied without lithium pretreatment. (4) The observed effect on
FEjj was compared with a second method for determining delivery from
the proximal tubules, fractional distal delivery (for All infusion). (5)
Subjects were studied during maximal water diuresis to ensure suppression
of antidiuretic hormone, which avoids an antidiuretic hormone effect on
lithium reabsorption in collecting tubules. (6) Subjects were taking no
regular oral medication and were forbidden to take aspirin or other NSAID.
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13.7 The effect of angiotensin II on the stoke volume response to beta-
agonism In man (chapter seven).
In this study we return to the possibility that there is an AII/SNS
interaction occurring at the level of the myocardium or an effect on intra¬
thoracic blood volume raised by the findings in chapter three, discussion
13.1
In considering the results of this study it is important to emphasise
several aspects of the use if ISO and All in experimental animals and man.
The haemodynamlc effects of Isoprenaline infusion: There is a well
recognised dose related increase in CO. This is associated with an
increased systolic BP and a fall in TPR reflected by a fall in diastolic BP.
The increase in CO caused by ISO can be separated Into two components.
Firstly there is a rise in HR in a dose related manner. Secondly there is
an initial ISO induced increase in SV at low doses but this SV increase
attains its maximum quickly with no further increase and even decreases
as the dose of ISO in increased further. This has been previously shown in
man with 6-15% increases in SV described (Krasnow et al, 1964; Stephens
et al, 1979; Goldstein et al, 1986), though the rise is frequently non¬
significant (Krasnow et al, 1964; Stephens et al, 1979). Our results confirm
these findings.
These actions of ISO contrast markedly with isolated chronotropic
change. When HR is increased by pacing, in the absence of inotropic
stimulation SV falls and CO is unchanged. When pacing occurs in the
presence of an inotrope SV is maintained and CO increases (Ross et al,
1965). Thus an important inotropic effect of ISO is the maintenance of SV,
which with rising HR leads to an increase in CO. It is also important to
note that sympathetic stimulation similarly results in a rise in heart rate
and an increase in myocardial inotropy, reflected by an increase in SV, and
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that these two effects are independent (Ilebekk et al, 1978). Thus, provided
cardiac preload and cardiac afterload are not altered, change in SV more
closely reflects change in myocardial inotropy than CO, a composite of SV
and heart rate.
Cardiac effects of angiotensin II: All has been shown to have variable
effects on the heart and circulation, dependent in part on the preparation
used for investigation. Thus All has been shown to have a positive
inotropic effect in isolated kitten papillary muscles (Koch-Weser, 1964),
rabbit atria (Trachte et al, 1981) and isolated cat whole heart (Dempsey et
al, 1971), but a negative inotropic effect on the myocardium in the intact
circulation of dogs (Frank et al, 1970). All also exerts a positive inotropic
effect on isolated human atrial muscle trabeculae (Moravec et al, 1990),
however infusions of All in man are associated with no change or small
falls in CO (Segel et al, 1960; Yu et al, 1961). These findings in the intact
circulation are attributed to an increase in TPR and cardiac afterload, and
baroreflex induced reduction in CO (Yu et al, 1961). Similar findings are
seen when an inotrope which also causes an increase in TPR such as NA is
infused. The main effect is to cause increases in systolic and diastolic BP
and TPR with a baroreflex bradycardia and little change or a fall in CO.
Interpretation of the present study: In this study our major finding is
that when All is infused with ISO, there is an augmented stroke volume
response with no effect on the chronotropic response. This occurs with a
dose of AN which alone causes no change or a small fall in SV. Ail alone
did cause some peripheral vasoconstriction as evidenced by small increases
in systolic and diastolic BP and TPR. However it is important that there
was clearly no change in HR confirming that the baroreflex was not
activated.
Our results confirm that All interacts with beta-sympathetic
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stimulation to enhance the stroke volume response. There are three main
influences on SV, the force of ventricular contraction (cardiac inotropy as
discussed above), cardiac preload, the Starling mechanism and cardiac
afterload. Our study is however limited in confirming the mechanism of
this interaction as further measures such as central venous pressure or
echocardiographic left ventricular dimensions were not available.
Nevertheless our data suggest that afterload is well matched in the PL/ISO
and the All/ISO study days. Afterload is determined largely by peripheral
vascular resistance, the physical characteristics of the arterial tree and the
volume of blood that it contains at onset of ventricular ejection and is
importantly influenced by arterial pressure. Our data show that TPR and
systolic BP and diastolic BP are no different on these study days and
together suggest that afterload is also similar. Thus it appears likely that
the interaction occurs either by enhanced contractility or by increased
preload. The latter mechanism is supported by animal data, which use more
invasive techniques and show that during ISO infusion All relocates venous
blood from the splanchnic circulation to the heart hence increasing SV
(Stokland et al, 1986). Although our data agree with that of Stokland et al,
we were not ethically able to measure such regional blood flow changes in
normal man by invasive cannulation. The hormonal data in our study
showing a trend for ANP to rise during infusion of both All and ISO
support the relocation of blood in the circulation towards the mediastinum.
Other investigators have shown that a rise in ANP is an indicator of right
atrial filling (Richards et al, 1986). However peripheral venous ANP levels
are liable to be a fairly insensitive measure of cardiac filling pressures in
normal man. It is therefore not surprising that the relatively minor changes
in filling pressures expected in this study were not reflected by significant
changes in the peripheral venous ANP levels. Furthermore previous data in
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man also support this proposed mechanism since Benjamin et al (1988) have
shown that All augments the venoconstrictive effects of sympathetic
stimulation, which is also liable to increase cardiac filling pressure. With
regard to this study the effect of infused ISO fits in with this theory in
that it has previously been shown to increase venous return in man (Leenan
and Reeves, 1987). There are however three alternative mechanisms which
may contribute or explain the observed All/ISO interaction and these are
considered below.
Firstly All may increase myocardial catecholamine release or decrease
catecholamine reuptake locally within the myocardium. There is a wealth
of animal data to support either of these possibilities (see Introduction).
Measurement of venous plasma NA as in this study is a useful indicator of
general SNS activity but is clearly not sensitive enough to reflect localised
changes in catecholamine release or uptake in the heart. With regard to
the possibility that AN facilitates NA release we measured venous plasma
NA. Clearly no increase in plasma NA was seen with AN alone. Neither
were the small increases in plasma NA caused by our low dose range of
ISO infusion affected by concomitant AN infusion. It is possible that
coronary sinus blood sampling may reveal local changes (Schwartz et al,
1979) but such investigation is ethically impossible in normal human
volunteers. With regard to the possibility that AN inhibits myocardial NA
uptake it is worth noting that ISO is not taken up by uptake-1 in the same
way as NA but is rather taken up by uptake-2 (Goldstein et al, 1985).
Therefore any postulated inhibitory effect of AN on NA uptake would not
similarly effect ISO uptake. This makes it unlikely that the augmented
stroke volume effect of ISO and AN together is due to any direct effect
on NA uptake. If this did occur, the sequence of events would have to
have two stages ie. ISO might release myocardial NA, the reuptake of
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which is then Inhibited by AIL
Secondly it is interesting that in an analogous experiment in man All
was able to increase SV and CO when given with a vasodilator (Landes and
Kummer, 1959). In our study All alone did cause some peripheral
vasoconstriction but ISO induced peripheral vasodilatation was able to
totally overcome this. It is therefore possible that the pharmacologically
induced afterload reduction allowed All to manifest its inherent inotropic
effect.
Thirdly a further factor tending to limit the myocardial response to
All is that All causes a decrease in coronary blood flow (Fowler and
Holmes, 1964; Xiang et al, 1985). This reduction may also have been
abolished in our study by ISO, as ISO infusion as well as reducing TPR also
increases coronary blood flow (Krasnow et al, 1964; Gwirtz and Stone,
1982).
We also found no augmentation of the systolic BP response with the
All /ISO combination, which contrasts with our earlier experiment in which
All and NA combined caused a significant synergistic interaction in rise in
SBP (chapter three). SBP depends not only on SV and the character of
ventricular ejection during systole but also on aortic and large vessel
compliance. ISO may have increased large vessel compliance and, as with
TPR, this vasorelaxant effect may have been unaffected by concomitant
All infusion. In this way the synergistic increase in SV seen in the present
study may not manifest itself as an augmented rise in SBP due to a
concomitant ISO induced increase in aortic compliance.
In summary, our results suggest that small. increments of All can
augment the stroke volume response to beta-agonism in man. This action is
probably due to All relocating blood into the mediastinum and hence
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increasing cardiac filling pressures, but several other possibilities merit
further investigation.
13.8 The effect of angiotensin II on endogenous noradrenaline release in
man (chapter eight).
In this study, when we were choosing an All infusion rate to use, we
were aware of two opposing considerations once more. We wanted to infuse
enough AN so that our methodology could detect any AII/NA interaction.
On the other hand, we aimed to use as low a dose of AN as possible so
that the baroreflex would not be activated as this would complicate
interpretation of the results. As a compromise we chose 1.5 ng/Kg/min.
This dose was certainly low enough to bring about no haemodynamic
effects (Table 8.1). However we were unable to demonstrate any
augmented increase in NA release in response to physiological stimulation
of the SNS in the presence of this low dose of AN, despite a wide range
of different levels of sypmathetic activation. It is possible that our chosen
dose of AN was too low to reveal such an interaction. However, the rise
in plasma AN during infusion was similar to that seen in chapter three in
which there was a significant AII/NA interaction with regard to systolic
blood pressure. Also the control values of AN obtained in our study
correspond well with those obtained by others with constant sodium diets
(129-150 mmol/day) in normal volunteers and the rise in plasma angiotensin
II is similar to that found during low sodium intake diets (9-12 mmol/day)
(Oelkers et al, 1974) as noted earlier. Indeed our AN samples for this study
were all assayed in the same laboratory as Oelkers et al 1974. The effect
of higher doses of All infusion during SNS stimulation have not yet been
investigated.
One further possibility for our failure to demonstrate an interaction
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is that venous plasma NA may not be an adequate reflection of
intrasynaptic NA release. In general the measurement of venous plasma NA
provides a useful estimation of average sympathetic outflow (Goldstein et
al, 1983). Thus plasma NA is increased by a variety of stimuli thought to
activate the SNS (Lake et al, 1976; Robertson et al, 1979; Watson et al,
1979) and is decreased by physical disruption of sympathetic nerves
(Nielsen et al, 1980) or pharmacological interference such as postganglionic
blockade by debrisoquine (Flammer et al, 1979). Wallin et al (1981) have
shown by direct measurement of sympathetic neural activity that plasma
NA is directly related to measured sympathetic activity. In addition plasma
NA has been shown to reflect activation and deactivation of the baroreflex
during pharmacological induced changes in BP (Eckberg et al, 1986). On the
other hand Brown et al (1982) have shown that synaptic cleft and plasma
catecholamine concentrations can be manipulated independently. More
recently Wallin et al (1987) have shown that the relative change of
venous plasma NA during isometric handgrip is less than the change in
recorded muscle sympathetic activity. Furthermore, although plasma NA is
a useful indicator of global sympathetic activity, it cannot necessarily
reflect changes if selective activation of parts of the sympathetic nervous
system occurs. There is evidence of the non-uniformity of sympathetic
efferent activity to various organs (Abboud, 1979a; Shepherd, 1982). Thus
there are well recognised limitations in using venous plasma NA as an
index of sympathetic activity and these limitations may contribute to our
inability to detect a facilitatory effect of All. It is however clearly not
possible to measure intrasynaptic NA directly in man but the fact that
there were no significant haemodynamic effects in this study does give us
further confidence that All genuinely does not have any facilitatory effect
on intrasynaptic NA release.
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In summary within the constraints of this study we have found no
evidence to support the enhancement of endogenous NA release by the
Infusion of this low dose of All.
13.9 The effect of angiotensin II on the haemodynamic and plasma
noradrenaline responses to tyramine infusion in man (chapter ten).
In this study we have therefore found that a low dose of All does
not potentiate the pressor response nor plasma NA response to TYR
infusion in man. This compares with our earlier finding that All does not
enhance the endogenous release of NA in response to physiological
stimulation of the SNS in man (chapter eight). However our results would
initially appear to contrast with those of Kaneko et al (1966) who show
that All can augment the pressor response to TYR in man. However the
studies are not directly comparable. The dose of All in the study of
Kaneko et al was much higher (approximately 4-15 ng/kg/min) and was
associated with a considerable rise in blood pressure during All infusion (16
mmHg rise in mean arterial pressure). When designing this study, it was
important that the dose of All chosen should have no effect on diastolic
BP in order to avoid the complicating effect of baroreflex changes. A
subpressor dose of All was therefore deliberately chosen for this reason
and also so that our study would complement that of Kaneko et al (1966)
rather than reproduce it.
The haemodynamic effects of Infused tyramine: In man infused TYR
is used as a standard method by which to release endogenous neuronal NA.
To understand these and other results, it is worth considering its
haemodynamic effects in a little more detail. As we have found, TYR is
known to cause a marked increase in systolic BP with little change in
diastolic BP (Cohn, 1965; Scriven et al, 1983). This by itself would suggest
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that TYR raises BP mainly by stimulating cardiac contractility.
Furthermore, as has also been described before, TYR causes a late and
relatively minor change in venous plasma NA in comparison to the large
increment in systolic BP (Blanchetti et al, 1982; Colombo et al, 1988). This
and its haemodynamic effects can be attributed to the fact that TYR
causes localised rather than generalised release of NA. Forman et al (1984)
have shown that despite causing only small non-significant changes in
arterial plasma NA levels, peripheral venous infusion of TYR results in a
more than fourfold rise in myocardial release of NA as demonstrated by
coronary sinus blood sampling in man. Localised myocardial release of NA
makes little contribution to the total circulating plasma NA (Goldstein et
al, 1983; Esler et al,1984) and would therefore not be reflected by changes
in peripheral blood.
Further support for a mainly myocardial action of TYR in man comes
from the study of Scriven et al (1984). The effect of propranolol on the
response to TYR infusion was examined. Propranolol attenuated both the
cardiac inotropic effects (estimated by systolic time intervals) and the rise
in BP seen with TYR. They conclude that TYR exerts its pressor effect
mainly by stimulation of cardiac beta-receptors. In a similar study Colombo
et al (1988) using a non-selective and a selective beta-blocker have shown
that the pressor effect of tyramine is mainly due to stimulation of cardiac
betaj-receptors. Thus it would appear that TYR mainly acts by releasing
myocardial NA which then stimulates cardiac beta j-adrenoceptors.
Interpretation of the current study: The current study is limited in its
power to exclude an interaction by virtue of the small group studied which
may introduce a Type II error (see discussion in section 13.10 below).
However the clearly superimposable haemodynamic and plasma NA results
argue against a major interaction. This study using TYR examines pre- and
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postsynaptic mechanisms at the same time. Venous plasma NA responses
after TYR infusion are a crude index of presynaptic NA release
particularly if the release is at a local, myocardial level, and the power of
the study can exclude only a major interaction (see discussion in section
13.10 below for power calculation). However the haemodynamic changes
reflect the end result of both pre- and postsynaptic effects and the power
of this study is sufficient to detect a small haemodynamic interaction.
Within these limitations this study did not find evidence for an AII/NA
interaction at either the pre- or postsynaptic site. This agrees with our
previous inability to detect a presynaptic interaction (chapter eight), but
contrasts with our earlier studies of postsynaptic effects. Firstly, we have
seen that a subpressor dose of All synergistically augmented the systolic
but not the diastolic BP response to exogenous NA (chapter three).
Secondly we found that a subpressor dose of All augments the cardiac
stroke volume response to an ISO infusion (chapter seven). The apparent
difference between these postsynaptic results and our previous positive
postsynaptic findings are difficult to explain.
The previous studies described in chapter three and chapter seven
used exogenous NA and exogenous ISO so that differences between TYR on
the one hand and NA and ISO on the other hand may provide an
explanation. One possible explanation lies in intrasynaptic events. TYR
releases neuronal NA which acts principally on intrasynaptic alphaj- and
betaj- adrenoceptors whereas exogenous NA and ISO act principally on
extrasynaptic receptors of the alpha2 and beta subtypes. In addition, TYR
causes high local intrasynaptic concentrations of NA, and may therefore be
more efficient at activating intrasynaptic feedback mechanisms which limit
sympathetic activity. Clearly there are major differences which may
explain the different responses in the presence of All. The second possible
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explanation lies in the fact that TYR, NA and ISO all produce different
patterns of regional haemodynamic changes. For example, TYR is mainly
inotropic (Scriven et al, 1984; Colombo et al, 1988), ISO is inotropic and
an arterial vasodilator (Krasnow et al, 1964) whereas NA increase venous
tone, inotropic activity and arterial tone (Cohn, 1965). In view of these
complex effects, it is perhaps not surprising that All interacts with TYR,
NA and ISO to produce different haemodynamic patterns. Further detailed
studies of regional haemodynamic changes are required before a full
explanation can be given for our current results.
In summary we have found no evidence to support the enhancement
of haemodynamic or plasma NA responses to TYR infusion by All in man.
TYR exerts its pressor effect mainly by release of myocardial NA and
stimulation of cardiac beta-receptors. We have found no evidence to
suggest that this process is facilitated by All in normal man.
13.10 Limitations of studies of the RAS/SNS interaction using intravenous
infusions and/or ACE inhibitors in man.
The use of ACE inhibitors: ACE inhibitors are potent inhibitors of the
angiotensin converting enzyme in animals and man and are a useful way to
manipulate RAS activity in experimental studies in addition to their
established therapeutic role. However some problems may be encountered
in using ACE inhibitors to investigate an AII/NA interaction. One premise
noted earlier is that the animal studies which support an interaction
between the RAS and the SNS have shown that this interaction occurs only
when the RAS is activated (Zimmerman et al, 1984). Despite this, previous
attempts to demonstrate an RAS/SNS interaction in man have nearly
always administered ACE inhibitors to normal volunteers and have hence
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investigated the differential effects of normal and low levels of RAS
activity.
Secondly inhibition of ACE, the same enzyme as kininase II, blocks
the degradation of bradykinin, a potent vasodilator. Opinion is divided as to
whether this may be of therapeutic importance with regard to the
hypotensive effect of ACE inhibitors. Nevertheless some groups have shown
increases in either plasma or urinary kinins (Swartz et al, 1979; Vinci et
al, 1979; Mimran et al, 1980), whereas other groups have not (Mookherjee
et al, 1983; Rasmussen et al, 1985). However the kallikrein-kinin system
may be more important as a local hormonal system regulating regional
blood flow (Carretero and Scicli, 1980) and local changes can occur without
change in circulating bradykinin levels or in urinary kallikrein (Johnston et
al, 1982). Furthermore alterations in bradykinin metabolism may stimulate
prostaglandin production (Regoli and Barabe, 1980). Increases in PGE2 in
plasma and urine metabolites have been demonstrated during ACE inhibitor
treatment (Swartz and Williams, 1982; Usberti et al, 1986). In experimental
studies Ishida and coworkers (1989) have confirmed that ACE inhibitor
treatment promotes very high bradykinin levels during bradykinin infusion.
Furthermore in dogs pretreated with ACE inhibitors higher plasma
concentrations of All were needed to produce pressor responses equivalent
to those seen in the same dogs under control conditions (Tree and Morton,
1980). The mechanism of this difference was not explored. In pithed rats
Antonaccio and Kerwin (1981) show that pressor responsiveness to
sympathetic nerve stimulation after ACE inhibitor treatment is not fully
restored by All infusion but was restored by All and indomethacin, a
prostaglandin synthetase inhibitor. These latter two studies and those cited
above show that bradykinin and prostaglandins may be altered by ACE
inhibitor therapy, though this may occur at a local rather than a
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circulating level. This may have little importance clinically but is
important in the design of studies reported in this thesis.
Finally the use of ACE inhibitors may be complicated by effects on
autonomic reflexes. Treatment with ACE inhibitors has been shown to be
associated with increased parasympathetic activity (Campbell et al, 1985)
and to cause resetting of the baroreflex set point (Dusing et al, 1987)
without affecting baroreflex sensitivity or sympathetic nervous reflexes
(Sturani et al, 1982; Dusing et al, 1987).
These effects are important complications rendering ACE inhibitors
imperfect tools with which to investigate the effects of All on SNS
activity. Thus, for the most part, in the studies presented here RAS
"activity" has been increased by infusion of All, and ACE inhibitors rarely
used.
The measurement of venous plasma NA as an index of SNS activity:
The general limitations of using venous plasma NA as an index of SNS
activity are discussed in section 13.8. It is also important to consider the
statistical power of these studies to demonstrate an interaction, considering
both a change in plasma NA and the power to demonstrate a change in
non-invasively recorded haemodynamics.
For illustration it is useful to consider the power in the smallest of
the studies, that is the effect of All on plasma NA and haemodynamic
responses to TYR infusion. This study, in six subjects, has a power of more
than 80% to detect an interaction in systolic BP of 10 mmHg and of 180
pg/ml in plasma NA. It is therefore clear that whilst small interactions
with regard to BP may be demonstrated, only large changes in global SNS
activity will be revealed by this approach, and more localised changes may
be overlooked.
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Because of these limitations a second approach was used to
investigate a possible haemodynamic AII/SNS interaction. The approach
chosen was that of infusion of hormone, drug and/or placebo into the
brachial artery of the non-dominant arm in healthy subjects. The vascular
effects were recorded by strain-gauge plethysmography. There are several
features of this technique that make it uniquely attractive for examining a
vascular interaction:
1. The vascular bed of the forearm is amenable to local infusion of
drugs in healthy man.
2. The blood flow to the forearm is approximately 1% or less of
total cardiac output. Thus by infusion of very low doses (many times lower
than used systemically), systemic effects of the drug can be avoided. The
forearm vascular bed may therefore be studied effectively in "isolation".
3. By avoidance of systemic effects the opposite, non-infused arm can
be used as control.
4. By avoidance of changes in systemic arterial pressure the local
vascular effect of the drug can be studied without activating neural or
hormonal reflexes.
5. Conversely the effect of the drug on vascular responses to
stimulation such as LBNP can be studied and again compared with the
control arm.
The studies described in chapters 10-12 use this technique and are
now discussed. The methodology and analysis of results are discussed in the
Methods (chapter two).
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13.11 The effect of angiotensin n on the forearm blood flow response to
noradrenaline (chapter ten).
and
The effect of local angiotensin II on the forearm blood flow response to
lower body negative pressure (chapter eleven).
In these studies we have shown that local intra-arterial infusion of
All, employing a dose which had no direct effect on blood flow, enhanced
the response to LBNP. In marked contrast, All did not affect responses to
locally infused NA. These studies employed doses of All (Chinn and
Dusterdieck, 1972) and NA (Chang et al, 1988) insufficient to cause a
systemic pressor response, and in the case of All, 1000-fold greater doses
do not affect blood flow in the opposite arm (Benjamin et al, 1989). Hence
the effects of the infusions used in the present studies may be assumed to
be limited to the infused forearm. LBNP has been shown to be a reliable
stimulus for reflex sympathetic vasoconstriction in the upper limb (see
Methods, chapter two for detailed discussion).
The dose of All infused (320 fmol/min), was chosen on the basis of
previously constructed dose-responses in the forearm (Benjamin et al, 1989),
to produce little effect on resting blood flow. Assuming a resting blood
flow in the forearm of 40-50 ml/min, this dose will have produced an
increment in All concentration in blood perfusing the forearm of
approximately 6-8 fmol/min, i.e. within the physiological range. In our
study it was not possible to confirm the increment in plasma concentration
of All, as angiotensinases within the peripheral circulation lead to marked
All clearance (Campbell, 1985) so that its measurement in venous effluent
would be of little value. In addition, distal arterial blood sampling would
have required a second arterial puncture and this was felt to be ethically
unacceptable. It was however important that the dose of All given was
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insufficient to produce reduction in local blood flow directly (tables 10.1
and 11.1), as reduction in resistance vessel calibre may non-specifically
alter responses to other vasoconstrictor stimuli (Doyle et al, 1959).
Our investigation has shown (figure 11.3) that with this small
increment in concentration of local All, producing no change in resting
blood flow, there was significant augmentation of the reduction in forearm
blood flow during sympathetic stimulation with LBNP, approximately
doubling the response. This effect of All confirms an interaction with the
sympathetic nervous system, and being confined to the infused limb, acts
at a peripheral site. From the results of our this experiment, this
interaction could occur presynaptically to produce increased NA release or
reduced reuptake, or act postsynaptically, either at the receptor or at a
postreceptor level.
In our first experiment the same dose of All (320 fmol/min) did not
affect the reduction in blood flow produced by local NA infusion (figure
10.1 ). As with LBNP, NA infusion reduced local blood flow, resulting in a
further small increment in local plasma concentration of plasma AIL
Resting blood flow was, however, lower in subjects receiving NA, leading,
if anything, to greater increments in All concentration in these subjects.
As LBNP and NA produced similar reductions in forearm blood flow,
differences in All concentration are unlikely to explain the absence of an
interaction between NA and AIL The absence of a postsynaptic interaction
might be explained by tachyphylaxis to either All or NA in the forearm
vessels. Although this may occur in vitro, it does not occur with either
agent during prolonged intra-arterial infusion in man (Whelan, 1967; Clarke
et al, 1989). Alternatively, the response to NA might be maximal with the
doses employed. We did not directly assess the response to higher doses of
NA. However, other workers have shown similar responses to our own with
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NA at 50 ng/min (Taddei et al, 1990), as well as further dose-dependent
reduction In local blood flow, at least to 200 ng/min (Taddei et al, 1990;
Collier et al, 1972b), and an 80% reduction in flow is achieved with 500
ng/min. On this basis, we are confident that the response to NA is not
maximal with the doses employed. Under these circumstances the failure of
All to affect the responses to NA implies that the major interaction in the
forearm in man is presynaptic rather than postsynaptic.
Studies examining the interaction between All and the SNS in man
have generally involved manipulation of circulating plasma All, either
through intravenous All infusion or systemic converting enzyme inhibition
(see introduction). In these circumstances it is not possible to localise the
site of any interaction. In the present experiments, with local All infusion,
interpretation of the findings is not confounded by the influences of
central, renal or cardiovascular reflex effects associated with systemic
administration. Based on the findings in animals and in vitro preparations,
the likely mechanism for presynaptic interaction is through an increase in
NA release from nerve endings, rather than by an effect on NA reuptake.
A major effect on reuptake in the present studies is unlikely in view of
the lack of interaction between All and NA. Other neurotransmitters may
be involved in peripheral sympathetic responses as, in man, forearm
vasoconstriction to LBNP is not abolished by the alpha-blocker
phenoxybenzamine (Taddei et al, 1990). There is evidence that stimulation
of purinoceptors may affect peripheral sympathetic responses in man
(Taddei et al, 1990) and animals (Holycross and Jackson, 1989). However,
at present, the evidence is against an interaction between purines and All-
induced potentiation of sympathetic neurotransmission (Holycross and
Jackson, 1989). Neuropeptide Y is also co-localised with NA in sympathetic
nerves. However, neuropeptide Y does not influence responses either to
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LBNP or NA in man (Clarke et al, in press). Thus, at present, there is no
evidence that a co-transmitter plays an important role in the interaction
between All and peripheral sympathetic nerves.
Basal concentrations of All in blood may also facilitate adrenergic
tone within peripheral blood vessels. Support for this hypothesis comes
from the experiments of Morganti and colleagues (1985a) who have shown
that, in patients with essential hypertension, the systemic administration of
an ACE inhibitor attenuates the increase of forearm vascular resistance
produced by LBNP. This issue may be further resolved by experiments
using the novel nonpeptide All antagonists (Timmermans et al, 1991).
In summary we have shown that All augments LBNP-induced
sympathetic vasoconstriction in forearm resistance vessels in man. The
absence of an effect of All on the response to infused NA suggests that
All facilitates sympathetic neurotransmission by a presynaptic action,
probably through increased NA release. The results of these studies, taken
together with studies in veins (Benjamin et al, 1988), suggest that
presynaptic facilitation of sympathetic neurotransmission represents an
important physiological action of All.
13.12 The effect of local angiotensin converting enzyme inhibition on the
forearm blood flow response to lower body negative pressure (chapter
twelve (a)).
and
The effect of systemic angiotensin converting enzyme inhibition and
reinfusion of angiotensin II on the forearm blood flow response to lower
body negative pressure (chapter twelve (b)).
In the first of these two studies evidence was sought for an effect of
endogenous All generation in the forearm vasculature on sympathetic
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neurotransmission. Assuming a resting blood flow in the forearm of 40-50
mls/min as before, infusion of enalaprilat (5 mcg/min) into the forearm
circulation should produce local concentrations of ACE inhibitor 2-3 times
the peak levels found in venous blood following oral administration of
enalapril lOmg (Biollaz et al, 1982). This dose of enalaprilat, when infused
into the forearm, has been shown previously (Benjamin et al, 1989) to
abolish the response to intra-arterial infusion of constrictor doses of
angiotensin-I, and markedly enhance the response to dilator doses of
bradykinin. This confirms that enalaprilat causes effective local blockade of
angiotensin converting enzyme and blockade of local generation of All. In
addition this dose of enalaprilat has no effect on resting blood flow when
infused alone. These results imply that local All and bradykinin metabolism
by ACE does not contribute to the maintainance of resting forearm
vascular resistance. The kinetics of the response are consistent with an
action on endothelially located, rather than plasma ACE (Benjamin et al,
1989). In the present experiment this dose, and a higher dose of enalaprilat
had no effect on resting forearm blood flow, or sympathetic
vasoconstriction with LBNP. The results suggest that, overall, local
angiotensin and bradykinin metabolism does not contribute to the
maintainance of forearm vascular resistance in these circumstances.
In this study therefore a major effect for locally generated All has
been excluded and in the second of these two studies, in which subjects
were pretreated by oral enalapril, the effects of circulating All were
examined. The dose of enalapril used (20 mg twice daily for two days)
produces maximal inhibition of converting enzyme and maximal reduction
of plasma All (Davies et al, 1984). The main difference between the
approach in the two studies is therefore that with local forearm
administration of enalaprilat (the active form of the prodrug enalapril)
231
local forearm vascular ACE activity is blocked and local effects are
examined but circulating All is unaltered. In contrast, with systemic ACE
inhibition, tissue, serum and vascular ACE activity is blocked throughout
the body and there is a major reduction in circulating All.
During systemic ACE inhibition there was a small but significant
reduction in systolic and diastolic BP and heart rate (Table 12(b).1) which
has been shown to occur in normotensive subjects in other studies. LBNP
caused no significant change in BP or heart rate and the forearm blood
flow responses to LBNP during systemic ACE inhibition were similar to
those seen earlier in the untreated group (chapter 11 and table 12(b).1).
These findings compare with those of others who have shown that there
was an enhanced response to LBNP (40 mmHg negative pressure) during
systemic ACE inhibition in normal subjects (Rasmussen et al, 1986) and
with the findings of Mancia et al (1988) who showed an attenuation of the
response to LBNP in hypertensive subjects treated with an ACE inhibitor.
Infusion of AN during systemic ACE inhibition caused a significant
dose dependent fall in resting forearm blood flow. Indeed, there was a
significant reduction in flow at both the same dose of AN (320 fmol/min)
and a lower dose (160 fmol/min) as that which had no effect on resting
forearm blood flow in subjects who were not treated with systemic ACE
inhibition (chapter eleven). Reduction in circulating AN may therefore
increase sensitivity to infused AII possibly by altering receptor availability
or numbers (Mendelsohn, 1985).
During AII infusion LBNP had no overall effect on reductions in
forearm blood flow. However, at a dose of AII 320 fmol/min the response
to LBNP was significantly enhanced (p<0.05). This dose was chosen to
produce plasma AII levels that approximate to normal physiological levels,
replacing the circulating AII withdrawn by systemic ACE inhibition. The
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finding that All enhances the response to LBNP in this study further
supports that circulating All facilitates sympathetic neurotransmission.
13.13 The effect of saralasin on the forearm blood flow response to lower
body negative pressure in sodium replete subjects (chapter twelve (c)).
and
The effect of saralasin on the forearm blood flow response to lower body
negative pressure in sodium deplete subjects (chapter twelve (d))_
These studies sought to investigate whether circulating All plays a
role in peripheral sympathetic neurotransmission by examining the effect of
blockade of All by saralasin infusion into the brachial artery at rest and
during stimulation with LBNP in both sodium replete and sodium deplete
subjects. An initial review of the effects of saralasin is necessary before
discussing the present studies.
Saralasin: A variety of specific peptide competitive antagonists of All
have been described. All are analogues of All with modifications in the 8
position with or without other position modification (Turker et al, 1974;
Marshall, 1976; Oparil, 1983). The substitution at position 8 with an
aliphatic side chain leads to a conformational change that impairs
activation of the All receptor. Substitution at the 1 position with amino
acids resistant to aminopeptidase cleavage leads to increased duration of
antagonism by blocking degradation. Sarcosine substitution at position 1
also increases binding affinity to the receptor site. The product with
combined substitution of sarcosine in position 1 and alanine in position 8,
saralasin, ([Sar'-Val5Ala®]-AII), is the most extensively used competitive
antagonist of All.
Actions of saralasin in vitro: Early experiments in vitro demonstrated
that these peptide analogues antagonised the effects of All in a wide
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variety of species and preparations (Pals et al, 1971a; Turker et al, 1971;
Yamamoto et al, 1972). The antagonism is specific for All in that the
responses to a variety of pressor agents including noradrenaline, tyramine,
phenylephrine and vasopressin were unaffected (Pals et al, 1971b;
Yamamoto et al, 1972). However antagonism occurred only in situations
where blood pressure was maintained by All, either by infusion of All, the
acute phase of unilateral renal hypertension, dehydration or in pithed rats,
but did not occur in normotensive rats, spontaneously hypertensive rats and
mineralocorticoid hypertensive rats (Pals et al, 1971a; Needleman et al,
1976). In addition the analogues exhibit some intrinsic agonist properties
under certain conditions (Turker et al, 1974; Needleman et al, 1976). These
analogues are therefore specific competitive antagonists of All with a
variable degree of partial agonist activity.
Actions of saralasin in man: Saralasin also antagonises the actions of
All in normal man during All infusion, salt deplete man and in patients
with "high renin" hypertension (Streeton et al, 1975; Case et al, 1976;
Hollenberg et al, 1976; Fagard et al, 1981). However in circumstances in
which plasma AN is normal or low, saralasin infusion causes a mild pressor
response and aldosterone release (Hollenberg et al, 1976; Fagard et al,
1981). In man therefore saralasin has proven to be a potent antagonist of
All, but also to exhibit some agonist activity particularly when plasma AN
concentrations are low (Case et al, 1976). This latter action is a limitation
in studies of specific AN blockade. It is possible that in the future specific
antagonists without agonist action may be more reliable. Recently such
non-peptide antagonists have been described (Wong et al, 1989).
Interpretation of the present studies: The expected findings if AN
exerts a tonic role in peripheral sympathetic neurotransmission, and that
this is blocked by saralasin acting as antagonist, are twofold. Firstly
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resting blood flow may be increased by the removal of direct and indirect
action of All, and secondly the reduction in forearm blood flow in response
to sympathetic stimulation with LBNP would be diminished compared with
control. The main finding of the first study in salt replete subjects was
that saralasin caused a dose dependent fall in forearm blood flow. This
suggests that saralasin was acting as an agonist at these doses in salt
replete subjects. The main finding of the second study was that whilst
resting forearm blood flow was not affected by saralasin infusion in salt
deplete subjects, there was significant enhancement of the reduction in
forearm blood flow with LBNP. This also suggests that saralasin is acting
as agonist in these conditions. The results of these studies are therefore
inconclusive, but the second finding is consistent with All agonism
facilitating sympathetic neurotransmission.
13.14 Methodological lessons learnt during the course of these studies for
future investigations.
1. Plasma noradrenaline. The limitations of measuring venous plasma
NA as an index of sympathetic activity have been discussed earlier (section
13.8 and 13.10). I would anticipate that measurement of arterial and
venous NA across a more limited vascular circuit would have a greater
sensitivity to demonstrate small differences and interactions. Examples of
such vascular circuits are the heart with arterial and coronary sinus
sampling, renal arterial and venous sampling, arterial and venous sampling
in the ipsilateral forearm and comparison of infused and contralateral non-
infused venous NA samples during intra-arterial infusion in one arm. There
are ethical restrictions to such studies.
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2. Haemodynamic measurements. The studies described in this thesis
have relied upon non-invasive assessments of systemic haemodynamics
including blood pressure, cardiac output and forearm blood flow. However
the studies suggest that the measurement of stroke volume, cardiac output
and central venous pressure are preferable.
3. Regional haemodynamic measurements. Regional haemodynamic
assessments would be a valuable extension of these studies, including
venous return, renal artery flow, liver blood flow and capillary blood flow.
Ethical constaints are likely to restrict such studies to ultrasound and
echocardiographic techniques with inherent limitations.
4. Pharmacological blockade of the RAS. The limitations of using
ACE inhibitors in these studies has been discussed in section 17.11. The
value of saralasin as an investigatory tool was examined in two studies
(chapter 13) with inconclusive results, most likely due to partial agonist
activity. However the recently described specific nonpeptide All blockers
will be exciting tools for use in future studies of RAS/SNS interactions in





This thesis has set out to systematically investigate the interaction
between the RAS and SNS in healthy man. There is a limited amount of
human data investigating this interaction directly with which to compare
the results of these studies. Earlier studies in the literature infused All in
doses of 1-10 ng/kg/min and showed no changes in venous plasma NA
(Beretta-Piccoli et al, 1980; Mendelsohn et al, 1980; Nicholls et al, 1981).
They are interpreted as providing evidence against an AII/SNS interaction.
Our results confirm a lack of effect of All on resting plasma NA. We also
showed no effect of All infusion in responses to a wide range of stimuli
known to activate the SNS and cause NA release. These stimuli include the
cold pressor test, forearm isometric handgrip, standing from lying, bicycle
exercise and tyramine infusion. These findings have also been confirmed by
recent studies of subpressor and pressor infusions of All both at rest and
during baroreceptor loading and unloading by head-down and head-up tilt
respectively (Goldsmith and Hasking, 1990; Goldsmith and Hasking, 1991). In
addition to haemodynamic recordings and plasma NA levels, NA spillover
was measured and the effects of All were compared with equipressor doses
of phenylephrine. Whilst there was no difference in plasma NA and NA
spillover with either infusion compared with control, a significant
bradycardia was seen with phenylephrine, which was not seen with AII
infusion. They conclude that All may inhibit the efferent response to
baroreceptor loading in humans (Goldsmith and Hasking, 1991). This finding
has been seen in both animals and man (Lumbers et al, 1979; Mace et al,
1985). The evidence from this type of investigation seeking a presynaptic
AII/SNS interaction using systemic intravenous infusion in man has not
revealed such an interaction.
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This conclusion however contrasts with our findings in the human
forearm vasculature in vivo. All caused a marked enhancement of reduction
in forearm blood flow in response to sympathetic stimulation with LBNP.
We have also, shown in the same circulation that All does not alter the
responses to infused NA. Our findings suggest that within the "isolated"
human forearm vasculature presynaptic facilitation of sympathetic
neurotransmission occurs. These findings await confirmation by
measurement of the arteriovenous difference in plasma NA across the
forearm circulation and NA spillover studies in the forearm. The technical
difficulty of performing this experiment has not yet been overcome.
Compelling evidence is also found in the venous circulation of the hand in
man. Benjamin et al (1988) show that doses of All that do not cause
venoconstriction alone cause dramatic enhancement of venoconstriction
caused by the deep breath reflex. The same dose of All had no effect on
the venoconstriction caused by infused NA. These findings suggest that All
augments sympathetically induced venoconstriction via a presynaptic
mechanism.
Also in contrast is that several studies in man now support a
postsynaptic interaction. In our first experiment we demonstrated that
during combined All and NA infusion there was a significant interaction
with regard to rise in systolic blood pressure but not diastolic blood
pressure. In a similar and simultaneous experiment Reams and Bauer (1987)
observed the same effect. They demonstrated that during a subpressor
infusion of All the dose of NA and the plasma NA level required to cause
small changes in blood pressure were significantly lower than during control
infusion. We also showed that All augments the stroke volume response to
ISO infusion in man, suggesting a postsynaptic All/beta-agonist interaction.
The major possibilities are that during ISO infusion All causes a relocation
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of blood from the splanchnic circulation to the heart or that All augments
myocardial contractility.
There are a number of conclusions that may be drawn. Firstly an
AII/SNS interaction has been clearly and directly demonstrated in man.
This interaction occurs at low doses of All that may be of physiological
and pathophysiological importance. The most compelling evidence for this
interaction comes from studies of the human forearm vasculature which
support a presynaptic AII/SNS interaction. The problems demonstrating a
more generalised presynaptic interaction with systemic intravenous infusion
are likely to be due to the gamut of cardiovascular reflexes tending to
obscure changes. In addition plasma NA is a crude index of SNS activity
with limited power in small studies to demonstrate an interaction. NA
spillover used by others has similar limitations, though takes account of
changes in NA clearance. The studies in this thesis suggest that All
increases the presynaptic release of NA but this is not of sufficient
magnitude to spill over into plasma, altering plasma NA. With regard to
the effect of NA after it has been released (postsynaptic effect), All does
not influence the effects of NA on peripheral resistance vessels, but at a
systemic level the intravenous infusion experiments show that All
synergistically augments the rise in systolic blood pressure seen with NA
and increases the effect of beta-agonism on stroke volume. The exact
location and mechanism of this interaction is not confirmed, but the most
likely mechanism is a redistribution of blood from the splanchnic
circulation to the heart.
My final paragraphs propose a general hypothesis. I suggest that both
presynaptic and postsynaptic interactions occur but that they do not
necessarily occur at the same location in the circulation. Thus in the
peripheral resistance vessels a presynaptic interaction occurs allowing rapid
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response to changes in RAS activity and thus increased vascular response
to a given amount of sympathetic outflow. In contrast within the heart a
postsynaptic interaction occurs whereby the heart, in addition to responding
to all relevant reflex changes, is also responsive to the circulating level of
NA, acting in a role as a circulating hormone. The full five litres of
cardiac output must pass through the heart which is therefore in an ideal
situation in the circulation to be exposed to and to respond to circulating
hormone or infused inotrope. On the other hand the peripheral vasculature
has an enormous surface area at the level of arteriolar resistance vessels
and large amounts of cardiac output is diverted to major organs. The
peripheral vasculature is under the influence of basal sympathetic tone and
a variety of cardiovascular reflexes alter sympathetic outflow. A
presynaptic interaction in the peripheral vasculature would therefore exert
a more responsive influence.
What evidence is there to support this hypothesis? Firstly the
evidence in humans and animals clearly demonstrates that when an isolated
circulation is examined a potent interaction is revealed. Our studies in the
human forearm suggest that a presynaptic interaction occurs. However we
have not been able to fully rule out a postsynaptic interaction. By contrast
studies in isolated vascular circuits of animals such as the dog hind limb,
paw and a variety of species mesenteric circulation, demonstrate beyond
doubt that a presynaptic interaction occurs. An increase in NA released
per nerve impulse has been demonstrated by radiolabelling studies in
addition to perfusate effluent studies. It is possible that species differences
occur. However our studies suggest that in the "isolated" vasculature of
the human forearm a similar interaction occurs.
Under what circumstances does the human heart demonstrate response
to circulating hormones? The only relevant "isolated" heart studies clearly
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demonstrating such a response have been performed in patients after
cardiac transplantation or heart-lung transplantation. In such patients the
heart is denervated, evidenced by resting tachycardia due to an absence of
vagal tone. Investigation has shown that their heart rate and cardiac
output response to dynamic exercise is sluggish and is heavily dependent on
circulating catecholamines as are responses to other stimuli (Stinson et al,
1972; Banner et al, 1990).
What evidence is there for a postsynaptic interaction between All and
the SNS at the myocardial or intrathoracic level? As discussed above a
number of human studies support a postsynaptic interaction. However these
have been performed by studying the effect of intravenous infusion of All
altering total systemic levels. The effects of All infusion on physiological
or pharmacological alteration of the SNS by stimuli such as LBNP, head-
down tilt and head-up tilt, and infusion of NA or other agonist have been
studied. It is not possible from these studies to separate the peripheral
vasculature from its reflex effects on cardiac performance, nor a
myocardial or intrathoracic effect in isolation from the peripheral
vasculature. I have argued that the study with ISO and All combined
(chapter seven), by matching after load, "removes" the peripheral resistance
vessels from consideration and comes closest to achieving separation. The
interaction in augmenting stroke volume may have occurred within the
splanchnic circulation or venous capacitance vessels rather than the
myocardium.
There are a number of exciting possibilities to be explored within this
area of research and following on from this thesis. One area of rapid
growth and interest is the new opportunities opened by the discovery of
specific nonpeptide antagonists of All and the demonstration of two types
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